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Background
Chronic obstructive pulmonary disease (COPD) is a long term condition
characterised by progressive narrowing of the airways and premature ageing
of the lungs. By 2020, it is estimated to be the third biggest cause of death in
the UK, after heart disease and stroke. COPD imposes a large financial
burden on health services and is among the most costly diseases in the UK.
Inhalation therapies are central to the management of COPD; they include
pressurised metered dose inhalers (pMDIs), dry powder inhalers (DPIs), and
nebulisers. Although, findings from previous studies reveal suboptimal use
and a wide range of problems with inhaler handling among COPD patients,
very little is known about how and why problems arise. Therefore, the aim of
this study was to examine how older patients made decisions regarding the
use of inhalers especially when combination of inhalation devices were used
at home, how those decision and difficulties contributed to suboptimal
outcomes and treatment failures.
Method
A cross-sectional study design using semi-structured face to face interviews,
observations of inhalation device users, with patients in their own homes,
was conducted with 46 patients. Based on previous studies among patients
with respiratory diseases, it was anticipated that the sample of 60 patients
would enable us to achieve the study objectives and would be able to reach
saturation level, additionally, this sample size was achievable within the time
and resources of the study. Patients were recruited from Pinn Medical Centre
and identified by the staff through patients’ medical notes. All COPD patients,
registered at Pinn Medical Centre, and prescribed a combination of at least
two different inhalation devices were invited to participate. The practice
6population includes patients of different ages, duration and experience of
inhalation therapies, ethnicity and disease severity. The data were audio
recorded for verbatim transcription. Qualitative and quantitative analysis were
conducted using Nvivo and SPSS programme, respectively. The study was
approved by Newcastle & North Tyneside 2 Research Ethics Proportionate
Review Sub-Committee.
Results
46 patients have been interviewed. Male (N=24) and female (N=22), the
mean age was 77 years (63-100). Two-thirds of participants (N=31), 67%,
used a combination of both pMDIs and DPIs, 10 participants (22%), used a
combination of DPIs, three participants (7%) used three different kinds of
inhalation devices (pMDIs, DPIs, and nebulisers), whereas the least used
group was a combination of pMDIs with just two participants (4%). Differing
expectations of treatment (e.g. regarding immediacy and extent of response),
and preferences for different type of device were expressed. Treatment
failures were of concern to patients who had experienced multiple episodes
of exacerbation. The study identified factors which were potential contributors
to treatment failures. These included adherence decisions which were
influenced by their beliefs about inhalation therapies and concerns of side
effects, especially with the long term such as steroids, and willingness to use
devices in public. The study findings also revealed practical and technical
issues in manipulation and cleaning the inhalation devices especially with the
use of DPIs.
Discussion and Conclusion
Treatment failures are a major concern for COPD patients. Most patients
experienced problems with inhalation devices used at home. To improve
treatment, continuous education and follow up needs to be done for COPD
7patients in order to provide all the necessary assistance in the future tailored
to each patient who is at high risk of treatment failures and/or experiencing
problems.
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1 Chapter One: Literature review and background
This chapter outlines the process of developing and informing the research
questions and discusses the rationale for conducting this study among the
group of patients selected. It also provides an introduction to chronic
obstructive pulmonary disease (COPD) including its definition, classification
and management.
1.1 The rationale for conducting this study
1.1.1 Why COPD?
COPD is one of the most prevalent diseases in the world, and its prevalence
is increasing every year not only in the UK but also around the world. As
reported by the Quality and Outcomes Framework (QOF) (DH, 2010), in
England in 2008, 15.4 million people had a long-term condition, including
COPD which was the third most common after coronary heart disease and
diabetes. By 2020, COPD is estimated to be the third biggest cause of death
in the UK, after heart disease and stroke (Mannino et al., 2006; BTS, 2008).
In the UK, it has been estimated that there are about three million patients
with diagnosed COPD, plus a further half million who have the condition
without diagnosis (BLF, 2008). There are about 900,000 patients with
diagnosed COPD in England and Wales. After allowing for under-diagnosis,
the true number of individuals is likely to be about 1.5 million (BLF, 2008).
COPD imposes a large financial burden on health services and is among the
most costly diseases in the UK. COPD is the second largest cause of
emergency admission in the UK (Healthcare Commission, 2006), with one in
eight (130,000) acute adult medical admissions per year. It is estimated that
the direct cost of COPD is almost £500 million a year; more than half of this
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cost relates to the provision of care in hospital (NICE, 2011). In addition,
COPD and other lung conditions cost business 24 million working days in
sick leave, while the indirect costs from lost productivity are £3.8 billion (DH,
2011).
Given the high prevalence of COPD and the healthcare costs, it was decided
to conduct this study among COPD patients in the UK to determine the
needs of this patient group, consider how to optimise their use of medicines,
and identify ways to reduce risks of treatment failures and financial costs to
the NHS due to unnecessary GP visits, hospital readmission and care.
1.1.2 Why study the use of medication among COPD patients?
Adherence to therapy is usually an important aspect of medication use,
specially the treatment of chronic conditions such as COPD (Chisholm-Burns
et al., 2003). The World Health Organisation (WHO) offers a definition of
adherence: "The extent to which a person’s behaviour taking medications,
following a diet, and/or execution of life style changes corresponds with
agreed recommendations from a health care provider” (WHO, 2008).
Medication non-adherence has been identified as a major public health
problem that imposes a considerable financial burden on healthcare services
(Vermeire et al., 2001). This burden has been estimated worldwide to cost
$100 billion each year (Vermeire et al., 2001). The WHO estimates that the
average non-adherence rate is 50% among those with chronic illnesses
including COPD (Chisholm-Burns et al., 2003). Non-adherence to inhalation
therapy was identified in more than 50% of COPD participants in seven
different studies (Melani et al., 2001; Boyter et al., 2005; George et al., 2005;
Mehuys et al., 2010; Trivedi et al., 2012; Huetsch et al., 2012; Cecere et al.,
2012). Among lung diseases, patients with COPD have significantly lower
adherence to treatment than asthmatic patients (James et al., 1985; Dolce et
al., 1991; Cochrane., 1992; Haupt et al., 2008). Strategies to improve
Chapter 1 - Literature review and background
23
adherence to inhalation therapy among patients (e.g. patient instruction and
education) have been shown to work among patients with asthma (Put et al.,
2003; Onyirimba et al., 2003), whereas, in COPD patients, these strategies
were less successful (Rand, 2005; Restrepo et al., 2008). Therefore,
adherence is a recognised problem among this group of patients, which may
lead to suboptimal outcomes and treatment failures.
Despite the sufficient evidence found in the literature supporting the fact that
medication taking among COPD patients was found to be suboptimal,
caution must be taken before drawing a conclusion due to the wide
differences in the estimated rate of non-adherence of COPD patients, which
range from 28% to 80% (see Chapter two: a review of the literature for more
details). This variation may be due to differences in patient populations,
definition of non-adherence, methods employed, disease status, or
respiratory conditions included in each study, as some studies included a
variety of lung diseases such as asthma and COPD (see Chapter two: a
review of the literature).
Non-adherence to medication remains an unresolved problem despite
decades of research, and is a factor resulting in suboptimal clinical outcomes
and poor disease control. Therefore, it was decided to study in detail whether
COPD patients are taking their inhaled drug regimens at home as directed or
not. If not, why they do not adhere, what beliefs they have about their
medicines which may affect medication taking. In addition, what problems
are faced by patients that may make them stop taking their medicines as
recommended, and how can this be resolved.
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What are the differences between this study and previous studies and
what are the gaps in the knowledge in regards to medication use?
The difference between this study and all other previous studies is that,
although all methods of adherence measurements have their advantages
and disadvantages (see Chapter two: a review of the literature), adherence in
these studies was evaluated mainly quantitatively, by measuring the amount
of medicine taken over a given time period (Van Grunsven et al., 2000;
Melani et al., 2001; Barta et al., 2002; Boyter et al., 2005; George et al.,
2005; Mehuys et al., 2010; Agh et al., 2011; Trivedi et al., 2012; Huetsch et
al., 2012; Cecere et al., 2012; Khdour et al., 2012); whilst this study is one of
very few studies that has measured and examined medicine taking and how
patients make decisions to use their inhalation therapy quantitatively and
qualitatively – quantitatively, to determine either adherence/non-adherence
behaviours to COPD medicines and qualitatively to examine patients’ health
decision-making processes and the reasons for these decisions, thereby
contributing answers to questions that were not clearly addressed by
quantitative data.
Almost all studies in adherence research among patients with COPD have
measured patients’ adherence using only one self-report questionnaire on
medication utilisation (Melani et al., 2001; Barta et al., 2002; George et al.,
2005; Mehuys et al., 2010; Agh et al., 2011; Cecere et al., 2012; Huetsch et
al., 2012; Khadour et al., 2012), whilst this study combined different
approaches, tools and methods to gather the data from different sources to
maximise the validity of the findings. These tools were the previously
validated self-report adherence measure (Morisky) and open/close-ended
questions in regards to medication consumption.
One of the most striking reasons for the lack of progress in adherence
research is the absence of the patient’s perspective (Vermeire et al., 2001).
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Therefore, this study will examine the use of inhalation therapy from patients’
perspectives, which has been understudied in previous research (Vermeire
et al., 2001).
This study is unique in examining the relationship between using multiple
inhalation therapies of all medication classes and/or devices and medication
adherence and decision to use the therapy together, which will enable
examining patterns to different medication classes used within the same
patient. Studies that have examined adherence to inhaled medications have
been restricted to only one (van Grunsven et al., 2000) or three medications
(Cecere et al., 2012; Huetsch et al., 2012). Additionally, many previous
studies of medication adherence in COPD patients were performed prior to
the common use of long-acting medications, and included only short-acting
medications (Dolce et al., 1991, Rand et al., 1995; Turner et al., 1995;
Corden et al., 1997).
The potential benefits of this research into the use of medications
Examining how patients made decisions regarding the use of inhalers
especially when a combination of inhalation devices was used at home, and
how those decisions and difficulties contributed to suboptimal outcomes and
treatment failures will help in recognising that collaboration should occur
between healthcare professionals and patients to improve patients’ use of
their medicines in order to achieve optimal health outcomes and minimise the
number of treatment failures and healthcare costs.
1.1.3 Why study the use of devices among users?
In regards to the devices used by patients in their homes, the review of the
literature in Chapter two reveals that incorrect use of inhalation devices is
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very common among patients with COPD, being frequently associated with
the use of pressurised metered dose inhalers (pMDIs) and dry powder
inhalers (DPIs) (Lenney et al., 2000; Hesselink et al., 2001; Khassawneh et
al., 2008; De Moraes Souza et al., 2009; Rootmensen et al., 2010).
Suboptimal inhalation technique will lead to suboptimal drug delivery.
Therefore, users may receive lower benefits from their treatment, which may
result in the prescription of unnecessarily high doses and higher healthcare
costs. It has been estimated that $5 to $7 billion in the United States is
wasted every year because of inhaler misuse (Fink and Rubin, 2005). The
rate of incorrect inhalation technique with the use of inhalation devices
reported in five past studies ranged from 2.9% (Ho et al., 2004) to 94.2% in
previous studies (De Moraes Souza et al., 2009). The review reveals
suboptimal use and a wide range of problems with inhaler handling.
However, very little is known about how and why problems arise and what
practical and technical issues COPD patients faced when using multiple
inhalation devices in combination. Therefore, there is a need for more studies
to examine how patients practically use their inhalation devices and what are
the frequency and range of problems experienced by patients in terms of the
technical aspects of inhaler use, cleaning and maintenance of devices that
may lead to suboptimal care or treatment failure.
What are the differences between this study and previous studies and
what are the gaps in the knowledge in regards to devices’ use?
The majority of past studies (N=6) have assessed the inhalation technique
among patients with a number of lung diseases, including asthma and COPD
(Hesselink et al., 2001; Ho et al., 2004; De Moraes Souza et al., 2009;
Rootmensen et al., 2010; Hämmerlein et al., 2011; Melani et al., 2011),
whereas this study is one of very few studies (N=3) that included only
patients with COPD, to focus on their problems and specific needs, which
may differ from those of patients with asthma (Lenney et al., 2000; Wilson et
al., 2007; Khassawneh et al., 2008). In addition, other past studies have
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included only one class of devices in the assessment process, i.e. pMDIs
only (Ho et al., 2004) or DPIs only (Wilson et al., 2007). This study included
all classes of inhalation devices, including nebulisers, which have not been
assessed previously in studies of COPD patients’ use of devices.
The decision to include only patients with COPD in the assessment process
in this study was because, despite the fact that both asthmatic and COPD
patients are prescribed multiple inhalation therapies to be used daily or when
required, the characteristics of COPD as a disease and its treatment differ.
For example, in asthma patients the airflow limitation is reversible with the
use of therapy, whereas this limitation is irreversible in COPD patients even
with the use of medication, which may affect patients’ use of their therapy.
Unlike COPD, asthma is episodic and is rarely a life-threatening disease.
These factors, including the nature of the disease and the treatment, were
found to influence patients’ use of inhalation therapy (Horne et al., 1999).
Previous studies have reported that incorrect inhalation technique was
common among both asthmatic and COPD patients. However, three
previous studies reported that COPD patients made or were more likely to
make more deviations from the recommended inhalation technique when
using their inhalers than those with asthma (Buckley, 1989; De Morales
Souza et al., 2009; Melany et al., 2011), and that up to 94% of inhalation
devices users with COPD used their devices incorrectly (De Moraes Souza
et al., 2009), which may result in suboptimal drug delivery and therefore
treatment failures.
Additionally, all previous studies have only measured the practical errors or
deviations made by COPD patients when performing the inhalation
technique, without paying attention to the technical issues experienced by
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users with the device itself (i.e., if there is a problem in the device itself or its
manufacture that may affect the drug delivery and therefore patients’ choices
and use). In addition, no study has been focused on examining inhalation
technique among patients with COPD using nebulisers. Previous studies
have considered only certain devices and included one aspect of
assessment, which is the inhalation technique. Since adequate disease
control relies on the appropriate use of the inhalation therapy or devices,
there is a need for more studies to examine how these patients practically
use their devices.
The potential benefits of this research into the use of devices
To our knowledge, this is the only study that has examined and described the
problems encountered by COPD participants with all aspects of the use of
multiple inhalation devices, including technical and practical issues of the
operation, cleaning and maintenance of inhaler equipment for all classes of
devices, including pMDIs, DPIs and nebulisers. By highlighting these issues,
which may affect patients’ use of their medicines, information will be
available which will help inform healthcare professionals in their support of
these patients in their use of such medicines at home, and therefore optimise
medicines’ use.
1.1.4 Why study the informal care provided for COPD patients?
Managing COPD can be complex because it usually occurs with other
chronic illness, each of which may require following pharmacological and
non-pharmacological recommendations (Pinto et al., 2007). In addition,
COPD mainly affects people over the age of 40 and becomes more common
with increasing age. The average age when it is formally diagnosed is around
67 years (Trivedi et al., 2012). This age can be associated with physical and
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functional limitations which may affect the use of medication among these
patients, suggesting an important role for carers.
The terminology used to refer to carers is unclear (Barnes et al., 2006). For
example, the phrase “family caregiver” was coined by Houts, et al. (1996)
and refers to the people who provide some assistance or help at home for
patients and are not getting paid by any caregiving services (Houts et al.,
1996). In 2006, the Department of Health in the United Kingdom adopted and
employed the term ‘carer’ to distinguish between the formal care provided by
health and social care professionals and the informal care provided by family
members, friends and neighbours (DH, 2006).
The majority of care that is delivered to patients with chronic illnesses
including COPD has shifted from secondary care (e.g. hospitals) towards
patients’ homes, as a result of the trend towards community-based care
(Spence et al., 2008). Assets and Health Dynamics among the Oldest Old
(AHEAD) data suggest that most caregivers are family members (informal
carers) (72%) (Clipp and Steinhauser, 2003). The care value provided by
informal carers such as family members has been estimated to exceed the
cost of care from nursing homes and paid healthcare (Schreiner et al., 2006).
It is estimated by the Office of National Statistics that about five million
individuals are providing informal care in the UK (The Information Centre for
Health and Social Care, 2010).
In 2011, the Department of Health published a report entitled ‘An Outcomes
Strategy for People with Chronic Obstructive Pulmonary Disease and
Asthma in England’ to ensure that people with COPD receive safe and
effective care which reduces the disease progression and enhances their
independence (DH, 2011). However, the few existing studies that have
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examined the informal care provided for COPD patients have focused on
carer experiences and needs (Bergs 2002; Simpson and Rocker, 2008;
Spence et al., 2008; Caress et al., 2009), and have neglected the needs of
the patients and the important role of informal carers in disease
management. Therefore, the nature of informal support provided for COPD
patients with their medication in their homes remains understudied. There is
a need to know if COPD patients are getting the required help or assistance
with their medicines, and how the carer helps – in which activity or tasks and
how often.
The potential benefits of this research into the care provided for
patients with COPD
Understanding the range and extent of care provided by informal caregivers
in relation to the use of inhalation therapy at home is crucial to support and
empower carers to fulfil their roles, and to ensure the effective use of COPD
medication by patients.
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1.2 Definition of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a long-term condition
characterised by progressive narrowing of the airways and premature aging
of the lungs. The obstruction of the airways may be partially reversible or
irreversible (BTS, 2008). The World Health Organisation (WHO) defines
COPD as “not a single disease but an umbrella term used to describe
chronic lung diseases that cause limitations in lung airflow, such as
emphysema and chronic bronchitis” (WHO, 2008).
Emphysema is characterised by destruction of the lung tissue, mainly air
sacs (alveoli). The smallest airways also narrow, lose their elasticity, and
tend to collapse during exhalation (Barnes, 2004; Porth, 2005). Chronic
bronchitis is an inflammation of the airways causing the glands that line the
airways to produce an excessive amount of thick mucus, which in turn
causes further obstruction of breathing. The result is often a chronic cough
that produces mucus or sputum and shortness of breath (Barnes, 2004;
Porth, 2005). The more familiar terms 'chronic bronchitis' and 'emphysema'
are no longer officially used, but are now included within the COPD diagnosis
(WHO, 2008).
1.3 Pathophysiology and aetiology of chronic obstructive pulmonary
disease
The mechanisms involved in the pathogenesis of COPD usually are multiple
and include inflammation and fibrosis of the bronchial wall, hypertrophy of the
submucosal glands and hypersecretion of mucus, and loss of elastic lung
fibres and alveolar tissue. All these changes cause mismatching of
ventilation and perfusion. Destruction of the alveolar tissue decreases the
surface area for gas exchange and loss of elastic fibres, which normally
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provide traction and hold the airways open, impairs the expiratory flow rate,
increases air trapping, and predisposes to airway collapse (Barnes, 2004;
Porth, 2005).
Cigarette smoking is the most important etiological factor in the development
of COPD. Smoking is suggested to account for 90% of cases, and while
decline in lung function after the age of 35 is part of the aging process, the
decline is two times faster among ‘at risk’ smokers (Alhadad, 2011). In the
UK, smoking is attributed as the main cause of COPD in 87% of males and
84% of females (Smeltzer and Bare, 2010). Smoking depresses the activity
of scavenger cells and affects the respiratory tract’s ciliary cleaning
mechanism, which keeps breathing passages free of inhaled irritants,
bacterial and other foreign matter. When smoking damages this cleaning
mechanism, airflow is obstructed and air becomes trapped behind the
obstruction. The alveoli greatly distend, diminishing lung capacity. Smoking
also irritates mucus glands, causing an increased accumulation of mucus,
which in turn produces more irritation, infection, and damage to the lung
(Smeltzer and Bare, 2010).
Although genetic factors have been suggested to play a role in developing
COPD among smokers, previous studies on these factors have not provided
full, clear explanations (Alhadad, 2011). The well-documented genetic risk
factor is deficiency of alpha-1 antitrypsin (A1AT) which is an enzyme inhibitor
that protects the lung parenchyma form injury. This deficiency of alpha-1
antitrypsin predisposes young people to rapid development of emphysema,
even if they do not smoke (Smeltzer and Bare, 2010).
Age and gender are other risk factors of COPD. The frequency of COPD
increases with age, with prevalence rates of 2% in men aged 45-65 years
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and 7% in men over 75. Men are more likely to be affected than women
(Smeltzer and Bare, 2010). The prevalence of COPD is 1.7% in men
compared to 1.4% in women. However, in some European countries there is
no gender difference in prevalence rates because these rates for women are
rising more rapidly than for men. This is in part related to the change in their
smoking habits and it also appears that women are more susceptible to
tobacco smoke. Women who smoke are estimated to be 13 times more likely
to develop COPD than a non-smoker (Smeltzer and Bare, 2010). Other risk
factors include: certain jobs with occupational risk factors and air pollution.
1.4 Classification of chronic obstructive pulmonary disease
This section describes the classifications of COPD based on disease
severity, in order to identify patients who were enrolled in this study as mild,
moderate, severe and very severe, based on the chosen classification from
the guidelines. The assessment of the severity is based on the FEV1 value
and has implications for therapy and prognosis.
In clinical practice, there are different classification methods used to
categorise the stages of COPD and its severity. Firstly, the severity of airflow
obstruction in COPD can be categorised according to the degree of reduction
in FEV1% predicted, which is defined as the maximum amount of air that can
be expired in one second following a full inspiration (NICE, 2010). However,
there is no international agreement in terms of classification of severity and
classifications and guidelines to follow are different between countries – for
instance the National Institute for Health and Care Excellence CG101 for
COPD, which is used in the UK (NICE, 2010), and the Global Initiative for
Chronic Obstructive Lung Disease (GOLD), which is used within Europe, and
the American Thoracic Society (ATS) and European Respiratory Society
(ERS) classifications, which are used in the USA and Europe respectively.
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The similarities and differences between the guidelines are shown in
Table 1-1.
Table 1-1: Classification of airflow obstruction in COPD according to different
guidelines. Values shown are all FEV1%predicted and in all categories post
bronchodilator FEV1/ FVC<0.7. Source: NICE, 2010
Another classification for the disease severity is the Dyspnoea scale, which is
a method of recording patients’ self-report of activities that cause them
breathlessness (see Table 1-2). The Dyspnoea scale is the most widely used
scale of activity limitation resulting from breathlessness, and was developed
by the Medical Research Council (MRC) (NICE, 2010). This particular tool is
graded from 1 to 5 and allows the patients to rate their breathlessness
according to the level of exertion required to induce their breathlessness
(NICE, 2010).
Table 1-2: Severity of COPD based on the Dyspnoea scale. Source: NICE, 2010
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The Dyspnoea scale is an easy tool to use and record but each grade is fairly
broad and may not be sensitive enough in some cases to measure the effect
of a treatment (Smeltzer and Bare, 2010).
In order to determine the severity of the disease of each participant enrolled
in this study, patients’ medical records in Pinn Medical Centre were accessed
to obtain this information (if specified, mild, moderate, severe and very
severe). If the disease severity was not specified by Pinn Medical Centre
staff, the FEV1% predicted or FEV1/FVC ratio were obtained, in order to
identify patients who were enrolled in this study as mild, moderate, severe
and very severe, based on the NICE guidelines classifications. The NICE
guidelines classifications were used in this study because the guidelines
were recently published in 2010 when the study was started in 2011, and the
guidance outlines recommended therapy for COPD within the National
Health Service (NHS) in the UK.
1.5 Management of chronic obstructive pulmonary disease
Despite the fact that COPD imposes a large financial burden on patients,
carers and healthcare system, it remains under-treated (BTS, 2008).
Although COPD cannot be cured, optimal disease management can provide
control of symptoms and slow the progression of the disease (Kaplan et al.,
2005; Rodriguez-Roisin et al., 2005). Effective disease management is
crucial to combat the huge impact of this condition on patients, carers and
healthcare system.
One of the objectives set out in the ‘Outcomes Strategy for Chronic
Obstructive Pulmonary Disease’ was to assure that safe and effective care is
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delivered to individuals with COPD, in order to reduce the progression of the
disease and encourage independence (DH, 2011). It is therefore advised in
the Outcomes Strategy to initiate treatment through evidence-based use of
pharmacological and non-pharmacological interventions that are tailored to
the patient’s choice and are often reviewed. In order to meet this goal;
implementing evidence-based guidelines on the effective management of
COPD is recommended. The National Institute for Health and Care
Excellence (NICE) in 2004 first issued clinical guidelines to treat patients with
COPD. These guidelines were reviewed and replaced with an updated
version (NICE, 2010). In 2010, the National Institute for Health and Care
Excellence (NICE) issued guidelines on the care and management for
patients with COPD. Pharmacological and non-pharmacological approaches
are recommended. The pharmacological strategy mainly consists of
bronchodilators and/or corticosteroids (Figure 1-1), whereas a non-
pharmacological strategy includes smoking cessation, influenza vaccinations,
oxygen therapy and pulmonary rehabilitation programmes. This study has
focused on the pharmacological strategy of managing COPD, as previous
studies have shown suboptimal use and a wide range of problems with
inhaler handling among COPD patients, and very little is known about how
and why such problems arise. Therefore, in this section the pharmacological
aspect of managing COPD will be discussed in detail to outline the therapies
available for the management of COPD, and the current policies and
guidelines implemented in the UK.
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Figure 1-1: Step-care pharmacotherapy in COPD. Source: British National Formulary
(BNF), 2013.
1.5.1 Pharmacological management
1.5.1.1 Bronchodilators
Inhaled bronchodilators are the mainstay of treatment in COPD because they
reduce breathlessness and improve exercise capacity (Clark, 2004;
Howland, 2006). They include short- and long-acting therapy, such as β2-
agonists and antimuscarinic agents. β2-agonists bind to the β2-adrenoceptor
which is present in the cell membrane of a number of airway cells including
smooth muscle cells, causing relaxation of the airway smooth muscles
(Howland, 2006). Antimuscarinic agents are muscarinic receptors’ (e.g. M1
and M3) antagonist, which inhibit cholinergic reflex bronchoconstriction,
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causing bronchodilation. In addition, antimuscarinic agents reduce mucus
hypersecretion by inhibiting M3 receptors (Howland, 2006).
A. Short-acting inhaled bronchodilators
Short-acting bronchodilators are the most commonly used therapy for COPD
(NICE, 2010; BNF, 2013). Bronchodilators relax the muscles in the airways
(bronchioles), causing the airways to open and dilate. They include β2-
agonists (e.g. salbutamol and terbutaline), which have been the mainstay
bronchodilator agents used for the management of COPD, and anti-
cholinergic agents (e.g. ipratropium).
These drugs have a rapid onset of action (usually within five to 10 minutes)
and duration of action of three to four hours, and are given to be used when
needed for quick relief of symptoms. They can also be used before exercise
to increase exercise tolerance or to relieve breathlessness (Clark, 2004;
Howland, 2006; BNF, 2013).
Some older patients may become less responsive to β2-agonists and may
achieve better improvement with anti-cholinergic agents. Short-acting anti-
cholinergic agents have a slower onset of action (15-30 minutes) than short
acting β2-agonists (five minutes) but the results of most comparative studies
suggest that they are equally effective in achieving symptom relief (Clark,
2004; Howland, 2006; BNF, 2013). In addition, they are both well tolerated,
but may cause tremor of the hands or palpitations (rapid and irregular
heartbeat) (BNF, 2013).
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B. Long-acting bronchodilators
Long-acting bronchodilators have similar effects on lung function to those of
short-acting bronchodilators. However, they are more effective in maintaining
relief from breathlessness than short-acting bronchodilators; their effect
continues for 12 hours compared with up to four hours for the short-acting
agents. Long-acting agents reduce breathlessness and give better exercise
tolerance (Clark, 2004; Howland, 2006; Beier and Beeh, 2011; BNF, 2013).
They are recommended to be given to people with stable COPD who remain
breathless or have exacerbations (exacerbations often occur where there is a
rapid and sustained worsening of symptoms beyond normal day-to-day
variations) despite using short-acting bronchodilators as required (NICE,
2010). Patients should be also given long-acting beta agonists (LABAs:
formoterol or salmeterol) or long-acting muscarinic antagonists (LAMAs:
tiotropium) as maintenance therapy especially if the FEV1 ≥ 50% predicted
(NICE, 2010). Long-acting bronchodilators are usually safe. However, some
adverse effects may emerge with the use of these therapies, including
palpitation, tremor, headache, muscle cramps and low potassium level in the
bloodstream, which are usually caused by LABAs, whereas dry mouth,
nausea, palpitation, headache and visual difficulties are caused by LAMAs
(BNF, 2013).
1.5.1.2 Inhaled steroids
Inhaled steroids (ICS) should be considered in those with more advanced
disease and repeated exacerbations (NICE, 2010). Although these therapies
do not have a big impact upon improving lung function or symptoms, they
may reduce the frequency of exacerbations. The most commonly used
inhaled steroids in COPD are beclometasone, budesonide and fluticasone
(BNF, 2013).
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Inhaled steroids can cause adverse effects to appear within the mouth and
throat such as oral thrush or alteration in voice quality (e.g. voice
hoarseness), which can be avoided by gargling or brushing the teeth after
using them or using a spacer device, which will be described later. In
addition, prolonged use of high doses of steroids may cause the skin bruising
and osteoporosis (BNF, 2013).
1.5.1.3 Inhaled combination therapies of LABAs and ICS
ICS should not generally be used alone in COPD; they are most often given
along with a LABA in a single inhaler. According to the NICE guidelines, the
addition of long-acting bronchodilators (LABA) to inhaled corticosteroids
(ICS) (in a combination inhaler) should be considered in people with COPD
who remain breathless or have exacerbations. Despite using SABAs as
required, patients should be given a combination therapy of LABA with an
ICS in one inhaler as maintenance therapy, especially if FEV1<50% is
predicted (NICE, 2010). Combined therapy may produce greater
improvements in exercise tolerance and a greater degree of bronchodilation
than either drug used separately (NICE, 2010). In addition, patients may find
this more convenient and adherence may be enhanced (Clark, 2004;
Howland, 2006).
1.5.1.4 Oral corticosteroids
The NICE guidance recommends that oral corticosteroids (e.g. prednisolone)
are only indicated for the treatment of exacerbations of COPD as they have
been found to reduce the severity and the duration of the episode (NICE,
2010). They should be considered in the following cases: firstly, in the
absence of significant contraindications, oral corticosteroids should be given
in addition to other therapies to all patients admitted to hospital with an
exacerbation, or in patients in the community who have an exacerbation with
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a significant increase in breathlessness which interferes with daily activities.
However, in these cases, the dose of oral corticosteroids should be kept as
low as possible and the therapy should be monitored for the development of
any side effects such as osteoporosis (NICE, 2010). Steroid tablets may be
prescribed for one or two weeks to deal with exacerbations and reduce
inflammation. They should not be used on a maintenance basis (Clark, 2004;
Howland, 2006; NICE, 2010).
1.6 Inhalation devices used for the treatment of COPD
Inhalation therapies are central to the management of COPD. A broad range
of inhaler devices is available in practice, generally categorised pressurised
metered dose inhalers (pMDIs), dry powder inhalers (DPIs), and nebulisers,
according to the method used for drug dispersion (see Figure 1-2).
Figure 1-2 includes inhalation devices which were most used by participants
in this study.
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Figure 1-2: Inhalation devices currently available
The pMDI is the most commonly used and prescribed inhaler compared to
dry powder inhalers (DPIs) and nebulisers (Child et al., 2002; Chystyn et al.,
2003; Rees, 2005; Taylor, 2013). When choosing a suitable inhaler, a
patient’s ability to use a device should be assessed as it forms an important
factor which determining the choice (Barrons et al., 2011), as successful
disease management totally relies on the patient’s ability to use the
inhalation devices properly and efficiently (Lannefors, 2006). There is great
variation between the available inhalers in the design and functionality, each
of which has advantages and disadvantages, which are considered below.
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1.7 The aerosol delivery system
1.7.1 Pressurized metered dose inhalers (pMDIs)
The component parts of the pMDI
The standard pressurized metered-dose inhaler (Figure 1-3) is the most
commonly used device for delivering inhaled drugs, especially
bronchodilators (BNF, 2013; Taylor, 2013), and in 2002 approximately 500
million were produced and their production is increasing annually (Brown,
2002). pMDIs contain a drug that is either dissolved or suspended in a
propellant under pressure which is manually actuated (Beaucage and
Nesbitt, 2002). Therefore, a good inhalation technique is required.
Figure 1-3: Schematic of a typical standard pressurized metered-dose inhaler. Source:
Lavorini, 2013.
The pMDI comprises several components, each of which is important to the
success of the whole device. These components are container, propellants,
drug formulation, metering valve, and actuator (Newman, 2005; Lavorini,
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2013). In pMDIs, the drug is either dissolved or suspended in liquid
propellant(s) such as hydrofluoroalkanes (HFAs) or chlorofluorocarbons
(CFCs), together with other excipients, liquid surfactants, and presented in a
pressurized canister fitted with a metering valve. A predetermined dose is
released as a spray on actuation of the metering valve. When released from
the canister, the formulation undergoes volume expansion in the passage
within the valve and forms a mixture of gas and liquid before discharge from
the orifice. The high-speed gas flow helps to break up the liquid into a fine
spray of droplets (Taylor, 2013). Table 1-3 gives more information about how
a pMDI device is operated and the optimal inhalation technique.
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Table 1-3: Inhalation technique for standard and breath-actuated pMDIs
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Advantages and limitations of the conventional pMDIs
pMDIs have the practical benefits of small size, portability, convenience and
they are relatively inexpensive. In addition, pMDIs are multi-dose which
means that a dose is immediately available when required. A dose can be
delivered in a few seconds, unlike nebulisation therapy, which typically takes
several minutes to be inhaled. Since the inhaler is pressurized, the contents
are protected from the entry of both moisture and pathogens. These factors
provide powerful reasons why the pMDI has been successful for a long
period of time (Beaucage and Nesbitt, 2002; Newman, 2005; Karotkin, 2011).
Conversely, the limitations of pMDIs have also been recognised for decades.
One of the main disadvantages of the pMDIs is that the drug delivery is
highly dependent on the patient’s inhalation technique. Reports of pMDI
misuse are commonplace in the literature, and failure to co-ordinate or
synchronise actuation with inhalation is said to be the most common problem
patients have with the use of pMDIs, which can result in a very poor drug
delivery, leading to suboptimal outcomes (Giraud and Roche, 2002; Karotkin,
2011; Lavorini, 2013). Another problem with some pMDIs is that, even with
good inhalation technique, the drug disposition in the lungs from the pMDIs is
less than 20% of the dose, with most of the dose being deposited in the
oropharynx (Newman, 1991; Karotkin, 2011). High oropharyngeal deposition
of some medication can cause localised adverse effects (Newman, 1991;
Karotkin, 2011). See Table1-4 for more information about the main
advantages and disadvantages of the pMDIs.
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Table1-4: Advantages and disadvantages of standard pMDIs. Adapted from: Newman,
2005 and Taylor, 2013
1.7.2 Spacers
Spacers are generally prescribed to enhance drug delivery from pMDIs for
those who find it difficult to coordinate inhalation with actuation (Taylor,
2013). Spacers make the pMDIs easier to use, because both coordination
and ‘cold Freon’ problems (Freon is the registered trademark of CFCs, in
which the arrival of the cold propellant spray on the back of the throat causes
the patient to stop inhaling) are reduced. The dose of pMDI is discharged
directly into the reservoir prior to inhalation. This reduces the initial droplet
velocity, large droplets may be removed by impaction, and efficient propellant
evaporation occurs and the need for actuation/inhalation coordination is
removed (Taylor, 2013). Additionally, this may reduce adverse effects of
inhaled steroids such as oral thrush. The disadvantage of traditional spacers
is that they may be cumbersome due to their large volume, e.g. Volumatic®
and Nebuhaler®, although smaller, medium-volume spacers are now
available, e.g. Aerochamber Plus® (Taylor, 2013) (Figure 1-4).
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Figure 1-4: Spacer devices prescribed for COPD participants. Source: Global Initiative
for Asthma (GINA), 2013.
1.7.3 Breath-actuated metered dose inhaler
These devices are alternatives to the standard pMDIs. They were introduced
to improve coordination of actuation of standard pMDIs with inhalation. They
are designed to actuate automatically as the patient inhales through them,
e.g. Autohaler and Easi-Breath (Newman, 2005; Karotkin, 2011; Grammer et
al., 2012).
The concept of a breath-actuated metered dose inhaler is good, because it
automatically releases the drug when a patient is inhaling, which resolves the
problem of patient coordination of actuation with inhalation (O’Callaghan and
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Wright, 2002). Patients seem to find breath-actuated MDIs easier to use than
standard pMDIs and may prefer them over other devices (Lenney et al.,
2000). This will be discussed in later chapters.
Advantages and limitations of breath-actuated pMDIs
Because some patients may have difficulty coordinating inhalation and
device actuation, breath-actuated pMDIs were developed to overcome this
problem. Table 1-5 gives more information about the advantages and
drawbacks of breath-actuated pMDIs (Berger, 2009).
Table 1-5: Advantages and disadvantages of breath-actuated pMDIs. Adapted from:
Berger et al., 2009
1.7.4 Dry powder inhalers
In the dry powder inhaler (DPI) system, the drug is inhaled as a cloud of fine
particles. The drug is either preloaded in an inhalation device or filled into
hard gelatine capsules or foil blister discs which are loaded into the device
prior to use. These devices are propellant-free and usually do not contain any
excipient, other than a carrier, which is usually lactose (Taylor, 2013). They
are breath-actuated, avoiding the problems of inhalation/actuation
coordination encountered with pMDIs (Taylor, 2013).
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Advantages and limitations of the dry powder inhalers
DPIs comprise both single and multi-dose models (Table 1-7). All currently
marketed DPIs are breath-actuated and no propellants are needed to
generate the aerosol (Smyth, 2003). In general, DPIs are very portable and
quick to use. In addition, spacers are not necessary with DPIs. Multi-dose
DPIs incorporate dose counters and are easier to use than pMDIs (Broeders
et al., 2009). Table 1-6 gives more information about the main advantages
and drawbacks of the DPIs. Table 1-7 demonstrates some examples of the
most used DPI devices by COPD participants in this study.
Table 1-6: Advantages and disadvantages of DPIs. Adapted from: Broeders et al., 2009
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Table 1-7: Examples on the most used dry powder inhalers devices by COPD participants in this study
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1.7.5 Nebulisers
Nebulisers deliver relatively large volumes of drug solutions and suspensions
and are frequently used for drugs that cannot be conveniently formulated into
pMDIs or DPIs, or where the therapeutic dose is too large for delivery with
these alternative systems (Taylor, 2013). Nebulisers also have the advantage
over pMDI and DPI systems in that the drug may be inhaled during normal
tidal breathing through a mouthpiece or facemask, and thus they are useful
for patients who cannot use pMDIs or DPIs (Murphy, 2007). Although there
are different types of nebulisers, including jet, ultrasonic and mesh
nebulisers, this study has been focused only on the Jet nebuliser, as
participants in this study used only this type. Therefore, it will be discussed in
greater detail in this chapter. Table 1-8 gives information about jet nebulisers.
Table 1-8: Jet nebulisers.
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Advantages and limitations of the nebulisers
When comparing nebulisers to pMDIs and DPIs, the nebulisers offer some
advantages including: they are independent of patient inhalation technique.
Thus, they are generally recommended for use by elderly patients who are
unable to use hand-held devices correctly and in case of emergency with
confused patients (Boe et al., 2001; Murphy, 2007). In addition, COPD
patients who are too ill will be able to self-administer drug therapy via a
nebuliser. Moreover, nebulisation delivery system is still the preferred
administration route in some situations. According to the Nebuliser Project
Group of the British Thoracic Society Standards of Care Committee and the
Quebec Pharmacology Advisory Board (Boe et al., 2001; Beaucage and
Nesbitt, 2002; Murphy, 2007), nebulisers are indicated for the following
circumstances:
 For those patients who are unable to use other types of inhalation
devices, for example, those who suffer from physical or cognitive
deficits.
 In hospital settings for severe dyspnoea and when high doses of
medication must be administered.
 Nebulisers can administer other drugs such as antibiotics which are
not available in other inhalers.
Despite their advantages, nebulisers have some drawbacks including:
nebulisation therapy is more expensive than treatment with hand-held
devices. Other disadvantages include: high maintenance of the nebuliser
device is required; it is a time-consuming process; nebulisers are usually
noisy, depend on outside power sources (electricity), and are less portable
than pMDIs and DPIs (Boe, et al., 2001; Murphy, 2007).
To summarise, this chapter has provided information about the background
and literature review of COPD which was done to build up the case for
conducting this study. It has defined the disease and illustrated the type of
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medications’ devices available for the management of COPD to help the
reader later on to understand the outcomes and the issues that have
emerged in this study. However, this was not sufficient. Therefore, the
researcher decided to conduct a review aiming to identify and select the
research evidence and provide a basis to refine the research objectives.
Another reason for conducting a review is that the identified articles and
evidence may allow the researcher to establish a theoretical framework in
relation to what has been done in this area, and help her in designing the
methodology of the study and in the selection of research tools which will be
used to meet the study objectives.
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2 Chapter Two: Review of the literature regarding
medications and devices use
The aim of this chapter is to review the research into how COPD patients use
inhalation devices to manage their disease in the context of their daily lives.
The objectives were, firstly, to establish the extent to which COPD patients’
behaviour regarding adherence to inhalation therapy has been studied and
review evidence regarding how they make decisions about the use; and,
secondly, to identify all research evidence relevant to problems COPD
patients have with inhalation devices in the operation, cleaning and
maintenance of inhaler equipment and to identify behaviours which may lead
to treatment failures or exacerbations.
2.1 Methods
2.1.1 Search strategy and eligibility criteria
The articles were selected through their titles and abstracts by the
researcher. The criteria for relevant studies were: (1) patients with COPD;
using multiple inhalation devices; in primary care; (2) studies reported in the
English language. The inclusion criteria were generated in order to achieve
the aim of the review and to help the researcher to determine the most
appropriate articles to best address the review questions. Therefore, only
articles that addressed the review questions and met the inclusion criteria
were included.
The review commenced with three main keywords/phrases: ‘chronic
obstructive pulmonary disease’, ‘inhalation devices’, and ‘adherence’ (or)
‘COPD’ (or) ‘inhalation technique’ (or) factors. Lists of search terms
associated with each keyword were generated from MeSH (medical subject
heading) terms in PubMed and term mapping database in Embase (Ovid), to
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provide a consistent way to retrieve information that may use different
terminology for the same concept, for instance ‘chronic obstructive
pulmonary disease’ and/or ‘COPD’ and/or ‘bronchitis’. Identifying COPD
studies was challenging due to different terms used to describe COPD.
Moreover, some studies described the use of respiratory medicines for a mix
of respiratory diseases including COPD and asthma in the same study, which
makes the analysis and data extraction challenging. As a result, the first
attempt was to identify suitable search terminologies; therefore, a number of
terms were required for searching, including: ‘chronic obstructive pulmonary
disease’, ‘COPD’, ‘bronchitis’, ‘emphysema’, ‘inhalation devices’, ‘puffer’,
‘pressurised metered dose inhaler’, ‘pMDI’, ‘dry powder inhaler’, ‘DPI’,
‘nebuliser’, and ‘vaporiser’. Keywords not listed as MeSH or Map Terms were
searched as phrases using the free text search mode. To ensure a scientific
evidence base this review includes only peer reviewed journal articles.
2.1.2 Data sources
Electronic databases of PubMed (Medline), Embase (Ovid) and International
Pharmaceutical Abstract (Ovid) were conducted for the period from 2000 to
2013, as this period witnessed the introduction of many therapeutic agents
and higher technological devices for inhalation therapy, especially with the
introduction of the patient-friendly devices DPIs. In addition, there was a
systematic review published in 2001 by Brocklebank, comparing the
effectiveness of inhaler devices in asthma and chronic obstructive airways
disease. Therefore, the researcher decided to take this review further to find
out how COPD patients and their behaviours have changed with regard to
their use of their medicines or devices since that review (Brocklebank et al.,
2001). The selected databases are large multidisciplinary bibliographic and
citation databases with extensive journal coverage especially in behavioural
medicine and modern respiratory treatment, including inhalational therapies.
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2.1.3 Process of data extraction
Electronic databases were searched and duplicate articles were removed. All
articles were reviewed manually by title, abstract and/or full-text for
relevance. The reference lists of retrieved articles were manually examined
for further applicable studies. Full text manuscripts were retrieved either
electronically or as hard copy for assessment. Information was extracted into
a proforma which included: primary author name and date of publication,
country of the study, study settings, sample, methods employed, measures
used and results. Studies of medication-taking behaviours of multiple
inhalation therapy and the technical aspects of operation of the inhalation
devices studies among COPD patients are attached as Appendix 1 and
Appendix 2 respectively.
2.2 Results
The electronic database search retrieved a total of 326 articles of which 29
were duplicates. Screening of titles, abstracts and/or full texts for the
remaining 297 identified that 19 were related to the review questions. A hand
search of retrieved articles from the electronic database and journals led to
identification of a further four articles. Therefore, a total of 23 studies were
included in this review. Of those, 12 studies examined patients’ behaviour
regarding adherence to inhalation therapy (Van Grunsven et al., 2000; Melani
et al., 2001; Barta et al., 2002; Boyter et al., 2005; George et al., 2005;
George et al., 2006; Mehuys et al., 2010; Agh et al., 2011; Trivedi et al.,
2012; Huetsch et al., 2012; Cecere et al., 2012; Khdour et al., 2012)
(Appendix 1). Eleven studies examined the aspects of operation of inhalation
devices and showed the frequency and range of problems experienced by
COPD patients when using their inhalation devices (Lenney et al., 2000;
Hesselink et al., 2001; Molimard, et al., 2003; Ho et al., 2004; Sestini et al.,
2006; Wilson et al., 2007; Khassawneh et al., 2008; De Moraes Souza et al.,
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2009; Rootmensen et al., 2010; Melani et al., 2011; Hämmerlein et al., 2011)
(Appendix 2).
These studies were mostly based in outpatient clinics (N=11) (Lenney et al.,
2000; Hesselink et al., 2001; George et al., 2005; Khassawneh et al., 2008;
De Moraes Souza et al., 2009; Rootmensen et al., 2010; Agh et al., 2011;
Melani et al., 2011; Huetsch et al., 2012; Cecere et al., 2012; Khdour et al.,
2012), and patients’ home (N=6) (Van Grunsven et al., 2000; Melani et al.,
2001; Barta et al., 2002; Boyter et al., 2005; George et al., 2006; Sestini et
al., 2006). Others were based in community pharmacies (N=3) (Mehuys et
al., 2010; Trivedi et al., 2012; Hämmerlein et al., 2012). Most of these studies
were conducted in Europe, especially the UK (N=6) (Lenney et al., 2000;
Barta et al., 2002; Ho et al., 2004; Boyter et al., 2005; Wilson et al., 2007;
Khdour et al., 2012), followed by Italy (N=3) (Melani et al., 2001; Sestini et
al., 2006; Melani et al., 2011), and the Netherlands (N=2) (Van Grunsven et
al., 2000; Rootmensen et al., 2010),  Belgium (N=1) (Mehuys et al., 2010),
Hungary (N=1) (Agh et al., 2011), France (N=1) (Hesselink et al., 2001),
Germany (N=1) (Hämmerlein et al., 2011), the USA (N=3) (Cecere et al.,
2012; Huetsch et al., 2012; Trivedi et al., 2012), Australia (N=2) (George et
al., 2005; George et al., 2006), Brazil (N=1) (De Moraes Souza et al., 2009)
and Jordan (N=1) (Khassawneh et al., 2008). The majority of studies that
measured and examined medication-taking behaviours were conducted
among patients with COPD alone (N=10) (Melani et al., 2001; Barta et al.,
2002; Boyter et al., 2005; George et al., 2006; Mehuys et al., 2010; Agh et
al., 2011; Cecere et al., 2012; Huetsch et al., 2012; Khdour et al., 2012;
Trivedi et al., 2012), or a mix of lung diseases including COPD, asthma,
bronchiectasis and other lung conditions (N=2) (Van Grunsven et al., 2000;
George et al., 2005). The studies that examined the aspects of operation of
inhalation devices and identified the frequency and range of problems
experienced in their use were conducted mostly among patients with asthma
and COPD (N=8) (Hesselink et al., 2001; Molimard et al., 2003; Ho et al.,
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2004; Sestini et al., 2006; De Moraes Souza et al., 2009; Rootmensen et al.,
2010; Hämmerlein et al., 2011; Melani et al., 2011), or COPD only (N=3)
(Lenney et al., 2000; Wilson et al., 2007; Khassawneh et al., 2008).
2.2.1 Measures employed for data collection on medication-taking
behaviour
Adherence among COPD patients has been found to be suboptimal.
However, caution must be taken before drawing conclusions due to the wide
variation in the estimated rates of non-adherence reported in previous
studies, which ranged from 28% (Van Grunsven et al., 2000) to 80%
(Huetsch et al., 2012). As a result, treatment failures were a major concern
for patients with COPD. However, this variation regarding the rate of non-
adherence could be due to the differences in patient populations, definition of
non-adherence, methods employed, disease status, or respiratory conditions
included in each study, as some studies included a variety of lung diseases
such as asthma and COPD.
The majority of research that has investigated medication-taking behaviours
(adherence) among COPD patients has employed quantitative approaches
(N=11) (Van Grunsven et al., 2000; Melani et al., 2001; Barta et al., 2002;
Boyter et al., 2005; George et al., 2005; Mehuys et al., 2010; Agh et al.,
2011; Trivedi et al., 2012; Huetsch et al., 2012; Cecere et al., 2012; Khdour
et al., 2012), by measuring the amount of medicine taken over a given time
period. There is a paucity of qualitative studies (N=1) that have investigated
patients’ adherence to their COPD medications; they have done so by
considering variables such as adherence decisions which were influenced by
patients’ beliefs about inhalation therapies and concerns of side effects
(George et al., 2006).
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There are a number of ways to measure adherence among patients with
COPD, and each method has its strengths and limitations. Most studies
focused on assessing medication adherence using self-report questionnaires
on medication utilisation (Melani et al., 2001; Barta et al., 2002; Boyter et al.,
2005; George et al., 2005; Agh et al, 2011; Khdour et al., 2012); others used
prescription refill rate by reference to pharmacy records of dispensed
prescription or manual recording of collected prescriptions (Mehuys et al.,
2010; Cecere et al., 2012; Huetsch et al., 2012; Trivedi et al., 2012). One
study used a semi-structured questionnaire (George et al., 2006) to explore
factors associated with adherence from COPD patients’ perspectives. To
measure the adherence, these studies included either multiple COPD
medications (Van Grunsven et al., 2000; Melani et al., 2001; Barta et al.,
2002; Boyter et al., 2005; George et al., 2005; George et al., 2006; Mehuys
et al., 2010; Agh et al., 2011; Khdour et al., 2012), or certain drugs such as
long-acting beta-agonists (Trivedi et al., 2012; Huetsch et al., 2012; Cecere
et al., 2012), corticosteroids (Huetsch et al., 2012; Cecere et al., 2012), or
ipratropium bromide (Huetsch et al., 2012).
The most commonly used self-report methods to measure the COPD
medication adherence were the Morisky scale (Agh et al., 2011; Khdour et
al., 2012) and the Medication Adherence Rating Scale (MARS) (George et
al., 2005), which are well-validated tools used widely for all chronic conditions
including COPD (see Chapter four for more information about the strengths
and weaknesses of different approaches and methods).
2.2.2 Non-adherence rates among patients with COPD
Previous reports have identified non-adherence to inhalation therapy in more
than 50% of COPD participants in seven different studies (Melani et al.,
2001; Boyter et al., 2005; George et al., 2005; Mehuys et al., 2010; Trivedi et
al., 2012; Huetsch et al., 2012; Cecere et al., 2012), whereas four studies
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reported adherence at >50% of the sample (Van Grunsven et al., 2000; Barta
et al., 2002; Agh et al., 2011; Khdour et al., 2012). As a result, treatment
failures might be a concern for patients with COPD.
2.2.3 Patients’ identification as adherent/ non-adherent
Three studies defined adherence to COPD medication as taking 80% of
doses as prescribed (Appendix 1) (Trivedi et al., 2012; Huetsch et al., 2012;
Cecere et al., 2012). Another method was based on the definition used by
previously validated questionnaires such as 4-item Morisky (patients scoring
3 or above were classified as ‘adherent’) (Agh et al., 2011; Khdour et al.,
2012), or the MARS score (a score of 25 indicates perfect adherence)
(George et al., 2005).
2.2.4 Factors contributing to medication use among COPD patients
The use of inhalation therapy was found to be influenced by patients’
decision, which in turn was guided by many factors. The most frequently
reported factors that influenced the use of medicines among COPD patients
were actual and perceived efficacy and safety of the inhalation therapy (Barta
et al., 2002; George et al., 2005; Huetsch et al., 2012; Cecere et al., 2012;
Khdour et al., 2012), socio-demographic factors, including age (Mehuys et
al., 2010; Agh et al., 2011; Trivedi et al., 2012; Huetsch et al., 2012; Cecere
et al., 2012), educational level (Cecere et al., 2012),  and ethnicity (Cecere et
al., 2012), in addition to the complexity of drug regimen (George et al., 2006;
Mehuys et al., 2010; Agh et al., 2011; Cecere et al., 2012). Other reported
factors include: smoking status (Agh et al., 2011; Cecere et al., 2012; Khdour
et al., 2012); disease severity (Huetsch et al., 2012; Cecere et al., 2012;
Khdour et al., 2012); presence of other co-morbidities (Huetsch et al., 2012;
Khdour et al., 2012); running out of medications (George et al., 2006);
forgetfulness (Melani et al., 2001); and presence of symptoms (Barta et al.,
2002; Cecere et al., 2012); in addition to social supports (Trivedi et al., 2012).
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All these factors were found to have an influence on patients’ decisions on
not to use the inhalation therapy, which might put patients with COPD at risk
of treatment failures.
2.2.5 Problems encountered with the use of inhalation devices in
regards to the inhalation technique
Eleven studies were found in the literature examining and identifying the
frequency and range of problems experienced by COPD patients in terms of
operation of the inhalation devices and performing the inhalation technique,
including: pMDIs alone or with large-volume spacers (Ho et al., 2004), DPIs
alone including Accuhaler, Turbohaler, Handihaler, and Aerolizer (Wilson et
al., 2007), or a combination of both pMDIs and DPIs (Lenney et al., 2000;
Hesselink et al., 2001; Sestini et al., 2006; Khassawneh et al., 2008; De
Moraes Souza et al., 2009; Rootmensen et al., 2010; Melani et al., 2011;
Hämmerlein et al., 2011). In all studies, COPD patients were found to be
using a combination of inhalation devices either from the same class (Ho et
al., 2004; Wilson et al., 2007), or different classes (Lenney et al., 2000;
Hesselink et al., 2001; Sestini et al., 2006; Khassawneh et al., 2008; De
Moraes Souza et al., 2009; Rootmensen et al., 2010; Melani et al., 2011;
Hämmerlein et al., 2011). These devices were commonly used to deliver
mainly the following: salbutamol by pMDIs, salmeterol/fluticasone by
Accuhalers; terbutaline and formoterol/budesonide by Turbohalers;
salbutamol, salmeterol/beclometasone or fluticasone by Accuhaler;
formoterol by Aerolizer and tiotropium by Handihaler.
2.2.6 Checklists for the inhalation technique assessment
Most previous studies have adopted checklists for the inhalation technique
assessment among COPD patients. They have been based on previously
published checklists or by using checklists given by pharmaceutical
companies or medical leaflets (Lenney et al., 2000; Molimard, et al.,
Chapter 2 - Review of the literature
64
2003;Sestini et al., 2006; Wilson et al., 2007), or previously published criteria
by Newman checklist, 2005 (Melani et al., 2011), or Van der Palen and
Beerendonk checklists in 1995 and 1998 (Rootmensen et al., 2010), or Plaza
et al., 1998; Steier et al., 2003; Molimard et al., 2003; Muchão et al., 2008
(De Moraes Souza et al., 2009), or Connolly, 1995 (Ho et al., 2004). Two
other studies developed their own checklists, based on information from the
drug information centre of the German Association of Pharmacists
(Hämmerlein et al., 2011), or the Dutch Asthma Foundation (Hesselink et al.,
2001).
2.2.7 Definition of inadequate inhalation technique
The majority of studies (N=9/11) defined the essential steps for optimal
delivery of the active drug into the lungs for each device. When one or more
deviations were made regarding these essential steps, the inhalation
technique was defined as inadequate or incorrect, potentially resulting in
suboptimal drug delivery to the lungs (Lenney et al., 2000; Hesselink et al.,
2001; Molimard, et al., 2003; Ho et al., 2004; Sestini et al., 2006; Wilson et
al., 2007; Khassawneh et al., 2008; Rootmensen et al., 2010; Melani et al.,
2011). Despite the importance of defining the adequate inhalation technique,
past studies have not used validated instruments when assessing the
inhalation technique. Only one study (Rootmensen et al., 2010) used a
validated scoring method, which involved viewing and assessing a video-
recorded inhalation demonstration by participants using device-specific
checklists and mutually agreed scoring rules by raters. Many past studies
have assessed inhalation technique among patients with a number of lung
diseases including asthma and COPD (Hesselink et al., 2001; Ho et al.,
2003; De Moraes Souza et al., 2009; Rootmensen et al., 2010; Hämmerlein
et al., 2011; Melani et al., 2011). Two of those have shown that COPD
patients made or were more likely to make more deviations from the
recommended inhalation technique when using their inhalers than those with
asthma (De Moraes Souza et al., 2009; Melani et al., 2011). Some other past
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studies have included only one class of device in the assessment process,
such as pMDIs only (Ho et al., 2004) or DPIs only (Wilson et al., 2007). No
previous study assessed the inhalation technique using all three classes of
inhalation devices to examine what device was associated with more errors
or deviations when assessing the technique.
To maximise the accuracy of the findings, some studies included more than
one rater in the assessment process (Lenney et al., 2000; Molimard et al.,
2003; Sestini et al., 2006; Wilson et al., 2007; Rootmensen et al., 2010;
Melani et al., 2011), whilst others included only one rater (Ho et al., 2004; De
Moraes Souza et al., 2009; Hämmerlein et al., 2011).
2.2.8 Deviations and problems encountered by COPD participants
when using their inhalation devices
In past studies, participants using pMDIs and DPIs were found to handle their
inhalation devices erroneously as the percentage of participants with COPD
who made at least one deviation from the recommended technique ranged
from 2.9% (Ho et al., 2004) to 94.2% (De Moraes Souza et al., 2009). The
percentage of COPD participants who made at least one deviation from the
recommended inhalation technique was greater among pMDIs users than
DPIs users (Lenney et al., 2000; Hesselink et al., 2001; Khassawneh et al.,
2008; De Moraes Souza et al., 2009; Rootmensen et al., 2010). However,
different studies by Melani et al (2011) and Ho et al (2004) reported that
pMDIs were correctly used by most patients, especially with large volume
spacers (Ho et al., 2004; Melani et al., 2011). Three studies found no
significant difference between the pMDIs and DPIs; therefore, they were
handled similarly by all patients (Lenney et al., 2000; Ho et al., 2004;
Hämmerlein et al., 2011). Examining the inhalation technique among COPD
patients with different devices is important, to detect whether users are using
them effectively or not, as suboptimal techniques affect the drug delivery and
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moderate the efficacy of the therapy and are a cause of treatment failures
and poor clinical outcomes (Rootmensen et al., 2010).
For the pMDIs, the steps concerning shaking inhaler (the canister) well
before use and actuating while inhaling deeply and slowly were the most
frequently performed incorrectly, with the inhaler not being shaken (N=7)
(Hesselink et al., 2001; Molimard, et al., 2003; Ho et al., 2004; Sestini et al.,
2006; Khassawneh et al., 2008; Rootmensen et al., 2010; Melani et al.,
2011), or the device being fired before start of inhalation or after end of
inhalation (N=4) (Ho et al., 2004; Sestini et al., 2006; Khassawneh et al.,
2008; Rootmensen et al., 2010). For the DPIs, the most common errors were
in not exhaling away from the inhaler before inhalation or exhaling into the
mouthpiece (N=5) (Molimard, et al., 2003; Sestini et al., 2006; Rootmensen
et al., 2010; Melani et al., 2011; Hämmerlein et al., 2011), and no/short
holding of breath for less than five seconds (N=4) (Molimard, et al., 2003;
Sestini et al., 2006; Melani et al., 2011; Hämmerlein et al., 2011).
Further studies of inhalation technique in DPIs (Accuhaler, Turbohaler,
Aerolizer, Handihaler and Diskhaler), reported that the percentage of COPD
participants who made at least one deviation from the recommended
inhalation technique when using DPIs was more when using single-dose
DPIs such as Handihaler (Wilson et al., 2007) and Aerolizer (Wilson et al.,
2007; Khassawneh et al., 2008; De Moraes Souza et al., 2009) than when
using the multiple-dose DPIs such as Turbohaler and Accuhaler. These
findings were contradicted by two other studies documenting that the
essential errors which compromise treatment efficacy were made more
among Turbohaler users than other DPI users using Aerolizer and Accuhaler
(Molimard et al., 2003) or Handihaler and Accuhaler (Melani et al., 2011).
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2.3 Discussion
This review brought together the information in the current literature
regarding how COPD patients use inhaled medicines or inhalation devices. In
previous studies, medicine taking or adherence to COPD medicines was
found to be suboptimal, influenced by several factors, such as patients’
perceptions about the efficacy and safety of the inhalation therapy. However,
careful attention must be paid before coming to such a conclusion because of
the wide discrepancy reported in the rates of non-adherence to COPD
medication, which ranges from 28% to 80%. This variation can be explained
by the dissimilarities in COPD population (e.g. age, disease severity,
smoking history, etc.), the differences in adherence/non-adherence definition
and the variation of methods employed. The results are also limited by the
duration of some studies, which ranged from two weeks (Boyter et al., 2005)
to six months (Cecere et al., 2012; Huetsch et al., 2012), and 12 months
(Mehuys et al., 2010). Although a number of instruments and methods have
been used to measure adherence, there was no gold standard method for
measuring medicine taking due to the advantages and disadvantages of
each method. For example, the easiest way to measure medicine taking is to
collect information from the patients themselves through questionnaires.
However, self-reporting methods may overestimate adherence (Smith, 2010).
Therapeutic drug monitoring also may overestimate adherence because
some patients tend to comply better for a short period of time before the drug
test (Smith, 2010).
The use of inhalation therapy was found to be influenced by patients’
decisions, which in turn were guided by many factors. However, the most
frequently reported factor that influenced the use of medicines among COPD
patients was actual and perceived efficacy and safety of the inhalation
therapy. However, there were some contradictory results among these
studies. For example, in four studies, it was found that, as complexity of the
medical regimen increases (e.g. the number of medications, frequency of
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dosage, etc.), medicine taking decreases (George et al., 2006; Mehuys et al.,
2010; Agh et al., 2011; Cecere et al., 2012), whereas the same factor was
not a significant predictor of non-adherence in George et al.’s, study (2005).
Other studies have shown that disease severity or the decline in the FEV1%
may be either not (Agh et al., 2011) or negatively (Cecere et al., 2012;
Khdour et al., 2012) related to medicine taking. Others have shown that
adherence is related to age: some authors found that, among adults, older
age had a positive association with medicine taking (Mehuys et al., 2010;
Agh et al., 2011), while others (Mehuys et al., 2010; Agh et al., 2011; Trivedi
et al., 2012; Huetsch et al., 2012; Cecere et al., 2012) found that older age
had a negative association with medicine taking due to risk of memory loss
and cognitive impairment, which are associated with age and may adversely
affect adherence.
This review demonstrates that incorrect use of inhalation devices is very
common among patients with COPD and is more frequently associated with
the use of pMDIs than DPIs. This review reveals suboptimal use and a wide
range of problems with inhaler handling among COPD patients. However,
very little is known about how and why problems arise. Therefore, there is a
need for studies that examine how patients make decisions regarding the use
of inhalers especially when a combination of inhalation devices is used at
home, and how those decisions and difficulties may contribute to suboptimal
outcomes and treatment failures.
2.4 Conclusion
Despite the extensive research, the review has illustrated that adherence to
COPD medications was suboptimal among COPD patients. Therefore,
COPD patients might be at risk of treatment failures, as the non-adherence
misuse of inhalation therapy remains an unresolved problem. Most published
studies have found that patients had many problems with inhalation
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technique, but this is different based on the used device. Therefore, the
research questions of the main study were:
 How do COPD patients use their multiple inhalation devices in the
management of their condition?
 How do they use their COPD medication in the context of their daily
lives and what beliefs and perceptions do they have in regards to the
efficacy and safety of the inhalation therapy.
 What are the frequency and range of problems experienced by COPD
patients in technical aspects of the operation, cleaning and
maintenance of inhaler equipment that may lead to suboptimal care or
treatment failure?
 What is the role of carers and what are the types of assistance with
medicines provided for COPD patients by family and friends.
 What are the priorities and concerns for patients in the context of
current and potential future service provision?
In addition to the evidence provided by previous research which informs the
research questions, preliminary fieldwork and discussion with Pinn Medical
Centre staff about this study were conducted, to identify the initiatives that
will be focused on in this study to contribute to the existing literature in
regards to the use of multiple inhalation devices by COPD patients in their
homes and to highlight the priorities and concerns of healthcare prescribers
in regards to the use of COPD medicines by COPD patients.
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3 Chapter Three: Preliminary fieldwork and
discussion with Pinn Medical Centre Staff
This chapter describes the preliminary fieldwork which was conducted to
identify the priorities and concerns of healthcare prescribers in regards to the
use of COPD medicines and/or devices by patients.
3.1 The study aim
The study aim was to examine the use of multiple inhalation devices by
COPD patients in the management of their disease in the context of their
daily lives and to consider how patients may most effectively be supported.
To achieve this aim five objectives were written.
3.2 The study objectives
 To examine the use of multiple inhalation devices used in
combination by COPD patients in the management of their
condition.
 To examine COPD patients’ use of their medication in the context
of their daily lives, information requirements, beliefs and
perceived effectiveness and safety of therapy.
 To identify the frequency and range of problems experienced by
COPD patients in technical aspects of the operation, cleaning and
maintenance of inhaler equipment that may lead to suboptimal
care or treatment failure.
 To document the role of carers and the assistance with medicines
that patients receive from family and friends.
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 To identify the priorities and concerns for patients in the context of
current and potential future service provision.
Before the study was formally designed preliminary fieldwork was done,
included discussions with professionals from the Pinn Medical Practice. The
discussion concerned some of the issues identified in the literature or in
practice relating to the use of inhalation therapy by COPD patients and the
feasibility of conducting the study.
3.3 Preliminary field work and discussion with Pinn Medical Centre
This work is in partnership with Pinn Medical Centre.
3.3.1 The aim of preliminary field work
The aims of the preliminary fieldwork were the following:
 To consider healthcare professionals’ views, thoughts and concerns
on the proposed subject when designing the work.
 To review the study aim and objectives and/or suggest any other
aspects of which the researcher was unaware to build up the study
aim and objectives, as healthcare prescribers may have rich
experience of the issues that COPD patients had in the past which
would help to raise the researcher’s awareness of the possible issues.
 To identify the number of COPD patients who are registered at Pinn
Medical Centre and are currently using multiple inhalation devices at
home including pMDIs, DPIs and nebulisers.
 To obtain some information on what inhalers were the most commonly
prescribed or used by patients at home.
 To discuss the feasibility of conducting the study and inform on
suitable methods for collecting data and recruiting participants from
the perspective of potential participants.
 To help the researcher in preparing and reviewing the documentation
such as the invitation letters, the questionnaire and the reply slip.
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3.3.2 Meeting with healthcare professionals at Pinn Medical Centre
The respiratory specialist at Pinn Medical Centre, Dr. Tricia Robertson, was
contacted by the researcher and a formal meeting was arranged with her and
the research team at Pinn Medical Centre on the 7th of September 2011.
Discussions at the meeting were focused on the following: the total number
of COPD patients who are registered at Pinn Medical Centre and are
currently using multiple inhalation devices at home including pMDIs, DPIs
and nebulisers, in addition to approaches to recruit COPD patients, the data
collection process, and the selection and assessment of COPD patients.
3.3.3 The impact of the preliminary fieldwork on the development of
the study
The preliminary fieldwork informed the development of the study methods
(Figure 3-1) and the instruments that should be used in this study to meet the
study objectives. After consulting with academics and the respiratory
specialist, it was decided to recruit COPD patients from Pinn Medical Centre
as it is considered as a large medical practice that serves 20,000 patients
and covers a large geographic area of North West London. It includes people
of different different age groups, ethnicity, disease status and smoking
history. This would confer some generalizability. Preliminary discussion with
collaborators and medical staff indicated that Pinn Medical Centre has 116
patients with COPD who are prescribed a range of inhalation devices and are
eligible for this study. Therefore, it was decided to target those who are using
a combination of pMDIs, DPIs, and nebulisers. Based on the information
obtained on the day of the meeting, the most appropriate way to approach
these COPD patients was to send an invitation letter to their home address
asking them to take part in this study. In addition to that, interviewing COPD
patients in their homes was seen as the most suitable method for data
collection and this will be described in depth in the next chapter. Therefore,
the preliminary fieldwork along with the literature review helped in developing
the study objectives and informing the choice of methods.
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Figure 3-1: Methodological design employed for the main study.
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4 Chapter Four: Research context and methodology
This chapter lists the aim and objectives of the main study and explores what
methods were the most appropriate to be used to meet the study aim and
objectives. In addition, it discusses the different methods used for data
collection and highlights the purpose of selecting a specific method over
others, followed by a discussion of how the data collection process was
carried out and the approaches taken to data analysis.
4.1 The study aim
From the review of the available literature, the study aim was to examine the
use of multiple inhalation devices by COPD patients in the management of
their disease in the context of their daily lives and to consider how patients
may most effectively be supported. To achieve this aim, five objectives were
written. These are:
 To examine the use of multiple inhalation devices used in
combination by COPD patients in the management of their
condition.
 To examine COPD patients’ use of their medication in the context
of their daily lives, information requirements, beliefs and
perceived effectiveness and safety of therapy.
 To identify the frequency and range of problems experienced by
COPD patients in technical aspects of the operation, cleaning and
maintenance of inhaler equipment that may lead to suboptimal
care or treatment failure.
 To document the role of carers and the assistance with medicines
that patients receive from family and friends.
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 To identify the priorities and concerns for patients in the context of
current and potential future service provision.
4.2 Study design
The study was undertaken during the period between February 2011 and
May 2014. This was a cross-sectional study design that took a mixed
methods approach using qualitative and quantitative methods and
observations of inhalation devices’ use with patients in their own homes. The
qualitative method included conducting semi-structured interviews with
COPD patients, in order to examine how patients make decisions regarding
the use of inhalers especially when a combination of inhalation devices were
used at home, and how those decisions and difficulties may contribute to
suboptimal outcomes and treatment failures to optimise medicine use,
therefore improving treatment outcomes. The quantitative method involved
administering questionnaires to measure the extent or the rate of non-
adherence (8-item MMAS) among COPD patients, patients’ beliefs about
their COPD medicines (BMQ), and inhalation technique assessment for each
patient individually using device-specific checklists. A retrospective review of
patients’ medical records in the surgery, including patients’ clinical data, was
also conducted to complement and validate the results obtained from the
face-to-face interviews. The data were collected from May 2012 to December
2012. Table 4-1 shows a summary of the methods used to fulfil research
objectives.
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Table 4-1: Summary of the used methods
4.3 Rationale for the chosen methods
4.3.1 Rationale behind choosing mixed methods approach (Qualitative
and quantitative)
The term “mixed methods research” refers to the type of research in which a
researcher combines elements of qualitative and quantitative research
approaches (Smith, 2010). Using a mixed method approach in a study was
useful because it enables generation of new knowledge and enhances the
validity of the research by, firstly, collecting the data from a variety of sources
qualitatively and quantitatively, which leads to greater validity than when
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either was used alone (Richey and Klein 2007); and, secondly, by answering
the research questions from a number of perspectives and confirming that
there was no gap in the data collected which cannot be met with the use of
one method (Smith, 2010; Hunter, 2011).
A mixed methods approach was used in this study in order to collect
qualitative and quantitative viewpoints, data and techniques for the reason of
developing broadness and a more complete knowledge and understanding of
the use of multiple inhalation devices by chronic obstructive pulmonary
disease patients in primary care, in order to develop or test theories,
compare groups or make strong predictions about the reasons for treatment
failures. This method was selected when the researcher and her team
believed that neither qualitative nor quantitative approach alone would
answer the research questions. Therefore, one method will inform the other.
A mixed method approach to research was referred to as triangulation. In the
construction of this research, the data were triangulated after collecting the
information from different sources, to ensure the validity of the data and allow
more accurate assessment (Smith, 2010; Hunter, 2011). In research this was
referred to as ‘triangulation’, which is defined as the use and comparison of
two or more methods of data in the same study, to make sure there was
enough evidence to make valid claims (Smith, 2010).
A triangulation was used in this study by collecting data through the following
sources: semi-structured interviews using a questionnaire comprising open
and closed questions, patients’ GP records’ review, and observational
method using inhalation technique and cleaning checklists with comment
boxes. When conducting this study, participants were observed and asked
questions to provide different perspectives on a set of issues related to the
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study aim and objectives. For example, it was aimed to examine how COPD
participants use and operate their inhalation devices, what they like or dislike
about them, what kind of problems they had with different inhalers, what
worked and what did not work, and how they clean and store their inhalers.
Therefore, to answer these questions, COPD participants were asked and
observed by the researcher to operate their devices and conduct the
inhalation technique, and to show and explain how these devices were
usually cleaned and stored using device-specific checklists with comment
boxes to be filled out by the researcher, to identify whether these participants
have any difficulties or problems when operating their devices. In addition to
this, participants were asked different questions through a questionnaire
about how they use their inhalers and whether they have/had experienced
any problem when using their devices in their homes.
Another example for triangulation was that when participants were asked
about their current COPD medicines and what they had been using in the
past, the data obtained from the interviews were compared with data
obtained from medical notes in the GPs’ surgery to see if participants were
accurate about what they had said. Moreover, in regards to patients’
adherence and beliefs about their COPD medicines, the data obtained from
interviews were compared to the data obtained from the self-reported
questionnaires such as Morisky scale and BMQ to ensure data validity by
comparing data on the same variables that have been obtained in different
ways, which enables more reliable estimates to be made (Smith, 2010).
4.3.2 Rationale behind choosing face-to-face semi-structured interview
method
Although there are a diversity of methods and approaches involved in
collecting qualitative data, interviews seemed to be the most appropriate
method to meet the aims and objectives of this research. Face-to-face
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interviews are an efficient and practical way of obtaining data about things
which cannot be easily noticed such as how people use their inhalers in real
life and in action (e.g. when assessing the inhalation technique). The
interviews provide direct contact between the interviewer (the researcher)
and the participants (respondents), making it easier to build a relationship
with the respondents and obtain more meaningful, detailed information and
considered responses. Moreover, these direct interactions could have
allowed the interviewer to gain direct access to participants who might not
otherwise have been willing or able to take part due to the severity of their
disease or the existence of other illnesses which may have prevented their
participation. As an example, if a patient was given a survey or a structured
instrument to complete, literacy problems would have had to be addressed
(Scanlan, 2002). Further, it is recognised by Hunter (2011) and Smith (2010)
that this method generally has high validity through allowing the respondents
to talk about their use of medicines and any problem they have with their
COPD medicines in detail and depth (Hunter, 2011), and because the data
obtained from respondents were ‘first hand’, which means they did not
depend on others’ reports of what they see or do, which might or might not
be accurate (Smith, 2010). In addition, it was also recognised by Bowling and
Ebrahim (2005) that interviews may have a higher response rate than
questionnaires as they are a less formal method and allow immediate data
collection (Scanlan, 2002).
Another advantage of this type of interview is that it is often conducted in a
natural setting (patients’ homes), which allows important detailed valuable
information to be gathered because patients will be more comfortable talking
about their medicines if they are sitting at home. In addition, the response
rate is known to be generally higher with face-to-face interviews, compared to
telephone interviews or surveys that are sent through the post (Hunter,
2011). Receiving a questionnaire through the mail can be ignored due to lack
of personal touch (Hunter, 2011). Moreover, semi-structured interview can
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make use of prompts: questions which were used in this study to clear up
any confusion or misunderstandings about complex questions. Furthermore,
it allows the interviewer (researcher) to act as an observer, giving him/herself
the opportunity to focus on non-verbal cues and to record the interview using
audiotapes (Hunter, 2011).
Like any other methods, face-to-face interview has disadvantages: firstly, it
depends on the interviewer’s skills and his/her ability to question during the
interview and follow. Secondly, although this method has high validity
because the information is obtained directly from its original source (the
patient), the interviewer has no real way of knowing if the respondents
answered truthfully. However, respondents may not intentionally misinform
but they may have imperfect recall. For example, if they were being asked to
remember what COPD medicine(s) they used in the last 24 hours, they might
remember very little about what happened, thus giving inaccurate and
incomplete information (Hunter, 2011). Thirdly, in terms of reliability, in this
project the data were gathered on one occasion because it was sometimes
difficult to do the interview more than once with the same focus group using
face-to-face interview and also the sample size of this kind of method is
usually not big, ranging from 30 to 60 participants. Fourthly, this research
was conducted in the Pinner area (Zone 5 in London). The travel time was
between 40 and 50 minutes and the travel ticket cost more than £8 per day;
thus, it was expensive and time consuming.
Interviews were then selected as the most suitable method to examine the
use of multiple inhalation devices by COPD patients in the management of
their disease in the context of their daily lives, from their perspectives, and to
consider how patients may most effectively be supported.
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There are a variety of methods that can be used for data collection in a
qualitative approach such as in-depth structured, semi-structured and
unstructured interviews which can be used in interviews, group discussion or
focus groups, and participant and non-participant observational studies
(Bowling and Ebrahim, 2005). However, the semi-structured research
technique was seen as the most appropriate method to be used to meet the
study objectives. Semi-structured instruments consisted of pre-prepared
questions related to domains of interest (COPD disease and medicines)
applied to a representative sample of COPD participants to identify factors or
variables to be analysed (Smith, 2010).
The reason for choosing a semi-structured technique was because this
technique is the most commonly used qualitative method as it is a flexible
tool which enables the researcher to set an agenda for the interview to
discuss interesting replies further and to clarify points of ambiguity in
participants’ answers to any given question (Pope and Mays, 2006). Another
reason for selecting a semi-structured instrument was because, firstly, it can
make use of both close-ended questions (quantitative data) (e.g. Do you
sometimes forget to take your regular COPD medicines?) and open-ended
questions (qualitative data) (e.g. How many times in the last week have you
missed a dose of your regular COPD medicines and why?), which allows
quantitative and qualitative analysis to be undertaken. In this project this
method was considered to gather information about respondents’ adherence
and beliefs about COPD medicines using predetermined structured
measures (close-ended questions) and more detailed examination of how
COPD patients use their current inhalation therapy to manage their condition,
what they were using at the moment or what they had been using in the past,
what they feel about using different devices used in combination, what they
like or dislike about them, how they make decision about the use, what
problems did they have in the past with different inhalers, what works and
what does not work, using predetermined unstructured measures (open-
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ended questions). Qualitative approaches (open-ended questions) are known
to be the most appropriate for ‘how’ and ‘why’ questions (Smith, 2002). It
helps to illustrate the way people act and think; additionally, it explores
patterns and barriers in people’s thoughts and behaviours. This sharply
contrasts with quantitative research, in which the researcher may be testing a
hypothesis, or explaining phenomena by collecting numerical data that are
analysed using mathematically based methods (Seidman, 2012).
Secondly, this method is used in exploratory studies to collect a substantial
amount of information by setting up an interview and talk (like a conversation)
following an interview schedule, which draws on principles of qualitative and
quantitative approaches (Smith, 2002). All questions in the interview guide or
interview schedule were prepared in advance; however, some of which may
raised by respondents during the interview. Therefore, the actual direction
and content of the interview, in terms of issues discussed, were determined
by the respondents’ viewpoints and answers. Thus, the researcher was
prepared to consider new issues and ask questions throughout the interview
process, in order to get a deeper understanding of phenomena of interest in
context of patients circumstances or environment and with their reasoning
(Smith, 2010; Seidman, 2012), emphasising the point that semi-structured
interviews allow the researcher to observe and ask questions that lead to a
deeper understanding of phenomena (e.g. How many times in the last week
have you missed a dose of your regular COPD medicines?/Why do you miss
a dose of your regular medicines?) in the context of which they occur and to
clarify any unclear responses (Smith, 2010). In regards to this study, this
flexibility from the semi-structured instrument would not have been obtained if
a structured interview or self-completion questionnaire had been used and a
totally unstructured interview approach would not have ensured that the
same topics were discussed and covered by all participants (Scanlan, 2002).
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4.3.3 Rationale behind choosing self-reported Morisky 8-items
medication adherence scale (MMAS)
Eight-item Morisky was chosen in this study in order to evaluate the extent
and rate of non-adherence to the inhalation therapy among patients with
COPD and therefore provide recommendations and feedback to healthcare
professionals first and patients second and the required interventions for the
purpose of maximising patients’ adherence especially that adherence plays
an important role in determining the successful disease management, since
inadequate adherence can lead to treatment failures, suboptimal health
outcomes and increase healthcare costs. Therefore, accurate assessment of
adherence behaviours to COPD medicines is an essential component for
successful management of the condition.
Various self-report tools have been used in previous studies to measure
adherence behaviours and associated health beliefs and attitudes in both
general and specific patient populations. However, there is no “gold
standard” measure of medication adherence (Kim et al., 2000), but in the last
20 years the most commonly used tool to measure patients’ adherence to
medication is perhaps the 4-item original Morisky scale (Lichtenberg, 2010).
Although a direct self-report method such as a questionnaire may
overestimate adherence and may be subject to memory biases, it was
chosen as the method for assessing adherence in this study due to its
simplicity and feasibility for most settings including home settings (Smith,
2002). According to Horne et al., when selecting a self-report tool for
adherence assessment, a readily reliable and valid questionnaire must be
used because it is the most efficient, cost-effective, and time-saving method
of assessing adherence, related beliefs and attitudes (Horne et al., 1999).
From a clinician’s point of view, self-reports are the most workable and useful
measures of adherence (Turner et al., 1995), as they can identify the reasons
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behind non-adherence along with its detection, which could then help in
addressing those underlying issues. When self-report and clinical
observations are combined, they have been shown to have better accuracy
than self-report alone (George et al., 2006).
From the researcher’s point of view, each method has advantages and
disadvantages; some are preferred in one setting than others. For example,
using direct measures which use drug metabolite in the urine or blood can be
useful in hospital settings where the laboratory can be accessed easily to
obtain the result, whereas prescription refill rate might be good for pharmacy-
setting studies where the patients’ drug history can be accessed as well.
Others such as patient self-reports and pill count can be more useful in
home-setting studies that involve treatment that the patient carries out at
home, by asking the patient several questions about medicine taking to get
the answer or counting the medication left in the patient’s drug bottle.
However, using patient self-report method or pill count does not guarantee
the accuracy of the result because some patients may want to please the
healthcare professional or the researcher by giving them incorrect
information about medicine taking maybe deliberately or in-accidentally.
This study was conducted in patients’ homes; therefore, the patient self-
report method was considered. Although pill count seems more reliable than
self-report method because the researcher will count the medication left
without relying on patients’ stories, it is a time-consuming process and there
is no assurance that the medicines missing from the inhalers were actually
taken by patients. As a result, it was decided to use the patient self-report
method to gather the information on adherence (Fairly et al., 2005).
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Having chosen self-report as the preferred method for assessing adherence,
the next step was to select which self-report questionnaire to include. Various
self-report tools have been used for studying adherence behaviours, and
associated health beliefs and attitudes in both general and specific patient
populations. However, it was decided to use the Morisky scale to measure
adherence as it is the most commonly used measure of adherence and can
distinguish between intentional and non-intentional non-adherence (George
et al., 2006). Moreover, the Morisky scale has shown to be correlated with
other measures of adherence (O’Donohue and Levensky, 2006) such as pill
count (Haynes et al., 1980) and pharmacy records (Fairly et al., 2005).
The Morisky scale was developed by Morisky and colleagues in 1986. It was
originally developed to measure adherence to antihypertensive medications
using a validated 4-item scaled questionnaire. After that, it has been used to
evaluate adherence across a wide variety of health conditions including
asthma and COPD (Agh et al., 2011). The Morisky instrument was validated
in a number of studies and shown to have good psychometric properties, and
adequate internal consistency (α=0.61), sensitivity (81%), and specificity
(44%) (Morisky et al., 1986). The four-item scale consists of the following
questions:
1. "Do you ever forget to take your medicine?"
2. "Are you careless at times about taking your medication?"
3. "When you are feeling better, do you sometimes stop taking your
medications?"
4. "Sometimes if you feel worse, do you stop taking your medications?"
To score the Morisky scale, each question that is answered with a "no"
receives a score of 1 and each "yes" answer receives a score of 0. The
possible scoring range is therefore 0 to 4. Patients who answer "no" to four of
these questions are classified as high adherence; those with two to three
"no" responses are classified as medium adherence; and those who answer
"no" to none or one of these questions are classified as low adherence.
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Although the original Morisky scale illustrated the ability to predict adherence,
it was not formed to describe patient’s long-term continuation of therapy,
which is considered to be an essential factor in the long-term management of
chronic diseases. Also, the Morisky scale was not originally designed to
categorise patients into a low/high continuum for motivation and knowledge.
As a consequence, additional items were added to better capture barriers
surrounding adherence behaviour (Morisky et al., 2008). A new 8-item self-
report Morisky Medication Adherence Scale (MMAS) includes the following
questions
5. Do you know the long-term benefit of taking your medicine as told to you
by your doctor or pharmacist?
6. Sometimes do you forget to refill your prescription medicine on time?
7. Taking medication every day is a real inconvenience for some people. Do
you ever feel hassled about sticking to your treatment plan?
8. How often do you have difficulty remembering to take all your
medications? (Please circle the correct number).
All questions on the 8-item MMAS are answered on a "yes" or "no" scale
except question number 8 which is answered on a "Never/Rarely", "Once in a
while", "Sometimes", "Usually" or "All the time" scale. Each "no" answer to
items 1-7 receives a score of 1 and each "yes" answer receives a score of 0
except question number 5 where a "no" answer receives a score of 0 and a
"yes" answer receives a score of 1. Question number 8, which asks
participants to rate the difficulty remembering to take all their medicines, is
scored as follows (never/rarely = 4, once in a while = 3, sometimes = 2,
usually = 1, all the time = 0). Item 8 was standardised by dividing this item by
4. The MMAS scores can range from 0 to 8, which have been categorised as
high, medium and low adherence (MMAS score of 8, 6 to <8, and <6,
respectively) (Morisky et al., 2008).
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The new scale has been determined to have a higher reliability and better
psychometric properties compared with the 4-item scale (α=0.83 vs. α=0.61)
(Morisky et al., 2008). As the 8-item self-report Morisky Medication
Adherence Scale (MMAS) showed a good reliability and favourable
psychometric properties and had been validated in a large patient population
with chronic conditions (Morisky et al., 2008), it was decided to use it for
measuring participants’ adherence in this study.
4.3.4 Rationale behind choosing Beliefs about Medicines
Questionnaire (BMQ)
In this study, the researcher aimed to know what patients think about their
COPD medicines in terms of overall drug necessity and concerns from their
perspective. Therefore, patients’ beliefs about the necessity of their COPD
medication and concerns about adverse effects were measured and
examined.
To improve adherence to treatment and therefore clinical outcomes, it might
be important to consider patients’ beliefs about medicines, especially given
that patients’ beliefs have been associated with medication adherence
(Horne et al., 1999). Therefore, it was crucial to examine beliefs of patients
with COPD about their therapy and investigate if these beliefs had any
influence on patients’ decisions to use or not to use the inhalation therapy,
which may lead to treatment failures and suboptimal outcomes. The beliefs
that patients have about their medicines have been shown to be an important
factor that influences medication-taking behaviours among COPD patients in
previous studies (Barta et al., 2002; George et al., 2005; Huetsch et al.,
2012; Cecere et al., 2012; Khdour et al., 2012). Therefore, measuring
patients’ beliefs about medicines can also provide a new angle and important
knowledge which may be used in optimising medicine taking, and it can be a
good reference for future intervention studies aiming at improving medicine
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taking in patients with COPD, resulting in optimising medicine use and
improving treatment outcomes.
To measure the above domain (beliefs about medicines), it was agreed to
adapt a suitable questionnaire from the literature which provides a reliable
response and a valid reflection of the issues to be measured as well as being
efficient and effective in collecting data of interest (Smith, 2002). Therefore,
the Beliefs about Medicines Questionnaire (BMQ) was considered.
The BMQ was developed by Horne in 1999, to assess commonly held beliefs
about medicines, and was validated on several medical samples including
COPD. This scale is comprised of two sections, the BMQ general and the
BMQ specific. The first section (the BMQ general), relating to beliefs about
medicines in general, also comprises two factors, general-overuse (beliefs
that medicines are overused by doctors) and general-harm (concerning
beliefs regarding the harmful effects of medicines). The second section (the
BMQ specific) comprises two factors, specific-necessity and specific-
concerns; both are related to beliefs about necessity of prescribed
medication and concerns about adverse effect. A patient with COPD is
usually given complex medication regimens including multiple drugs (inhalers
or tablets) with different frequencies and dosing schedules, some of which
may have many adverse effects, such as steroids, which might cause a
burden in medicine taking. In this study, it was decided to use the BMQ
specific tool because choosing a disease-specific instrument was preferred to
focus on a single specific disease and the personal beliefs patients have
about the necessity of prescribed COPD medication and concerns about
adverse effects.
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The BMQ is a reliable tool, and has been validated for use across a range of
different diseases including asthma, renal, cardiac and general medical
illnesses (Horne and Weinman, 1999). In the BMQ, participants were asked
to rate their agreement with a specific statement using a 5-point Likert scale
(1=strongly disagree, 2= disagree, 3=uncertain, 4=agree, 5=strongly agree).
The scores of each subscale were computed from the sum of all items within
that particular subscale and range from 5-25 from both subscales – BMQ
necessity and BMQ concerns. In addition, the necessity-concerns
differentials were computed by subtracting the total BMQ concerns subscale
score from the total BMQ necessity subscale score. A positive differential
score indicates that participants perceive the benefits of their medication to
outweigh their concerns about the risk of the medication. In contrast, a
negative differential score indicates that participants perceive the risk of
taking their medication to outweigh the benefits. The differential scores range
from -20 to 20 (Horne and Weinman, 1999).
4.3.5 Direct observation
From previous studies, it was seen that a high number of COPD patients use
their inhalers inappropriately and made many deviations when performing the
inhalation technique from what is recommended by the published guidelines.
The percentage of participants with COPD who made at least one deviation
from the recommended technique ranged from 2.9% (Ho et al., 2004) to
94.2% in previous studies (De Moraes Souza et al., 2009). Any deviation
from the published guidelines in regards to the recommended inhalation
technique may lead to insufficient drug delivery thus reduction in the clinical
effectiveness of the inhalation therapy and treatment failures. Therefore, in
this study, participants were asked to provide a practical demonstration of
their inhalation technique for the most difficult device used at home. If none,
they were asked to provide a practical demonstration for the most used
device at home using a placebo device. This was done under the supervision
of or by direct observation from the researcher. This was done to see what
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inhalers were more frequently associated with an incorrect inhalation
technique for the most used device at home among COPD patients; and,
additionally, to identify the frequency and range of problems experienced by
COPD patients in technical aspects of the operation which may lead to
suboptimal care or treatment failure.
One of the advantages of direct observation is that data were ‘first hand’
which means they do not depend on individuals’ reports of what they see or
do, which might or might not be accurate (Smith, 2010). However, it is often
not feasible especially for studies that involve large samples because an
observer (the researcher) can be present only in one site at a time. A further
disadvantage is that the validity of data collected might not be good because
of the ‘Hawthorne effect’, which is defined as a form of reactivity whereby
subjects modify or improve an aspect of their behaviour being experimentally
measured simply in response to the fact that they know they are being seen
or studied (Smith, 2010).
4.3.5.1 Obtaining placebo devices from pharmaceutical companies
Pharmaceutical companies were approached by the researcher with the aim
of obtaining placebo devices for an independently funded study. Placebo
devices were used in this research for two reasons: firstly, to identify the
frequency and range of problems experienced by COPD patients by
observing how patients use their inhalation devices in their homes and how
they perform the inhalation technique correctly and effectively without
inhaling the actual dose or the active drug; secondly, to minimise the risk of
cross-infection if the same device was used by different patients. Therefore,
an attempt was made by the researcher to contact the medical information
officers of all relevant pharmaceutical companies (e.g. GlaxoSmithKline,
Pfizer, and AstraZeneca), to ask them to provide a number of placebos such
as pMDIs, Accuhaler, Handihaler, and Turbohaler (see Appendix 3).
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Before considering delivery of placebo devices, some companies asked for a
full protocol which should be approved by the UK Research Ethics
Committees. In addition, the researcher stated that any gift of placebo
devices from any source will be acknowledged in the PhD thesis, or in any
publications arising from it. After providing all the necessary documents and
explanations, AstraZeneca responded immediately and the request was
actioned in a few days. Therefore, a pack of 20 Turbohalers was sent to the
researcher. After a couple of weeks, no response was received from the
other companies. Therefore, a reminder email was sent. Although the
response was very slow and many communications were made over the
telephone, eventually the researcher was given all the placebos she
requested from each company (see Appendix 4)
4.3.5.2 Developing checklists for the inhalation technique
assessment
In developing check-lists to assess the inhalation technique for each device,
the researcher must ensure that these check-lists are effective in gathering
the data for the study objectives, and that they are workable, feasible and
acceptable in the study settings (Smith, 2010). Three device-specific check-
lists (Appendix 5), were developed for all classifications (pMDIs with or
without spacer, breath-actuated pMDIs; DPIs, device specific check-lists; and
nebulisers), to identify the frequency and range of problems experienced by
COPD patients in technical aspects of the operation and cleaning of inhaler
equipments that may lead to suboptimal use or treatment failure. These
check-lists were then reviewed by the researcher supervisor Prof. Taylor
(Professor in Clinical Pharmaceutics), who has been actively involved in the
preparation and characterization of formulations for delivery from nebulisers,
pMDIs and DPIs, to ensure that they are accurate, feasible and workable.
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Assessment of the inhalation technique was done using the previously
developed checklists for each inhaler. These checklists were developed
based on the previously published literature, guidelines set by different
professional organisations, and the package leaflet of each inhaler from the
pharmaceutical companies. These steps were divided into three columns that
contain yes, no, and a comment box to specify and give a description of the
problem. The number of errors made by the COPD participants was
compared for each device separately using SPSS program. The quantity of
errors made by COPD participants when using different devices was also
compared (see Chapter six).
Five types of inhaler device were examined for inhalation technique
assessments: three types of dry powder inhalers, Diskus/Accuhaler
(GlaxoSmithKline, UK), Turbohaler (AstraZeneca, Sweden), Handihaler
(Pfizer, USA), the pressurised metered-dose inhalator (pMDI) with or without
a spacer, and nebulisers. Briefly, the method of assessment consisted of a
direct observation of inhalation demonstrations, one time, for each patient,
using device-specific checklists.
4.4 Study setting
The study was conducted in patients’ homes in the Pinner, North Harrow,
Northwood and Northwood Hills areas of North West London. Using homes
as an interview site can be time consuming for the researcher. However,
conducting this research in patients’ homes had many advantages: firstly,
patients talked freely about their problems and needs due to being
interviewed in a familiar, more peaceful and nonmedical environment (Smith,
2010). Patients in their own homes may feel more relaxed to talk and give
details on how they use their medicines, problems they face and how they
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were dealing with them in the context of their real environment. However,
only a limited number of studies have been conducted in patients’ homes
among patients with COPD (N=6) (Van Grunsven et al., 2000; Melani et al.,
2001; Barta et al., 2002; Boyter et al., 2005; George et al., 2006; Sestini et
al., 2006).
Despite all these advantages, there was an ethical challenge raised by the
Research Ethics Committee (REC), when applying for approval for this
research, which required special consideration when conducting this
research in patients’ home. This challenge was related to the researcher’s
safety when visiting patients in their homes. In response to this and in
compliance with the ethical requirements, the researcher was asked to notify
another person from the research team of the time and location of the home
visit and carry a mobile phone to report when the visit had been completed.
In addition, participants have to be known to the collaborator or surgery staff
at the medical centre.
4.5 Sampling strategy
The aim of the sampling strategy was to obtain a sample which would meet
this study’s objectives. A sample was needed that would provide an
understanding of medication-taking behaviours of patients using multiple
inhalation devices for COPD.
Justification of the chosen medical centre and representativeness:
The selection of participants was conducted in Pinn Medical Centre by
medical centre staff through patients’ medical notes. Pinn Medical Centre is a
large medical practice that serves 20,000 patients and covers a large
geographic area of North West London. In addition, it includes people of
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different age groups, ethnicity, disease status and smoking history. This
would confer some generalisability. Moreover, preliminary discussion with
collaborators and medical staff indicated that Pinn Medical Centre has 116
patients with COPD who were prescribed a range of inhalation devices and
were eligible for this study. Therefore, it was seen that this site would be
enough to achieve the targeted sample size.
Justification of the sample size:
1. Based on previous studies among patients with respiratory diseases, it is
anticipated that the sample of 60 patients would enable us to achieve the
study objectives and will be able to reach saturation level (i.e., sampling
to the point at which no new information is obtained). However, the
researcher determined the sample size when no new topics, themes and
issues emerged from the data (when reaching saturation level).
2. This sample size of 60 patients is achievable within the time and
resources of the study. However, issues of availability and willingness of
patients to participant in this study affected the sample size.
3. The sample size and potential recruitment rate was based on discussions
with a member of practice staff and the research supervisors’ experience
of supervising a previous PhD project looking at the use of nebulisers in
this patient group: Alhadad, 2011, University of London.
4. The sample size was not based on probability statistics because this
study took a mixed methods approach, which means including some
descriptive or qualitative data. Therefore, the sample size of this kind of
research is often limited.
The later sections will discuss patient’s eligibility to enrol in this study, the
sampling procedure, recruitment of participants from primary care and
interview procedure for subjects with COPD.
4.5.1 Inclusion criteria
For COPD patients:
 Patients with a confirmed diagnosis of COPD from medical notes.
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 Patients who are over 18 years old.
 Patients who are prescribed at least two inhalation devices including
p-MDIs, DPIs and/or nebulisers.
 Patients who use their inhalers in their own home.
 Patients who are able to speak and understand English.
4.5.2 Sampling procedure and recruitment of participants from primary
care
Recruitment of patients from primary care:
Potential participants were identified by medical centre staff through patients’
medical notes. Patients’ information was obtained from their medical notes
after identification (Appendix 6). The following information was needed:
 Patients’ current and previously prescribed medicines: to get an
overview on what COPD medications patients use to manage their
condition, what they were using at the moment, for what, and what
they had been using in the past to manage their condition, and to
compare the information obtained from the medical notes in the GPs’
surgery with data collected from COPD patients themselves to see if
this corresponded with what they said and if they were taking their
medicines as prescribe.
 Presence of other conditions: to get an overview of what other
diseases or conditions COPD patients have which generally result in
more complex treatment regimens that may lead to problems with
medicines’ use.
 Patients’ details such as age and smoking status (if recorded).
All documentation and information packs were prepared by the researcher.
After identification of the potential participants, an information pack was sent
to eligible patients. The information pack included an invitation letter
(Appendix 7), information sheet (Appendix 8), and patient consent form
(Appendix 9). The patient consent form had to be read carefully, understood
and signed before the interview date. A reply slip (Appendix 10) with a pre-
paid envelope was also included in the information pack to be returned
indicating patients’ willingness to take part. The information sheet informed
potential participants of the purpose of the study, study procedure and how it
would be conducted, possible disadvantages and benefits from taking part,
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sponsorship, confidentiality of data and the researcher’s contact details. The
pack included a photograph of the researcher so that participants knew who
to expect if they participated in the study. In addition, if the participants
required any further information, all contact details of the researcher were
provided on all forms to give participants the opportunity to ask any question
before the interview date.
Patients who returned the reply slip indicating their willingness to take part
were contacted by the researcher to arrange a suitable date and time for a
home interview. The interviews with patients were conducted on one
occasion at their home.
4.6 The interview topic guide
The interview topic guide (Appendix 5) was informed by the literature and
designed to examine COPD patients’ use of their medication in the context of
their daily lives, information requirements, beliefs, and perceived
effectiveness and safety of therapy. In addition, these questions were
developed after consulting with academics and a respiratory specialist.
Respondents were invited to express their views regarding:
 How do COPD patients used their medicines to manage their
condition?
 What were they using or what had they been using in the past?
 What did COPD patients feel about using different devices used in
combination; what did they like or dislike about them?
 How did they make decisions about the use?
 What problems were experienced by COPD patients in technical
aspects of the operation, cleaning and maintenance of inhaler
equipment did they have? What worked and what did not work?
 What medicine-taking behaviours and beliefs about medicines did they
have?
 What kind of assistance with medicines did patients receive, if any?
The interview schedule consisted of open and close-ended questions that
defined the aim and objectives of this study. Closed questions were used to
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gather factual data (e.g. do you sometimes forget to take your regular COPD
medicines?), whereas open questions were used to expand the participant’s
viewpoints and experiences that were relevant to the topic of interest (e.g. for
your regular medicines, people often do not take their medicines exactly as
prescribed for different reasons, thinking of the medicines you use for your
COPD, when was the last time you did not take the dose of your regular
medicines and why?). Probing questions, on the other hand, were also used
during the interviews to gather more details regarding any important issues or
views outlined by the respondents, as recommended by Smith (2002). For
example, when was your (COPD/ bronchitis/emphysema) diagnosed? (Which
year or how long ago?). Leading questions were avoided as they could
introduce bias. In addition, participants were allowed to talk freely without
particular order (Smith, 2002). This allowed the exploration of topics
according to the importance placed on them by participants.
4.7 Permission to use the questionnaires
In order to comply with the copyrights of the developers for the chosen
instruments, a permission to use the questionnaires in this study was sought
from the developers. Authorisation to use the MMAS and BMQ were granted
free of charge from their developers.
4.8 Ethical approval
The required documents to apply for the Research Ethics Committee (REC)
were prepared ahead of the scheduled committee meeting on the 23rd of
December 2011 and enclosed with a cover letter for review. The sent
documents included the following: interview schedules, copies of the
questionnaires, letter of invitation, patients’ information sheet and all other
relevant materials. The IRAS form was also submitted to the REC and the
committee advised the researcher to respond to their emails and queries to
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provide further clarifications if needed. A copy of the Research Ethics
Committee (REC) application form, a list of questions, queries and issues
raised by the REC (North East REC centre) are attached in Appendix 11 and
Appendix 12.
The study was then independently reviewed and approved by Newcastle &
North Tyneside 2 Research Ethics Proportionate Review Sub-Committee
(North East REC centre) [11/NE/0392]. In addition, the study has also been
approved by [R&D of local PCT]. The letter of favourable opinion from NHS
REC or the provisional decision letter from NHS REC is attached as
Appendix 13.
4.9 Data collection
On the day of the interview with each participant, the researcher was wearing
an identification badge and introduced herself to the patient, explained the
study’s aim and objectives and read the information sheet with the
participant. The participant was given the chance to ask any question prior to
starting the interview. The participant was asked to sign the consent form,
after reading and understanding the patient information sheet if they had not
already done so. The researcher then asked the patient if the interview could
be audio-recorded. If the patient did not wish the interview to be audio-
recorded, field notes only were taken. Permission was sought to record
information about participants’ COPD such as FEV1, FVC, FEV1/FVC ratio
and all prescribed medicines on their medical notes at the surgery.
Participants were assured that only the research team will have access to
this information, which will be kept in a coded format during the study and
destroyed after completion of the study, and that they will be not identified in
the final report. Prior to the commencement of the interview, written consent
was obtained.
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Each interview with COPD participants took 45-60 minutes and followed a
semi-structured schedule. Firstly, participants were asked to show the
researcher all medicines they were using for their COPD and document the
use of each and report what they had been using in the past. Secondly, they
were asked about decisions they made to use/not use their therapy or
devices, missed doses, and technical and practical problems experienced
previously with the use of their devices. Thirdly, device-specific checklists
were used for all types to assess participants’ inhalation technique, so
patients were asked to provide a practical demonstration of their inhalation
technique for the most difficult device used at home. If none, they were asked
to provide a practical demonstration for the most used device at home using
a placebo device. This was done under the supervision of or by direct
observation from the researcher. Fourthly, they were asked about the
assistance or help they received from others especially informal carers
(family or friends). Finally, two validated instruments of adherence (Morisky
scale) and beliefs about COPD medicines (Beliefs about Medicines
Questionnaire [BMQ]) were applied. This enabled qualitative and quantitative
data to be collected as required by the objectives of the study.
The interview questions were read by the researcher to minimise the degree
of bias and to subject each participant to standard interview conditions.
Enough time was given to each participant in order to answer each question.
In addition, prompts and probes were also used in the interview to expand
the question that was answered to cover the topic broadly. Any unexpected
ideas or responses made during the interview were also followed up by the
researcher and a note of this was made on the interview schedule. If
participants agreed, interviews were audio-recorded to allow data analysis,
but this was not a requirement to take part.
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4.10 Data protection
The data collected were handled with confidentiality throughout the study
period and kept in a coded format without the name of the patients, and
locked all the time in a designated cabinet storage for this purpose. Data
were stored in university computers where all files were password protected
and only the research team was allowed access. Storage was the
responsibility of Prof. Felicity Smith. Data will be destroyed at the end of the
study period (after publication).
4.11 Use of computer software
A qualitative data indexing software package, Nvivo 10, was used to facilitate
coding and retrieval of the qualitative data. This software allowed storing of
the transcribed text in an organised form, searching and retrieving particular
segment of texts for inspection after coding segments of texts, and linking
relevant data to form categories. This was all done in English. In addition, a
quantitative data software package, SPSS 21, was also used to interpret the
quantitative data.
4.12 Analysis and presentation of the interview data
4.12.1 Transcription of the data
All interviews were conducted by the researcher in English. Of the 46
interviews, 40 were audio-recorded for verbatim transcription, whereas three
participants stated their unwillingness to be audio-recorded. Therefore, their
interviews were written by hand. Subsequently, all interviews were
transcribed. All the stages of the data analysis including development of
themes and codes were undertaken in English.
Chapter 4 - Research context and methodology
101
4.12.2 Thematic framework
To enable the data analysis, a thematic framework was used in this study.
Thematic framework was developed by the National Centre for Social
Research (NatCen), UK in the 1980s for policy research for which the
information requirement is known in advance. Although diverse qualitative
methods are available for data management, a framework approach was
selected to support data analysis. Firstly, the framework approach is
especially fit for analysing cross-sectional descriptive data, enabling different
aspects of the phenomena under investigation to be captured (Spencer and
Ritchie, 2003). Secondly, moving from data management to developing the
analysis effectively to answer research questions may be a difficult and
confusing task for researchers. Thus, the interlinked stages in the framework
approach simply describe the processes that guide the researcher through
the systematic analysis of data from initial management to the development
of descriptive to explanatory accounts (Spencer, 2003).
Qualitative data analysis can be done deductively or inductively. A deductive
approach can be done by developing a theory, which begins with establishing
objectives. For example, when the study objectives are identified, key
definitions and assumptions should be stated. After that, a logical structure
should be generated to accomplish the objectives, based on the definitions
and assumptions. This methodology is often described as going from the
general to the specific (Hinkin, 2005). The deductive approach is widely used
for data analysis in qualitative research. One of the main advantages is that it
can test or expand an existing theory by searching systematically for patterns
to give a detailed description of a phenomenon, which enables developing of
meaningful themes (Braun and Clarke, 2006). In addition, if properly
conducted, it will assure the data validity in the final scale. In most situations
where the theory does exist, the deductive approach would be appropriate
(Clark, 2011).
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When developing the themes of this study, a single method approach to
qualitative data analysis was considered. This approach was an inductive
approach by building up a theory from the ground, derived from the data
obtained from COPD participants (grounded theory) (Hinkin, 2005).
Therefore, the researcher developed these themes and sub-themes based
on a series of factors that were raised by COPD participants during the
interviews. This approach is useful to guide the researcher when conducting
exploratory research (Clark, 2011).
After audio-recording the interviews for verbatim transcription, they were fully
transcribed and typed into a Word document. After that, they were printed out
and read many times to manage the data and reach data familiarisation,
which means becoming familiar with the data by reading and re-reading it.
This stage was very important to gain richness and depth and glean insights
into the data, and therefore to identify initial themes (Roe, 2008). After
reading the first seven interviews, the researcher was able to see and identify
some common themes and issues. After reading and re-reading all
transcripts, the key themes were marked and identified for a range and
diversity of coded data upon the topic under discussion (e.g. the timeline of
the condition=1, COPD medicines=2), using Nvivo. The major key themes
were then created as codes or nodes, and each transcript was read on the
screen and coded. Each key theme was subdivided into related sub-themes.
Some quotes were coded twice because they were covering several codes or
sections. A coding matrix was then generated and the codes from each
theme that was generated from the data were lined or grouped based on the
study objectives seeking wider application of concepts and themes (Roe,
2008). During the coding process, when any new theme arose from the data,
it was incorporated into the coding matrix (see Table 4-2).
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4.12.3 Data management using a case- and theme-based approach
An initial sample of 10 participants, who were firstly interviewed, was
selected from the whole sample and their interview transcripts were read
several times to identify the recurring themes and concepts. Codes and
categories were developed considering each line, phrase or paragraph of the
transcript as an attempt to summarise the findings. The process initially
involved using printed versions of the transcripts with key phrases highlighted
and comments written in the margins to gather preliminary thoughts. After
that, a conceptual framework was developed for the 46 participants into more
formal ideas from which a coding matrix was generated to ensure clarity at
conceptual level of the issues and to represent a range of experiences.
Transcripts were then entered into the NVivo sheet to generate the codes.
Each NVivo code initially formed a potential category but, as coding
progressed and the number of categories developed, they were grouped
together into broader categories. Similar categories were eventually brought
together to form initial themes. These categories and themes formed a
‘coding index’ that was used as a means of organising the whole dataset
(Table 4-2).
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Table 4-2: The coding themes
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4.12.4 The validity and reliability of the data
The validity of the data refers to the extent to which the chosen method
measures what it is intended to measure (Polit, 1991), whereas the reliability
refers to the degree of consistency between measures (Polit, 1991). The
following discussion aimed to outline the validity and reliability issues related
to this study.
The validity refers to the extent to which the research findings present reality
(Scanlan, 2002). The literature review in two formed the basis for the
validation of this study. Past studies have been taken into consideration
when designing this research to aid ensuring that this research included all
problems, issues and difficulties in regards to the use of inhalation therapy
and/or devices among COPD patients. Therefore, the review highlighted the
area of importance in regards to COPD and its therapy. These included how
older patients made decisions regarding the use of inhalers, and how those
decisions and difficulties contributed to suboptimal outcomes and treatment
failures.
The review also helped to ensure that the data collection instruments
covered all angles and topics which belonged to COPD and its therapy.
Themes that were repeatedly found in the review were considered significant
and questioning about these topics was included in the interview schedule,
such as the use of inhalation therapy by patients in terms of adherence and
inhalation technique and issues related to them. In this way, it will be ensured
that the data collection instruments had content validity, which means being a
measure that the data collection instrument covered all angles and domains
of the topic under investigation (Scanlan, 2002).
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At the end of this study a comparison was carried out between its findings
and the existing knowledge, theories or established literature of the use of
inhalation therapy by COPD patients, in order to validate the accuracy of the
findings of this study, despite using different methods to gather the data. The
findings were checked and discrepancies between this study and data
obtained from previous studies were compared before and during analysis.
In this research, data were gathered from different sources and a triangulated
methodology applied, to validate the data and to allow a more accurate
assessment. Triangulation is defined as the use of two or more methods of
data in the same study. It is a way; the chances of obtaining a true picture of
events are high (Scanlan, 2002), in another word to make sure there is
enough evidence to make valid claims (Smith, 2010).
To increase the validity of the findings of this research, it was decided to
conduct face-to-face semi-structured interviews, which enabled the
researcher to follow any interesting points and gave the participants the
opportunities to add any further information that they felt was crucial or was
missing from the schedule in order to ensure that the interview covered all
topics of relevance to the study and participants. As reported by Scanlan in
2002, exploration of issues in this manner means that participants’ answers
were placed in context and the researcher was able to probe the exact
meaning of the patient’s response. In this way participants were able to tell
their own stories, which enhanced the study validity.
In this study the threats to the validity were minimised in the following ways:
 The literature review and preliminary fieldwork were conducted to ensure
that the study covered the relevant data collection domains. In addition,
after the researcher had conducted a literature review and developed the
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interview schedule, Pinn Medical centre staff including healthcare
providers were asked to review and give advice on the methodology used
in this study and the interview schedule, including wording of the
questions and the way of questioning, to ensure the inclusion of all
relevant issues concerning the phenomena. As a result, the interview
schedule and the methodology were advised.
 The checklist for each device was also seen and reviewed by the
researcher’s team to ensure that it is workable and applicable for all
COPD participants. Checklists were used to standardise the collected
data during patient observations.
 The review of the literature was used in the data analysis and discussion
of this study. These reviews provided concepts which can be checked
using our actual data.
 To ensure the validity of the data obtained from participants' interviews
the following procedure was undertaken:
 Two courses regarding discussion and training in conducting a
qualitative research and the use of questionnaires in research
were attended by the researcher at the University of Surrey and
the University of London before conducting the study. In
addition, the researcher was taught how to conduct a qualitative
research and the use of questionnaires in research, in relation
to previous MSc research undertaken by the researcher at the
University of Strathclyde, Scotland.
 Different books on interviewing techniques (e.g. Conducting
your pharmacy practice research project: a step-by-step guide
by Felicity Smith; Research methods in pharmacy practice by
Felicity Smith; Interviewing as qualitative research: A guide for
researchers in education by Irving Seidman) were read by the
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researcher, which informed the development of the methods
and helped the researcher to make the best choice regarding
the instruments that should be used to answer the research
questions.
 The choice of instruments for the quantitative data, which includes
measuring adherence and beliefs about COPD medication, was based on
previously published reports of the validity and reliability of these
instruments (Morisky scale and BMQ) by other researchers among the
same group of patients to ensure the validity of the quantitative data.
 The data was audio-taped and transcribed verbatim to assist in applying
analytical procedures. One way to assure the reliability and the validity of
the data collected was audio-recording the patients’ interview, which has
been used widely within qualitative research, replacing the researcher's
handwritten notes. This was done to review and transcribe the conducted
interviews at a later date; additionally, to verify the questions asked during
the interviews. When using the audio-recording responses, this will ease
the analysis by ensuring that no points were missed and that the
researcher has not unintentionally paraphrased the participants’
responses. This ensures that the data collected is true and
comprehensively reflects their issues (Scanlan, 2002).
 After conducting the first three interviews, the findings obtained from the
interviews were examined and reviewed by the researcher’s team to
ensure that these findings were accurate and representative.
 The collected data from each interview was independently coded and the
coding was compared and reviewed by the researcher’s team for
agreements, which is known as assessing reliability for ensuring accuracy
of the data. The results showed close agreement on the main themes.
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 Using a computer indexing software package, Nvivo 10, was useful to
ensure the validity of the findings, by identifying all data relating to issues
of interest for inspection or to support theory building.
 Whenever a new code was added, all the previous interviews were
rechecked for relevance of this code, which ensured consistency and
carefulness of coding.
 At the end of this study a comparison was done between the findings of
this study and the existing knowledge, theories or established literature on
the use of inhalation therapy by COPD patients.
In terms of the reliability, as identified by Scanlan (2002), the reliability of the
study relies on the reproducibility of the findings and the assumption that if
the data were collected using identical techniques or methods at the exactly
the same point in time the same findings would be obtained, and if the data
were analysed using the documented method of data analysis the same
conclusion to the study would be drawn. To ensure this, a number of
considerations were made when designing this study to reduce threats to the
reliability, including:
 The data collection process was clearly documented and research
procedures were followed as per the data collection protocol during
the research process.
 To ensure that participants considered the same topics during the
home visits, a semi-structured interview technique was undertaken
using prepared questions which involve prompts and probes.
 To assure the consistency of each participant’s responses, the
interview questions were read out loud by the researcher and only one
researcher was used throughout the research to do the interviews with
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participants, to limit the bias and to avoid different approaches to the
interview.
To summarise, the methods employed in this study were to enable collecting
of extensive data both quantitatively and qualitatively to meet the study
objectives. The collected data that were obtained from different sources were
triangulated and considered using a matrix approach to analyse, validate and
complement the study findings.
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5 Chapter Five: Characteristics of participants, their
disease and medicines
This chapter reports the response rate of the study sample and summarizes
the study participants’ characteristics and participants’ disease
characteristics (e.g. demographics and clinical characteristics) and
participants’ COPD medicines, which are essential for interpretation of the
results. In addition, it summarizes non-participants’ characteristics.
5.1 Response rate
A total of 116 COPD patients were invited to participate in this study by
sending an invitation letter to their home address. Of those who responded
by sending back the reply slip stating their willingness to take part, 46
respondents were eventually interviewed. The response rate following an
initial mailing was 28%, as only 33 patients responded following an initial
mailing. Twenty-six patients with COPD declined to participate and no reply
was received from 57 patients.
To increase the participation rate, a reminder letter was sent to those who
had not yet responded (N=57), asking them for the second time to take part.
In response to the reminder letter, 13 patients agreed to take part and were
subsequently interviewed. Of the 44 remaining patients, 15 declined to take
part in the study and 29 did not respond despite being invited and sent the
reminder letter. To summarize, a total of 41 patients declined to participate
and 29 did not reply. The remaining 46 participants who met the criteria and
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agreed to take part were all enrolled in this study and interviewed (response
rate 40%).
5.2 Characteristics of the sample
The characteristics of the 46 participants, who met the inclusion criteria and
agreed to take part, were entered into a data base in SPSS v.21. The mean
age of the 46 participants was 77 years (SD = 8), and median was 76 years
(Interquartile range IQR = 72-83 years). Participants ranged in age from 63 to
100. Almost an equal number of participants from each gender (Male=24 and
Female=22), were included.
Smoking is a leading cause of COPD; most participants who enrolled in this
study were current smokers or ex-smokers. Three-quarters of the participants
(N=34) were ex-smokers, whilst seven participants were still smoking.
Regarding their living arrangements, two-thirds of participants (N=31) were
living either with a spouse or family (see Table 5-1)
5.3 Participants’ disease characteristics
Participants’ information and clinical characteristics obtained from the clinical
notes and during the interviews are presented in Table 5-1.
Table 5-1: Characteristics of the participants and participants’ disease (N=46)
Parameter Mean (SD); Median
Age (years) 77 (8.23); 76
Number of regular medicine 7 (2.84); 7
Number of years since the diagnosis 12 years (9.69); 10
Number of COPD medicines 3 (0.79); 3
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Continue Table 5-1: Characteristics of the participants (N=46)
Parameter N (%)
Gender
Male 24 (52%)
Female 22 (48%)
Ethnicity
White (English, Welsh, Scottish) 39 (85%)
White Irish 4 (9%)
Any other White background (Italian) 1 (2%)
Asian British (Indian) 2 (4%)
Living arrangements
Lives alone 15 (33%)
Do not live alone 31 (67%)
Severity of the disease according to NICE guidelines
Mild airflow obstruction (FEV1= 50-80%) 14 (30%)
Moderate airflow obstruction (FEV1= 30-49%) 29 (63%)
Severe airflow obstruction (FEV1<30%) 3 (7%)
Smoking status
Current smoker 7 (15%)
Ex- Smoker 33 (72%)
Never-smoked 6 (13%)
The mean (SD) and median are given for continuous variable, whereas, numbers (%) are given for
categorical variables
In this study, the number of years since the participants were first diagnosed
with COPD ranged from 1 to 35 years with a mean of 12 years (SD=9.7). The
median of the number of years since the diagnosis was 10 years.
From the surgery records, the FEV1 (forced expiratory volume in 1 second),
was classified in the medical records based on the NICE guidelines
classification of the disease severity three categories: mild airflow obstruction
(FEV1 from 50 to 80% predicted), moderate airflow obstruction (FEV1 from 30
to 49% predicted), severe airflow obstruction (FEV1 < 30% predicted). Of the
46 participants, nearly two-thirds (N=29) had moderate COPD, whilst, a few
participants (N=3) had severe disease status.  Although, it was not possible
to access different lung function tests for non-participants to compare the
generalizability of the sample between participants and non-participants
because no consent was obtained, the sample of this study tends to have a
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range of people with different disease status comprising mild, moderate and
severe COPD status which makes the sample diverse.
5.4 Characteristics of participants’ medicines
5.4.1 Inhalation therapy
All the information provided regarding patients' own medications and what
they were prescribed for their COPD was taken from patients’ medical
records in the surgery, their prescriptions or medications checklists and/or
memories (see Table 5-2).
Table 5-2: The COPD medications prescribed for use by participants to manage their
condition (N=46)
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According to Table 5-2, all participants (N=46) were prescribed short-acting
bronchodilators such as short-acting β2-agonists (SABA) and short-acting
muscarinic antagonists (SAMA), to be used when required. The second most
prescribed medicine (N=28) was the long-acting antimuscarinic
bronchodilator (tiotropium), followed by the combination therapies of
formoterol/budesonide (N=20) and salmeterol/fluticasone (N=16)
respectively. These findings are consistent with those of previously published
guidelines such as NICE, BTS, ATS/ERS and GODL. All guidelines
recommend escalation of inhalation therapy with increasing severity of
disease, starting with short-acting bronchodilators used on an as-needed
basis, proceeding to scheduled administration of long-acting bronchodilators,
and advancing to ICS in patients with severe disease status or exacerbation
(ATS/ERS, 2004; NICE, 2010; GOLD, 2013).
5.4.2 Inhalation devices
In this study, COPD participants used a wide range of inhalation devices
ranged from two to five inhalers including multiple inhalers of pMDIs only,
multiple inhalers of DPIs only, a combination of both pMDIs and DPIs, or a
combination of pMDIs, DPIs and nebuliser. The largest number of
participants was using a combination of two inhalation devices. For example,
of the COPD participants, nearly half (N=22) used a combination of two
devices, whereas more than one-third (N=19) used three devices, and five
used more than three devices.
From the pie chart (Figure 5-1) it can be seen that two-thirds of participants
(N=31), 67%, used a combination of both pMDIs and DPIs, 10 participants
(22%), used a combination of DPIs, three participants (7%) used three
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different kinds of inhalation devices (pMDIs, DPIs, and nebulisers), whereas
the least used group was a combination of pMDIs with just two participants
(4%).
Figure 5-1: The percentage of participants who used different types of inhalation
devices in their home (N=46)
Regarding the type of device used, pMDIs were the most frequently
prescribed and used devices by COPD participants in this study, whilst, the
second most widely prescribed and used devices were the DPIs followed by
nebulisers. Among the DPIs, the Handihaler device was the most commonly
prescribed and used device, followed by the Turbohaler and Accuhaler (see
Table 5-3).
Table 5-3: The number of participants who used each type of device (N=46)
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According to Table 5-3, the participants were distributed as follows: all
participants (N=46) used pressurised metered-dose inhalers including pMDIs
and breath-actuated pMDIs; 44 participants used DPIs (Handihaler® (N=28);
Turbohaler® (N=20); Accuhaler® (N=16); Clickhaler® (N=1) and Aerolizer®
(N=1). Seven used pMDIs with a spacer. For the nebuliser system, three
used a side-stream nebuliser. These findings are consistent with the
recommendations given by the NICE guidelines which state that for the
delivery of bronchodilators and ICS, pMDIs and DPIs are highly advised to be
used, with the consideration of a nebuliser device only for those who are
unable to use pMDIs and DPIs or who have been diagnosed with severe
disease status (NICE, 2010).
5.5 Characteristics of the non-participants
According to the data obtained from the medical records, the mean age of
the 70 non-participants was 71 years (SD=16) and the median was 76 years.
There was almost an equal number of non-participants from each gender
(Male=34 and Female=36). Based on ethnicity, 60 non-participants were
from the white ethnic background – English, Welsh, Scottish and Irish –
which formed 86% of the non-participants. Asians including Indians (N=8)
were the largest minority group (11% of the non-participants), whereas the
smallest minority group was other ethnic group including Arabs (N=2).
According to the information obtained from the 41 non-participants who
returned reply slips, 15 reported reasons for not participating in the study.
The most common reasons given were feeling unwell, time constraints,
moving home, being an employee, or out of the country during the period of
study.
Chapter 5 - Characteristics of participants, their disease and medicines
119
When comparing the practice population including participants to the non-
participants, patients’ characteristics appeared similar in age, gender and
race. See Table 5-4 for more information on the sample and its
representativeness when comparing the practice population including
participants to the non-participants:
Table 5-4: Characteristics of non-participants to the participants
Parameter Non-participants and
non-respondents
Mean (SD)
Participants
Mean (SD)
Statistical
Significance
(p)
Age (years) 73 years (16) 77 years (8) 0.119
Parameter Non-participants or
non-respondents
N (%)
Participants
Mean
N (%)
Ratio
Gender
Male 34 (47%) 24 (52%) 1:1.4
Female 36 (53%) 22 (48%) 1:1.6
Ethnicity
White (English, Welsh,
Scottish)
60 (86%) 44 (95%) 1:1.4
Asian British (Indian) 8 (11%) 2 (4%) 1:4
Other ethnic group
(Arabs)
2 (3%) 0 1:0
In compliance with the ethical requirements, no data were obtained from the
medical records regarding medications and disease characteristics due to the
fact that the researcher did not receive written consent from non-participants
giving their permission to access their medical records in the surgery.
However, based on the available characteristics of non-participants and non-
respondents there were no significant differences between the two groups in
regards to the age, gender and race, but it should be accepted that there
might be some other differences of which we are not aware.
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6 Chapter Six: The use of inhalation devices by
patients with COPD
This chapter describes how COPD participants operate and maintain
different inhalation devices at home. It also identifies the frequency and
range of problems experienced by participants in the technical aspects of the
operation, cleaning and maintenance of inhaler equipment. The results
presented in this section provide insights into participants’ inhalation
techniques for different inhaler types in terms of preparing the device before
taking the dose, inhaling the dose, and maintenance, which includes
cleaning, sterilization and replacement of disposable parts if required.
6.1 A description of the inhalation devices
Familiarity with the components of each inhalation device encountered in this
study and their product characteristics is a very important stage to be
illustrated before describing how these devices were operated and used. A
table was constructed by the researcher for the devices which were used
most frequently by participants in this study (see Table 1-7, Table 1-8 and
Figure 1-3), in addition to a table summarizing product characteristics (Table
6-1).
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Table 6-1: Summary of inhaler characteristics
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6.2 Sequence of using the inhalation devices and the reason behind
each sequence
In this section, it was decided to explore how COPD participants usually
administer their inhalation therapy in regards to which order was followed in
the administration of their inhalation devices. The study also explored
whether a patient’s decision to follow a certain order was directed by clinical
practice guidelines and/or practitioners’ recommendations, or whether it was
determined by the patient’s personal views. Therefore, 46 participants with
COPD who were using multiple inhalation devices in their homes were asked
during the interview to state which inhaler they usually used first, second and
third. The analysis of the interview data revealed that the sequence of
administration of the inhalation devices differed between participants. The
majority of participants (N=37) used their inhalation devices randomly, with
no identified sequence, having not being informed by their doctor about a
specific sequence.
I do not follow any order. My GP did not tell me that I have to do them in
sequence
Female, 76 yrs old, using Ventolin Evohaler pMDI and Clenil Modulite pMDI
The most common followed sequence by participants who reported a specific
order was to use bronchodilator inhalers first followed by the inhaled steroid
inhalers. For some participants this sequence was not based on scientific
evidence or medical recommendations, whereas for others this was due to
advice given by neighbours or healthcare providers.
I take this one first [tiotropium], one inhalation in the morning and after five
minutes I take two puffs of that one [Symbicort]. Ammm, I have been on this one
[Symbicort] for a few years now and I used to use it first but then my neighbour,
who is living across the road and has got the same devices too, told me this is
incorrect as the doctor told him to use Spiriva first, then he told me and he said
the doctor told him so I never argue.
Male, 68 yrs old, using Symbicort Turbohaler and Spiriva Handihaler
Amm, I believe I was told by my GP that was the right order [to use the Spiriva
before the Symbicort].
Male, 67 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler, Spiriva
Handihaler and Phyllocontin tablets
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By looking at the mode of action of both drugs, it can be seen that
bronchodilators are used to open and relax constricted airways to ease the
breathing, whereas steroids are mainly given to minimise the inflammation of
the airways. Therefore, it makes sense to use bronchodilators first, followed
by inhaled steroids as opening the airways by bronchodilators first may
permit enhanced deposition of steroids. However, the evidence regarding the
need for a certain sequence when using the inhalation devices is very limited.
In addition, there is no strong evidence in the literature suggesting that this
sequence alters the outcome of treatment favourably. A previous study of
patients with moderate to severe asthma separated them into two groups:
those who administered bronchodilators first and then steroids, and those
who took steroids first and then bronchodilators, concluded that there was no
ideal sequence for administering the inhalation therapy and that the efficacy
of both medicines on the lung function and the clinical outcomes were proved
completely independent of a particular sequence (Dal Negro et al., 2006). As
this is only a single study, further studies are required to provide some
evidence on whether following a certain sequence would be effective in
improving the lung function and the clinical outcomes or not.
In regards to the device itself, some participants had established their
sequence of administration based on two things: firstly, the age of the device
and, secondly, the ease of use. For example, four participants declared that
the priority was given for the first prescribed inhaler because they had been
using it for a long time. One participant tended to use pMDIs first followed by
DPIs because pMDIs were much quicker and easier to use than other
handheld devices.
I take one inhalation of Symbicort [Turbohaler] first and I take another inhalation
of Spiriva [Handihaler] second. The reason is Spiriva was recently prescribed,
just two weeks old.
Male, 76 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler and
Spiriva Handihaler
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I always take Ventolin [pMDI] before Seretide [Accuhaler] because Ventolin is
easier and quicker to use.
Male, 74 yrs old, using Ventolin Evohaler pMDI with spacer and Seretide
Accuhaler
These findings suggest that in general there was no dominant sequence for
applying the inhalation therapy; each participant worked out his/her own
preferred sequence, which was not based on scientific evidence but on
patient’s preference and convenience. These sequences were also directed
by the type of the prescribed medication and/or advice. In conclusion, due to
the lack of evidence proving the effectiveness of using a certain sequence,
there were no concerns in terms of the differences in the sequence of drug
administration among COPD participants. However, further investigations
and experimentations into the sequence of inhalation devices’ administration
and its effectiveness are needed. If any sequence was proved to be more
effective than others, it should then be followed and implemented to
maximise the efficacy of therapy and therefore the clinical outcomes.
6.3 Comparing inhalation devices in terms of operation
This was an observational part of the study carried out between May and
December of 2012. The sample comprised 46 participants with COPD,
treated at Pinn Medical Centre in Pinner, UK. All participants (N=46) were
asked to demonstrate and describe how they operate their inhalation devices
using a placebo device provided by the investigator.  Participants were asked
to select the most difficult device to operate at home (from participants’
perspective) or the one which they may have a problem using.  Some
participants claimed that they did not have problems or difficulties in using
any inhaler, so they were asked by the researcher to demonstrate the
inhalation technique for the device they used most frequently at home. The
selection criterion of the included devices in the assessment is potentially
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biased because it was based on patient's choices and judgments regarding
the definition of the mishandling of each device.
A total of 46 inhalation demonstrations were performed by the 46
participants; DPIs (N=35) including [Turbohaler (N=17), Accuhaler (N=11),
Handihaler (N=7)], pMDIs (N=8), and nebulisers (N=3). Although only three
participants demonstrated the inhalation technique using a nebuliser, among
those no errors were reported. Statistical comparison of other devices with
nebulisers was thus not possible since only three participants used
nebulisation therapy and no error was made.
For this study, an error in the technique was defined as any deviation from
the recommended steps required for optimal drug delivery which are given in
the checklists derived from literature provided by pharmaceutical companies
for their own devices. The method of assessment was investigated in regards
to reliability of the observer and checklists; firstly, the assessment process
was performed accurately by direct observation from a properly trained
observer (the researcher), who had three sessions of training under the
supervision of her academic supervisor Prof. Taylor, who has been actively
involved in inhalation aerosol research. In addition, using one observer for
the assessment process avoided the possibility of inter-observer variability
(defined as a failure to identify or measure the number of deviations made by
participants from the recommended technique when using their devices
accurately, which results in an error), which may arise from the presence of
multiple observers. Secondly, the checklists used in the assessment were
developed based on the previously published literature and guidelines set by
different professional organisations and the package leaflet of each inhaler
from the pharmaceutical companies, and were reviewed by the academic
supervisors before use, to ensure that they are accurate, feasible and
workable.
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Twenty-eight participants (61%) made at least one deviation/ error when
using their inhalation device, with only 18 COPD participants (39%)
performing all of the steps completely and correctly (Table 6-2).
Table 6-2: Participants who made at least one deviation (error) when using inhalation
devices
Type of device The number of participants
who demonstrated this
device (N=46)
The number and percentage of COPD
participants who made at least one
deviation (error) when using the device
pMDI 8 7 (88%)
DPI 35 21 (60%)
Nebuliser 3 0 (0%)
The percentage of participants who made deviations/errors when using
specific DPI devices is shown in Table 6-3. The proportion of participants
who made at least one deviation was greater for the Handihaler device than
when for the Turbohaler or Accuhaler. In addition, the mean number of
errors/deviations made by 35 participants when using Handihaler, Turbohaler
and Accuhaler devices was 2.7, 1.4 and 1.2 respectively.
Table 6-3: Participants who made at least one deviation/error when using dry powder
inhalers
Type of device The number of
participants
demonstrated this device
(n=35)
The number and percentages of COPD
participants who made at least one
deviation (error) when using inhalation
device
Handihaler® 7 6 (86%)
Turbohaler® 17 10 (59%)
Accuhaler® 11 5 (45%)
The problems encountered by participants, when using these devices are
shown in Table 6-4.
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Table 6-4: The number of mistakes made by participants per step
When comparing the number of errors per step made by pMDI and DPI
users, errors were recorded most (N=16) in cleaning the inhalation devices,
breathing out away from the inhaler (N=14) and holding breath for less than
five to 10 seconds (N=13) (Table 6-4). For the pMDIs alone, the steps
concerning shaking inhaler (the canister) well before use and actuating while
inhaling deeply and slowly were those most frequently performed incorrectly;
with inhaler not being shaken (N=6), the device being fired before start of
inhalation, or after end of inhalation (N=4). For the DPIs, the most common
errors were in cleaning the device according to the manufacturer’s
instructions (N=14), exhaling away from the inhaler (N=12) and holding
breath for about five to 10 seconds (N=11). Errors in cleaning were reported
in not cleaning the device at all or cleaning the device but not according to
the manufacturer’s instructions. Errors with DPIs in the technique were seen
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in not exhaling before inhaling the dose or breathing out into the device, or
no/short breath-hold.
In summary, the data showed that deviations from the recommended
inhalation technique when using the inhalation devices were common among
participants (N=28; 61%). The study also revealed that 88% of pMDI users
and 60% of DPI users made at least one deviation from the recommended
technique. Among the DPIs, the data showed that more patients using the
Handihaler device made deviations/errors in the technique compared with
those using Turbohaler and Accuhaler. Reasons for the inhalation devices’
mishandling can be divided into three categories namely: patient issues,
practice issues and device issues. These are addressed.
6.4 Issues encountered by participants using inhalation devices
The clinical effectiveness of the inhalation devices depends not only on the
ability of the devices themselves to deliver the medication, but also on the
ability of the patient to use these devices properly and effectively.
6.4.1 Pressurised metered dose inhalers
NICE guidelines (NICE, 2010) state that pMDIs are the most prescribed
inhalation devices as most medications are available in this form, whereas;
the selection of DPIs is limited by the choice of medication because not all
devices are available to deliver all drugs. When a patient is first diagnosed
with COPD, the pMDI is usually given as a first option to be used to deliver
short-acting bronchodilators (NICE, 2010). However, the use of a pMDI
device may be problematic for some elderly patients who have impaired
handgrip strength, for instance if they have arthritis, or have problems with
coordinating inspiration and actuation. In this case, a spacer device and other
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hand-held devices should be considered (NICE, 2010). In this study, pMDIs
were the most commonly prescribed and used inhalers (N=43). Despite being
the most prescribed device and the one that had been used for the longest
time, findings of participants’ handling of their inhalation devices were in
agreement with previous studies which have reported that pMDI devices had
higher rates of incorrect handling than DPIs (Lenney et al., 2000; Molimard et
al., 2003; Khassawneh et al., 2008; De Moraes Souza et al., 2009;
Rootmensen et al., 2010; NICE, 2010). The percentage of pMDI users who
made at least one deviation from the recommended inhalation technique
when using their pMDIs was 88% compared to 60% of DPIs users.
The correct use of pMDIs by participants was affected by numerous
problems, which are listed in Table 6-4. In general, the most frequent errors
were: firstly, failure to shake the device before inhaling the dose. The
ingredients of some pMDIs in the canister are likely to settle over time.
Shaking the pMDI is crucial to ensure that the formulation is appropriately
mixed and homogeneous (Fink and Rubin, 2005). The second most common
problem was failure to hold the device in upright position. pMDIs should be
maintained in the upright position during administrating the dose; failure to do
so may cause problems for drug disposition in the mouth or throat, which in
turn can cause suboptimal drug delivery and side-effects (Colombo et al,
2012). Thirdly, problems in coordination emerged: patients are required to
coordinate actuation at the beginning of inspiration. Actuation before one
second of inspiration decreases the inhaled mass and the drug disposition
deep in the lungs. Similarly, actuation after the inhalation can lead to
exhalation of the drug before it can enter the target airways (Fink and Rubin,
2005; Colombo et al, 2012). Therefore, if there is a delay between actuation
and inhalation, or if a participant inhales the dose very rapidly, the drug
delivery to the lower airways will be detrimentally affected.
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In terms of patients’ preferences, the data indicate that participants made
judgments in regards to their preferences and needs for using a certain
device. However, most participants (N=37) had a conviction that all inhalation
devices were the same and there were no differences. In addition, they
strongly believed that these devices were given to them by their doctors to be
used for their benefit and to meet their needs. Consequently, they had no
preference for one device over another, and they believed that they had no
choice but to use them even when they experienced difficulties in their use.
In terms of patients’ preferences for pMDIs, the results of this study have
shown that participants expressed no preference for the pMDIs, especially
with the need of good inhalation technique for effective drug delivery.
However, this did not affect participant’s decision to use the pMDIs,
especially because most of the pMDIs (N=34) were prescribed to deliver
short-acting bronchodilators to be used when needed, so patients were not
using them every day. However, this made pMDIs difficult to use for some
patients. Adding a spacer device to the pMDIs may help in eliminating poor
hand-lung coordination. However, patients’ ability and conviction to use the
spacer must be assessed before prescribing.
Actually, I do not like the fact that I need to inhale while actuating these two
[Clenil pMDI and Ventolin pMDI], I rather prefer to take my medicines via this
one [Handihaler] because I do not need to go through this complex technique.
Female, 72 yrs old, using Ventolin pMDI with spacer, Clenil Modulite pMDI and
Spiriva Handihaler
This study’s results were compared with the findings of previous studies, in
regards to the most errors patients make when using their pMDIs. The errors
were similar between these studies in terms of the following: inhaler not
shaken (Hesselink et al., 2001; Molimard, et al., 2003; Ho et al., 2004; Sestini
et al., 2006; Khassawneh et al., 2008; Rootmensen et al., 2010; Melani et al.,
2011), and firing the device before the start of inhalation or after the end of
inhalation (Ho et al., 2004; Sestini et al., 2006; Khassawneh et al., 2008;
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Rootmensen et al., 2010). In addition, in this study, when pMDIs users were
asked to explain the reason for disliking their pMDIs, they said that these
devices contain propellants which need to be pressed hard to operate; they
are unlike breath-actuated inhalers; and they found it difficult to use them
correctly especially because of coordination difficulties. Newman’s reported
similar drawbacks with the use of pMDIs (Newman, 2005).
Although the existence of these difficulties did not stop patients from using
their pMDIs, careful attention must be paid to the inhalation technique to
ensure the best drug delivery, as the clinical effectiveness of the inhalation
therapy depends not only on the efficacy of the devices themselves or
patients’ decision to use them but also on the ability of the patient to use
these devices properly and effectively. Patients’ inhalation technique should
therefore be assessed regularly to ensure the proper use of pMDIs. However,
if any patient is found to be unable to use the pMDI effectively even after
receiving educational sessions regarding the use, for instance due to issues
such as manual dexterities, other devices should be introduced, such as
DPIs or spacers (NICE, 2010).
6.4.2 Spacer Devices
Spacers are generally prescribed to enhance drug delivery from pMDIs for
those who find it difficult to coordinate inhalation with actuation (NICE, 2010).
Inappropriate use of a pMDI device can lead to insufficient drug delivery,
therefore, insufficient lung deposition, subsequently increasing the possibility
of treatment failure (NICE, 2010). Adding a spacer to pMDIs improves the
inhalation technique and is associated with fewer errors when compared to
the pMDIs alone (Connolly, 1995; Ho et al., 2004; Rootmensen et al., 2010).
Chapter 6 – The use of inhalation devices by patients with COPD
133
Seven participants were prescribed spacers to be used with their pMDIs. As
reported by participants, spacers were given to ease the administration of
aerosolised medication delivered by pMDIs and minimise the local adverse
effects such as oral thrush. Participants perceived their spacers were
effective in delivering the medication.
The chemist told me if I use it [Aerochamber spacer] I will get all the good effect
and the full amount of the puff of my medicine. I will be telling a lie if I told you it
did not work for me.
Male, 74 yrs old, using, Ventolin pMDI with Aerochamber spacer and Seretide
Accuhaler
I was advised by [Dr. Name] to use a spacer. I went to him because I could not
get on well with these [salbutamol pMDI or salmeterol/fluticasone pMDI],
because of my tongue. When I use these [pMDIs] I feel the medication is going
all on my tongue, and I cannot get rid of my tongue [laughs], so when I was
telling [Dr. Name], he gave me this [Aerochamber spacer].
Female, 80 yrs old, using AeroChamber Spacer attached to adult comfortSeal
mask with the Ventolin pMDI, Seretide pMDI, Seretide Accuhaler and
prednisolone tablets
I think when I started doing it, I think it is a case of you do have to get used to
knowing how to use it and [Dr. Name] who I just mentioned to you, she gave me
that adapter thing [Nebuhaler spacer] you just adapt to that. She suggested it
and I did not know there was such a thing then she suggested I use the spacer
with this one [beclometasone pMDI].
Female, 72 yrs old, using Ventolin pMDI with Nebuhaler spacer, Clenil Modulite
pMDI and Spiriva Handihaler
The results of this study showed that the pMDI users were prescribed a
variety of spacers including Nebuhaler® (N=1), Volumatic® (N=2) and
Aerochamber® (N=4) spacers. The data indicated that three participants,
who were prescribed either Volumatic or Nebuhaler to be used with their
pMDIs, found it difficult to handle these spacers, due to their large size and
the lack of a facemask to ease the drug administration.
I use it [spacer] each time I take Ventolin but I do not take the spacer with me
when I go out because it is heavy to carry round and it takes time to administer
compared to this one alone [pMDI]
Male, 74 yrs old, using Ventolin pMDI with Volumatic spacer, Symbicort
Turbohaler, Spiriva Handihaler and Carbocisteine Capsule
Participants’ decision regarding the discontinuation or the intermittent use of
spacer devices (Volumatic® and Nebuhaler® spacers) was associated with
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device characteristics and properties (e.g. the shape, weight, being generally
bulky and difficult to carry around) (Figure 1-4), participants’ preference and
convenience (e.g. a spacer device can be time consuming to use, particularly
if a patient is on multiple medications). These participants who were advised
to use a spacer device were unwilling to continue using their spacers
(Volumatic® or Nebuhaler®) regularly as advised especially because they
were less portable than a pMDI alone and less comfortable to use. Others felt
awkward using them, especially when going out. As a result, one participant
decided to discontinue using his spacer, whilst two participants stated only
intermittent use of their spacers as they acknowledged that they were not
using them when they were out of the home and resuming their use when
they were at home. In all cases, healthcare providers were not informed
about these decisions.
I found it [Volumatic® spacer] not very comfortable to use and I felt awkward
with it, holding it and pushing the centre and I said it does make sense. I can
understand what medical people are talking about because they feel that a lot of
people like me are not taking the full amount of the puff into their mouth and
through this machine you are but the spacer kept falling out or fiddling and
something like that. So, I stopped using it without telling my doctor.
Male, 74 yrs old, using Ventolin pMDI with Volumatic spacer, Seretide
Accuhaler
I do not use it [Nebuhaler® spacer] all the time because it not easy to carry
around and you cannot use it in public because it looks weird.
Female, 72 yrs old, using Ventolin pMDI with Nebuhaler spacer, Clenil Modulite
pMDI and Spiriva Handihaler
Participants who were prescribed and used other types of spacers such as
Aerochamber spacer (N=4) reported having no difficulties in dealing with their
spacers and stated advantages of the Aerochamber spacer including being
small, portable, and having a facemask for use with the spacer. Those
acknowledged receiving benefits from the COPD medicines with the use of
the Aerochamber device and reported optimal outcomes and good disease
control. Aerochamber users were willing to continue using their spacers
without any complaint because they felt that they were making best use of
their pMIDs.
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I find them [Ventolin pMDI and Seretide pMDI] very easy to use especially after
using them with a spacer [Aerochamber® spacer] and a mask, so it [mask] goes
over my nose and I feel that I am getting all the contents in. I presume it does
me good.
Female, 80 yrs old, using AeroChamber Spacer attached to adult comfortSeal
mask with the Ventolin pMDI, Seretide pMDI, Seretide Accuhaler and
prednisolone tablets
I think it [Aerochamber® spacer] is easy to carry around and easy to use.
Male, 84 yrs old, using AeroChamber Spacer with Ventolin pMDI and Symbicort
Turbohaler
To conclude, seven pMDI users were prescribed a variety of spacers
including Nebuhaler® (N=1), Volumatic® (N=2) and Aerochamber® (N=4). Of
those, three had experienced difficulties in handling their spacers especially
Nebuhaler® and Volumatic®. Aerochamber users were happy to use their
spacers and did not report any problem with the use. They perceived their
spacers were effective in terms of drug delivery and had experienced a sign
of improvement in their symptoms, when compared to Volumatic and
Nebuhaler users. Therefore, Volumatic and Nebuhaler users should be
reassessed and re-educated on how to use their spacers properly and other
spacer devices should be considered, such as Aerochamber spacer, if
appropriate.
6.4.3 Nebulisers
Nebulisers are usually considered in patients with severe disease status or
frequent exacerbations (or ‘flare up’) of COPD (NICE, 2010). In this study,
three participants with severe COPD used a jet-nebuliser. These patients
were given a nebuliser to administer bronchodilators or saline because they
scored FEV1<30% (severe stage of COPD). They were the only participants
who have used all types of inhalation therapy in this study, including pMDIs,
DPIs and nebulisers, whereas all the rest (N=43) used a combination of
pMDIs and/or DPIs. Therefore, the judgments of these three participants
about the inhalation devices and their preferences are considered potentially
important as they reported the benefits of a jet-nebuliser, and felt that they
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were the best to use of all inhalation devices. Newman’s review (2005)
reported that nebulisers were the hardest device to prepare and the easiest
to perform the inhalation technique appropriately, whereas pMDIs were the
opposite. In this study, the three participants using a jet-nebuliser were able
to prepare it easily and correctly and performed the inhalation technique
efficiently.
There is evidence that a person is most likely to use correctly the device that
they prefer (Lenney et al., 2000). Based on the data obtained from the
interviews and the observations of the patients’ inhalation technique using
the jet-nebuliser, it was found that the nebuliser was used correctly by all
nebuliser users (N=3), and was preferred over all other hand-held devices.
Firstly; using the nebuliser required no specific inhalation technique, as jet
nebulisers are fairly intuitive to use and tidal breathing is sufficient. The data
obtained from the interviews were triangulated with the findings of the
observations of the inhalation technique for each patient when using the
inhalation devices. It was found that the jet nebuliser device was used
correctly by all three patients, with no recorded errors in the use (Figure 6-1).
Additionally, participants considered the ability to mix more than one
medication in a nebuliser and deliver them simultaneously as an advantage.
By contrast, all nebuliser users criticised their large size and the heavy
weight compared to other devices, especially pMDIs, which were considered
easy to use and carry around.
I cannot carry that around [Nebuliser], can I? If I can carry this one [A jet
nebuliser] with me I would, because it is easier to use with no specific
technique, you just have to breath and that’s it.
Female, 77 yrs old, using Ventolin pMDI, Seretide Accuhaler, Spiriva Handihaler
and Salamol Steri-Neb delivered by nebuliser
I use my nebuliser twice in the morning to take these two [ipratropium and
salbutamol] which I like because you can use the same machine to take your
medicines.
Female, 76 yrs old, using Ventolin pMDI, Seretide Accuhaler, Spiriva
Handihaler, Salbutamol and Atovent delivered by (Side-stream nebuliser/ Porta-
neb compressor)
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Another reported advantage of nebulisers over hand-held devices was the
benefits of the ability to use very high drug doses, especially antibiotics for
seasonal infections in COPD patients, which would be impossible to deliver
with a pMDI or DPI. Additionally, no adverse effect was reported with the use
of nebulisers unlike other hand-held devices.
I find the nebuliser very helping especially after my lung infection; I had to take
lots of antibiotics. Before I got it, I was complaining of shortness of breath and I
used to feel chesty all the time, but, later, I was just fine with using this machine
and it does help me breathe better. So, it is the one I prefer most.
Female, 76 yrs old, using Ventolin pMDI, Seretide Accuhaler, Spiriva
Handihaler, Salbutamol and Atovent delivered by (Side-stream nebuliser/ Porta-
neb compressor)
Of course, my nebuliser, I find it the most helpful and easy to use. I really
cannot live without it but this one [Seretid Accahaler], I do not know if it is doing
any good but it loses my voice and makes me cough; it is dreadful, dreadful.
Female, 80 yrs old, using Ventolin Nebul delivered by Side-stream nebuliser/
Porta-neb compressor, Seretide Accuhaler, Spiriva Handihaler, Phyllocontin
continus tablets and Carbocisteine Capsule
Figure 6-1: Ease of use and operation of the inhalation devices.
According to the NICE guidelines (NICE, 2010), nebulisers have the
advantage over other hand-held devices of being independent of inspiratory
effort or breathing pattern when a patient has poor coordination or inhalation
technique. This means that they are easier to use than hand-held devices. In
addition, they also have the advantage of allowing multiple drugs (e.g.
bronchodilators and antibiotics) and high doses of medication, to be delivered
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safely in patients with severe disease status and during a chest infection
(NICE, 2010).
A further preferred advantage expressed by participants when comparing
their devices was that nebulisers and pMDIs promote confidence in their use
compared to DPIs as they usually generate a visible mist, making
participants confident that they were getting the medication, whereas they felt
nothing when using some other hand-held devices.
I think I used to prefer the old Seretide [Seretide pMDI]. I was happy with it and I
did not want to stop it but the doctor suddenly told me to stop it and go for the
new one [Seretide Accuhaler]. With that one [nebuliser] and the old one
[Seretide pMDI] I used to feel something going into my lungs and I have noticed
some improvement but with the new one [Seretide Accuhaler] I feel nothing.
Female, 76 yrs old, using Ventolin pMDI, Seretide Accuhaler, Spiriva
Handihaler, Salbutamol and Atovent delivered by Side-stream nebuliser/ Porta-
neb compressor
To conclude, among nebulisers, the jet-nebuliser was the predominant form
that was used by patients at home. Jet-nebulisers were considered the
easiest of all the aerosol devices and the most preferred by three participants
who had experienced using all types of inhalation devices – pMDIs, DPIs and
nebulisers. However, this cannot be extrapolated to all patients, as only three
out of the 46 participants in this study used nebulisers. When selecting an
inhaler device for a COPD patient, these points (e.g. the likelihood that
participants are able to use the device correctly, preferences and adherence)
should be considered by the healthcare prescribers to optimize medicine,
though nebulisers have a restricted use in the treatment of COPD (NICE,
2010).
As recommended by NICE guidelines, nebulisers should not continue to be
prescribed until proper assessment is undertaken to ensure one or more of
the following: reduction in symptoms or improvement in lung function,
increase in exercise capacity or in the ability to undertake activities of daily
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living (NICE, 2010). In addition, they should not be prescribed without
examining patient’s ability to use them correctly (NICE, 2010). Other
recommendations made by the researcher include the following: to maximise
the drug delivery and to achieve optimal outcomes, patients’ inhalation
technique with the use of nebulisers should be assessed periodically or
annually. In addition, side effects such as tachycardia or tremor should be
assessed or examined when there is regular use of high doses of
bronchodilators via a nebuliser. The efficiency of the nebuliser system should
be assessed as well because the performance of the nebulisation system
may decrease with improper cleaning and/or maintenance.
6.4.4 Dry Powder Inhaler Devices
According to the NICE guidelines, in most COPD cases bronchodilators are
best administered by hand-held devices, including pMDIs and DPIs, unless
there are some special cases that require nebulisation therapy (NICE, 2010).
In this study, most patients (67%) were prescribed a combination of pMDIs
and DPIs inhalation devices to deliver the inhalation therapy. In regards to
the DPIs, bronchodilators were given to patients either alone by Accuhaler
(e.g. salbutamol), Turbohaler (e.g. terbutaline) or Handihaler (e.g. tiotropium),
or in combination with inhaled steroids which include Turbohaler (e.g.
formoterol and budesonide) and Accuhaler (e.g. salmeterol and fluticasone
propionate). The most used DPI devices in order were the Handihaler,
Turbohaler, Accuhaler, Diskhaler, Aerolizer and Clickhaler devices.
Therefore, it was decided to study whether these devices were used properly
and correctly by patients.
As a result of the inhalation technique assessment, it was found that the
deviation from the recommended technique was common among pMDIs and
DPIs users, though COPD participants made more errors when using the
pMDIs than DPIs.
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The two most common errors made by participants when using DPIs were
exhaling through the mouthpiece device or not breathing out away from the
inhaler before inhaling the dose (N=12) and failing to hold a breath for five to
10 seconds post-dosing (N=11) (Table 6-4). Exhalation into the device may
cause two issues: firstly, exhaling air into the mouthpiece can lead to blowing
of the powder out of the chamber, which makes it unavailable for inhalation.
Secondly, this exhalation contains a high amount of humidity, potentially
causing aggregation of the drug powder and therefore reducing its ability to
disperse during the inhalation process (Newman, 2005; Colombo et al,
2012). The second error regarding no breath-hold for about five to 10
seconds affects the lung deposition; studies found that the lung deposition is
better after holding the breath for five to 10 seconds rather than four seconds
or less (Newman, 2005; Colombo et al, 2012). Giving a time by breath-
holding enables drug diffusion and sedimentation in the lung, which
increases the amount of inhaled drug that is deposited (Newman, 2005;
Colombo et al, 2012). The first error was defined as a crucial or essential
error by Newman (2005), which may result in no drug delivery. However,
both errors were common among COPD patients in previous studies
(Molimard et al., 2003; Sestini et al., 2006; De Moraes Souza et al., 2009;
Rootmensen et al., 2010; Hämmerlein et al., 2011; Melani et al., 2011), as
well as this study.
Apart from the inhalation technique, when asking the participants about their
preferences for the DPIs, a number of them expressed their preference for
the multiple-dose devices (e.g. Accuhaler and Turbohaler), being easier to
load and operate when compared to the single-dose devices (e.g.
Handihaler), which contain capsules that need to be filled and loaded in the
device every time before each use.
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That one [Handihaler] is a bit fussy because you get to go through a long
process to clean and use. You have to take the capsule out [from the sealed
blister], open this [mouthpiece ridge], put the capsule there [centre chamber]
and pierce it. Unlike, this one [Accuhaler], all you need to do is press this [dose
release lever] and the medicine comes out.
Male, 95 yrs old, using Ventolin pMDI, Seretide Accuhaler and Spiriva
Handihaler
The Seretide [Accuhaler] is the one I prefer most and I think it is doing me good.
I do not have a reason but maybe because it is easier to use.
Female, 84 yrs old, using Ventolin Accuhaler with Aerochamber plus spacer,
Seretide pMDI and Spiriva Handihaler
In a previous study that assessed COPD patients’ preference and ease of
use of a multiple-dose DPI (Accuhaler) and a single-dose DPI (Handihaler),
by Moore and Stone (2004), it was found that 79% of Accuhaler users and
46% of Handihaler users were happy to continue using these devices, if this
was suggested by their physicians. A preloaded device with a month’s supply
of medication (e.g. Accuhaler) was preferred to the one that required single
doses to be loaded before use (e.g. Handihaler). The Accuhaler was
preferred by 67% of users who strongly preferred the preloaded device
compared to 33% of users who strongly preferred single doses (Moore and
Stone, 2004).
In this study, participants were also asked to state if they had a preference or
if they thought that their inhalers were all essentially the same in terms of
ease of use; more than three-quarters of the study participants (N=37) had a
conviction that all inhalation devices are similar, despite experiencing some
specific technical and practical issues. These respondents had no choice but
to use their inhalers as suggested. A few participants (N=7) stated their
preference for multiple-dose DPIs (e.g. Accuhaler and Turbohaler) over
single-dose DPIs (Handihaler), being quicker to load and easier to use
because most multiple-dose DPIs hold the powder in a reservoir, from which
individual doses are metered, or in individually sealed foil blisters within the
device (Newman, 2005).
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A further advantage for multiple-dose devices which made them superior or
preferred by some participants over the single-dose devices is their use with
fewer errors or deviations when performing the inhalation technique. The
observations of inhalation technique showed that the percentage of
participants who made at least one deviation from the recommended
technique when using DPIs was less when using Accuhaler (45%) and
Turbohaler (59%) than Handihaler (86%). Previous studies have shown
similar findings of a greater number of errors and lower patient preference
with single-dose devices compared to multi-dose devices (Moore and Stone,
2004; Wilson et al., 2007).
Moore and Stone (2004) reported that, when asking the patients to rate the
most important features of an ideal inhaler device, the three most reported
features were: being quick to use, overall ease of use and having a dose
counter that tells how many doses are left in the device. This is similar to the
findings of the current study, which found that patients’ preferences for a
certain device depended on being easy to use and load quickly.
This one is the one I prefer most [Accuhaler]. I do not have a reason but maybe
because it is easier to use. Another thing is that this [Accuhaler] has this window
which tells you how many doses you have left which is good.
Female, 84 yrs old, using Ventolin Accuhaler, Seretide Evohaler with spacer
and Spiriva Handihaler
Participants’ decisions to use the inhalation devices were not affected by the
type of the prescribed device or by the number of practical or technical
problems they experienced when using these devices, but by other factors
which were more integrated with patients’ perception about the need for
therapy, and the actual and perceived effectiveness and safety of the COPD
medication, which will be described in detail in the next chapter.
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6.5 Device handling
Apart from the inhalation technique, the majority of COPD participants did not
report experiencing any technical problems when using their inhalation
devices at home. However, a few participants reported some technical issues
only with the DPIs at home. These issues are addressed in details bellow
and should be taken into account for future practices in order to maximise the
medicine use. However, these issues did not affect participants’ decisions to
use the inhalation therapy as most of these patients were coping with these
issues differently, which is also described below. See Table 6-5.
Table 6-5: Technical problems reported by COPD participants with the DPIs
6.5.1 Issues with the Accuhaler devices:
In Moore and Stone’s study, 69% of COPD patients had no problems using
the Accuhaler device at home as well as this study which showed that three-
quarters of Accuhaler users (75%) reported no technical problem with the
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use of this device. However, a number of participants (N=6) reported
experiencing a problem with the use of Accuhaler device (Figure 6-2). In
Moore and Stone’s study, the most common issues encountered by
participants when using the Accuhaler device were opening the device and
sliding the lever (Moore and Stone, 2004), whereas, in this study the most
common issues reported were not being able to read the numbers in the
integrated dose counter, not being able to hear the click when sliding the
lever and doubts behind if the active drug was actually released when the
device was used. These issues have not previously been reported in the
literature.
Figure 6-2: Technical problems reported by participants with multiple-dose devices
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The integrated dose-counter of the Accuhaler
The dose counter facilitates dose tracking when patients administer multiple
doses and reduces the risk of running out of medication. However, reading
the dose counter or indicator that records how many doses remain in the
device was a problem for three participants using the Accuhaler. They
complained about being unable to read the numbers due to poor eyesight, or
the small font size on the dose counter. These difficulties arose with aging,
as vision continuously worsens, or with the emergence of a new condition,
such as a cataract, which in turn influenced their ability to use inhaler devices
properly. These patients either used reading glasses or a magnifying glass to
help them read the numbers, or they received help from family members.
Since I had my cataract surgery a few years ago I started using some eye drops
and I find it too difficult to read the doses left on that one [Seretide Accuhaler]
because these numbers are tiny. So what I usually do is either use my reading
glasses or ask my wife to read it for me.
Male, 85 yrs old, using Ventolin pMDI and Seretide Accuhaler
I just find the number of the doses left is too small to be read [Seretide
Accuhaler]. Sometimes, I have got to get my husband to have a look especially
if it comes to number two or seven, you know, the red colour [laughs].
Female, 84 yrs old, using Ventolin pMDI, Seretide Accuhaler and Spiriva
Handihaler
Having a dose counter that tells how many doses are left in the device was
one of the top three attributes of an ideal inhaler rated by patients, in Moore,
et al.’s study of 2004. To address these problems, firstly, pharmaceutical
companies such as GlaxoSmithKline should consider a larger window and
font size for the Accuhaler device to facilitate reading. Secondly, patients’
visual acuity should be assessed annually, especially for those who have
poor eyesight or cataracts, as this could affect the successful use of the
inhalation devices.
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Sliding the lever of the Accuhaler until it releases a dose
Two participants aged over 80 years acknowledged that a hearing problem,
either tinnitus or poor hearing due to age, affected their ability to hear the
click of the Accuhaler device when pushing the lever as far as it goes to
release the dose, raising the concern of unintentional non-adherence with
either no dose or extra dosing. Overdosing was likely for one of them, as he
admitted clicking the lever of the Accuhaler twice just to release the drug
because he was unable to hear the click the first time.
I just have more problems with the emergency blue inhaler [Ventolin Accuhaler],
I just push my thumb away from me as far as it will go until I hear a click but the
problem is I do not hear the click because I have tinnitus you see.
Female, 84 yrs old, using Ventolin Accuhaler, Seretide pMDI with Spacer and
Spiriva Handihaler
Because of my age I have some hearing difficulties so I cannot hear the click of
that one clearly [Seretide Accuhaler], so I use hearing aids to listen to the click
or ask my wife to make sure that I did it properly. I might click it sometimes
twice.
Male, 85 yrs old, using Ventolin pMDI and Seretide Accuhaler
These patients consult their doctors and have their medication reviewed to
assess their ability to use the Auccuhaler properly. If appropriate, hearing
aids or informal care can be introduced to avoid the misuse of this device by
these patients. If these solutions are not possible to be applied, a
replacement device may be appropriate, such as the Turbohaler device.
Concerns whether drug is actually released when the device is activated
A further problem stated by one participant who was unable to hear the click
when using the Accuhaler device was uncertainty whether the active drug in
the Accuhaler was actually released or not. One of the main characteristics of
pMDIs is that these devices contain propellants that produce a rapid-moving
plume of aerosol, which often feels cold on the back of the throat as the
propellants evaporate (Newman, 2005), whereas DPIs do not have this
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feature of releasing a small amount of fine powder. For this reason, one
participant reported being unsure whether she was using her Accuhaler
device correctly because she felt nothing after using it, unlike the pMDI
selected and used previously. The Seretide Accuhaler formulation contains
lactose (see Table 6-1), but clearly the patient did not experience the taste of
the sugar.
With the old one [pMDI] I used to feel something going into my lungs and I have
noticed some improvement but with the new one [Accuhaler] I feel nothing.
Female, 76 yrs old, using Ventolin pMDI, Seretide Accuhaler, Spiriva
Handihaler, Salbutamol and Atovent delivered by side-stream nebuliser/ Porta-
neb compressor
This issue may be a psychological matter or result from misuse of the device,
not a problem with the device itself, since the same patient reported two
technical problems with the same device: being unable to hear the click and
feeling nothing after the use. All these issues must be taken into
consideration when reissuing the same device to the same patient. In
addition, to ensure the greatest adherence to inhalation therapy, participants
should understand how a particular device works. If a device does not seem
to be working for a participant, non-adherence problems may emerge.
6.5.2 Problems with the Turbohaler device
As for the Accuhaler, the integrated dose counter and the uncertainty about
the release of the medication were problems for Turbohalers users. These
were common among 11 users of Accuhaler and Turbohaler, raising
concerns of device mishandling. Seven users reported experiencing these
problems with the use of Turbohaler: being unable to read the number of the
doses that are left in the device and uncertainty whether the active drug was
actually released (Figure 6-2).
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The integrated dose-counter of the Turbohaler
For the Turbohaler, when a red mark first appears in the dose counter
window it means that the Turbohaler has 20 doses left, and when it appears
at the bottom it means that the device is empty and a new device should be
obtained. In this study, three users of a Turbohaler device reported being
unable to see the red mark when it first appears. One participant reported
using her Turbohaler device for two consecutive weeks without knowing that
it was empty because she could not see that the red mark had reached the
bottom of the window, indicating an unintentional non-adherence. To
overcome this problem, one participant acknowledged disposing of his
Turbohaler devices before they get to the red mark, to limit the risk of running
out of medicines which would be cost ineffective and causes waste of health
resources; whereas another reported receiving help from his wife in regards
to this matter.
The last two weeks I was on and off the Symbicort [Turbohaler] because if I got
better you know I do not need to take them every day if I feel ok. I probably
missed them five or six times in the last two weeks. Let me show you my
Symbicort… Ooooh, it is down to zero. I could not see it. It must be empty then,
so I need a new one then.
Male, 71 yrs old, using Bricanyl Turbohaler, Symbicort Turbohaler and Spiriva
Handihaler
For the Symbicort [Turbohaler]: as a design it is not particularly clear how many
doses are left, so I tend not to go right down the red because it has got few
extra doses over a month. I tend to almost throw it when it gets near the end
and start on a new one.
Male, 63 yrs old, using Symbicort Turbohaler, Spiriva Handihaler and
Pyllocotincontius M/R tablets
As I get older, I do have sight problems, so sometimes if I do not have my
magnifying glasses I would ask my wife to help me to read this [the doses
remaining on the dose counter of the Turbohaler] .
Male, 77 yrs old, using Ventolin pMDI and Symbicort Turbohaler
These patients could be at risk of running out of medications, leading to
unintentional non-adherence, if no action is taken to resolve this problem.
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Concerns whether drug is actually released when the device is activated
Four Turbohaler users reported uncertainty regarding the release of
medication from the Turbohaler. This problem was reported more among
Turbohaler users than Accuhaler users (Table 6-5). Despite the Symbicort
formulation containing lactose (see Table 6-1), clearly patients did not
experience the taste of the sugar, which raised concerns about inhaler
mishandling. Participants compared their experience with the pMDI devices
when the spray was felt going into the lungs, as well as when using the
Handihaler devices, when a rattling sound was heard during use. These
experiences assured participants that they had received the dose of their
medicines, whilst they felt nothing when using their Turbohalers.
Well, as I said I do not know about this one [Turbohaler] and what it is doing but
this one [pMDI] at least I feel the puff and you feel something going into your
lungs.
Female, 78 yrs old, using Ventolin pMDI and Symbicort Turbohaler
I do not know but with this [pMDI] I used to feel something with it. You know
what I mean, but, when I am taking these [Turbohalers], I do not feel anything
going in. That is why I did not know if I am using these correctly. But if you use
those [pMDIs], and you press in [hpointed on the canister], you can actually feel
something, so I think they are better in that way.
Male, 83 yrs old, using Bricanyl Turbohaler and Symbicort Turbohaler
Actually, with this [Handihaler] I can hear something happening but with that
[Turbohaler] I cannot
Male, 63 yrs old, using Symbicort Turbohaler, Spiriva Handihaler and
Pyllocotincontius M/R tablets
To assure the greatest adherence to inhalation therapy, participants should
understand how a particular device works and what a drug actually does. If
an inhaled device does not seem to be working for a participant, other types
of inhalation devices can be considered.
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Twisting the coloured grip of the Turbohaler device to release the dose
In this study, one participant reported experiencing difficulties in twisting or
rotating the grip of the Turbohaler device. Wilson et al. (2007) reported that
failure to turn the wheel on the base or the grip was one of the major or fatal
errors during assessing the technique which result in no drug delivery
(Wilson et al., 2007). The same participant reported cleaning his device
inappropriately by washing it with water despite being told not to do so. This
resulted in accumulation of powder in the base of the device, which may
have affected its performance. A consequence of the lack of knowledge
regarding how to clean these devices was that their performance was
affected and blockage in the inhalation channels may have been caused.
Another problem was with the Symbicort [Turbohaler]: I have got one or two of
the Symbicort inhalers, so when it was not rotating quite well, then [I] started to
use another one. Maybe it is stopped rotating because it seems to be a build-up
of some powder or whatever, so what I did is just wash it but it did not work
afterwards.
Male, 67 yrs old, using Ventolin pMDI, Symbicort Turbohaler, Spiriva Handihaler
and Phyllocontin tablets
The manufacture’s cleaning instructions should be followed and applied step
by step as the performance of the inhalation devices and drug delivery could
be affected by improper cleaning and maintenance. All users of inhalation
devices, including the Turbohaler users, should be taught how to maintain
inhalation devices in a good condition. In addition, to obtain optimal results
from therapy, inhalation device functionality should be checked and
maintained.
6.5.3 Problems with the Handihaler device
When the inhalation technique was observed by the researcher, the
percentage of participants who made at least one deviation from the
recommended inhalation technique was more when using the Handihaler
device (86%) than when using the Turbohaler (59%) and Accuhaler (45%). In
addition, when participants were asked about how they handle their devices
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and whether they have experienced any technical problem with the use, most
problems were reported by Handihaler users. The Handihaler is considered
the most complex device to use when compared to the multiple-dose
devices, as it involves more preparatory stages to receive medication, so
more problems are likely to occur (Moore and Stone, 2004). Other studies
have also shown that patients were at a significantly higher risk of making an
error when using capsule-based DPIs (Hesselink et al., 2001). However,
these issues with the Hanidhaler device that were raised by users were not
detrimental to the use the device.
A previous study by Moore and Stone (2004) reported that the most common
errors in using the Handihaler device were opening the cover and/or
mouthpiece and removing the capsule from the foil. In another study of 30
COPD patients assessing the ease of use of four different DPIs, it was found
that failure to press the button to pierce the capsule was the most important
error, which would result in no drug delivery (Wilson et al., 2007). In this
study, the most common problem experienced by participants with the use of
the Handihaler involves the capsules, as illustrated below (Figure 6-3).
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Figure 6-3: Technical problems reported by participants with the Handihaler, single-
dose device
Problems in piercing the capsule
With regard to operating the Handihaler device, 10 out of 26 participants who
used the Handihaler device reported that it was not working appropriately.
The most common problem reported by participants was in piercing the
Spiriva capsule (Figure 6-3). For example, five participants stated that when
pressing the green button to pierce the capsule and release the dose, it
sometimes made the hole too large or fractured the capsule rather than
piercing it. This was problematic for some patients who were abroad and had
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only a few numbers capsules with them to use. Consequently, some tended
to use another capsule, which meant an extra dose was inhaled, leading to
overdosing. It can be concluded that inhalers with a complex operator (e.g.
Handihaler) can result in medication being misused or wasted when
operating the device. The misuse of the inhalation devices can result in the
medication being prescribed by physicians with a higher dose or adding other
medications to the existed regimens, leading to an increase in the direct and
indirect healthcare costs.
Occasionally with that one [Spiriva Handihaler] I am not actually sure if it makes
the hole too large sometimes, so I am not sure if the stuff comes out properly
then. It happened maybe once or twice. I am somehow felt it did not feel right.
Maybe because it gets a very distinctive noise when it is working, it rattles, so
when I checked it out and it did made the puncture hole in it. It did not seem to
make it any particularly larger but it definitely had a different sound. So, what I
did was I took another capsule put it in and did it again.
Male, 63 yrs old, using Symbicort Turbohaler, Spiriva Handihaler and
Pyllocotincontius M/R tablets
Sometimes it can make the hole bigger or fracture a little bit so you get a little
amount inside but I am very careful because then I look at it again and if I feel it
is not right.. I inspect it.
Female, 74 yrs old, using Ventolin pMDI, Seretide pMDI and Spiriva Handihaler
I think this thing [Spiriva Handihaler] does not sometimes puncture a capsule
properly. Sometimes it seems to break it rather than puncture it.
Male, 83 yrs old, using Ventolin pMDI, Clenil Modulite pMDI and Spiriva
Handihaler
One of the suggested reasons behind the failure in piercing the capsule
properly is that Spiriva capsules are made of two-piece hard gelatine
capsules, which may pose a problem for some patients of advanced age or
who have dexterity problems that may affect the proper use of their inhalers.
Another suggested reason is the improper storage of gelatine capsules,
which may have caused water loss from the gelatine and made it hard to
pierce. Capsules may get dried out when they are exposed to air due to
inappropriate storage or because of carelessly peeling back the foil too far
and exposing the next capsule to the air as well. All these factors can cause
problems when using the Spiriva capsules.
I have an awful gym to get these capsules out [Spiriva capsules]. I cannot get
them out but I have got a pair of scissors to help me get them out, so I cut the
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foil with scissors and leave them out to use them [Spiriva capsules] when I
need.
Female, 100 yrs old, using Atrovent pMDI with spacer, Spiriva Handihaler,
Pulmicort Turbohaler and Bricanyl Turbohaler
The capsule appears to be empty
Three participants reported that the Spiriva capsule appeared almost empty,
unaware of the fact that the Spiriva capsule contains only a very small
amount of powder; each capsule contains 18 mcg tiotropium blended with
lactose monohydrate. The delivered dose (the dose that leaves the
mouthpiece of the Handihaler® device) is only 10 mcg (EMC, 2013), the
capsule also contains lactose as an excipient. See Table 6-1 for a summary
of products.
I have often suspected that the capsule of the Spiriva [Handihaler] is empty. I
cannot really check it before I use it but after each dose I take, I open the
capsule and there is a tiny amount of powder left in there, so this obviously has
something in it. But occasionally I feel that there is nothing. I suspect that
perhaps if there is meant to be 30 capsules in a pack there are only 25 capsules
filled with powder and five are false.
Female, 70 yrs old, using Ventolin pMDI and Spiriva Handihaler
Lately I have had two failures of this one [the capsule of the Handihaler]. Just
recently, recently, I do not know if it was different manufacturer. Most unusual
but this happened within a week when I went ooooof [he took a deep breath]
nothing happened because nothing was in the capsule. That is the problem.
The capsule was empty.
Male, 74 yrs old, using Ventolin pMDI, Clenil Modulite pMDI, Spiriva Handihaler
and Becotide Diskhaler
One-third of the Handihaler users (N=9) reported experiencing issues with
the Handihaler capsule being either empty, hard to pierce or wrongly
administered. Great attention must be paid to these points when prescribing
a Handihaler device for COPD patients, as these issues can be real and not
belong to the patient’s psychology. The Handihaler capsule is used as a
dose-holding system that allows participants to check if the dose has been
administered successfully by opening the capsule to check whether it is
empty or not; in addition to that, when the capsule is put into the device and
when the dose is taken, participants should feel or hear the capsule vibrate
or rattle during inhalation from the Handihaler. In the case of not hearing a
Chapter 6 – The use of inhalation devices by patients with COPD
155
rattling sound, participants are advised by the researcher to open the capsule
and put it on a dark surface and if a fine powder comes out that means that
the drug was not released or fully taken.
In the past I opened them [capsules] and put the capsule on a dark surface but
the powder was still in there.
Female, 84 yrs old, using Ventolin pMDI, Seretide Accuhaler and Spiriva
Handihaler
To overcome this problem, participants should be educated about the
Handihaler device and the content of the capsule and how it can be
successful administered and checked to make sure that the device has been
used efficiently. In addition, healthcare prescribers should be aware of the
consequences or potential problems with the use of the Handihaler. If a
certain patient reports experiencing problems with the Handihaler more than
once, another device can be considered.
Erroneous administration of the Spiriva capsule
In this study, the unintended oral administration of a Spiriva capsule was
reported by two participants. This error stems from the fact that these
capsules resemble those taken orally, which is obviously not desirable.
What I have done on occasions is I swallowed one of these capsules [Spiriva
capsule] twice [a laugh].
Male, 74 yrs old, using Ventolin pMDI, Clenil Modulite pMDI, Spiriva Handihaler
and BecotideDiskhaler
The Spiriva capsule I should be very careful with because it looks very much
like a capsule that I need to swallow which I did once, so I mean if I took them
out and put them somewhere unless I actually know which tablet I might get
mistaken and swallow it. That is why I always keep it separated from all other
pills.
Male, 78 yrs old, using Ventolin pMDI and Spiriva Handihaler
Spiriva capsules should only be used with the Handihaler device and inhaled
through the mouth. According to the FDA, in 2005 they received 30 cases
regarding the accidental oral consumption of the Foradil Aerolizer and Spiriva
Handihaler capsules. Although no adverse event was reported, there were a
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few cases that had difficulty in breathing following oral ingestion (Tezky,
2005). Healthcare professionals should be aware of the potential for
accidental errors in regards to the unintentional oral administration of Spiriva
capsules as this may lead to adverse effects or a delay in the onset of action
and minimise the drug efficacy.
As a result, it is suggested that, when prescribing Spiriva to patients with
COPD, a cautionary label indicating that this capsule is "for inhalation use
only", "for use with inhaler only" or "for inhalation use with special inhaler
only" in the principal display panels of the labels, should be provided by the
unit-dose section in the pharmacy, if this was not on the manufacturer
package. In addition, pharmacists are advised to dispense a Handihaler
device for patients every time they collect their Spiriva capsules from the
pharmacy, even if a patient did not ask for a new device, to encourage
patients to always keep them together, which may be a good way to remind
them that this capsule is made for inhalation. This may help in avoiding the
misadministration of the capsule.
To conclude, it is important to consider the problems encountered by COPD
participants with the use of inhalation devices. These problems may result in
suboptimal adherence either intentionally (patients’ decision to not use a
certain device) or suboptimal drug delivery (patient has improper inhalation
technique or other technical problems), which may lead to suboptimal
disease control or treatment failures.
To summarise, as a result of the inhalation technique assessment, it was
found that the deviation from the recommended technique was common
among pMDIs and DPIs users, although COPD participants made more
errors when using the pMDIs than DPIs. Among the DPIs, it was found that
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the deviation from the recommended technique was more common among
Handihalers users than Accuhaler and Turbohaler users and this was the
same for the technical/practical issues encountered by participants when
using the inhalation devices at home. The number of participants who
reported experiencing technical issues with the use of DPIs was greater
among Handihalers users than Accuhaler and Turbohaler users.
With regards to inhalation technique, only 18 participants performed all the
steps correctly when using their inhaled medication, leaving nearly two-thirds
of the sample (N=28) at risk of inadequate drug delivery due to their
suboptimal inhalation technique. As a result, it is highly recommended to
counsel the patients about their inhalation technique in the context of the
problems faced at home with these devices, aiming to achieve the best
clinical outcomes.
Since adequate disease control relies on the appropriate use of inhalation
therapy, it is noteworthy that practical measures may be implemented to
reduce the number of deviations from good practice made by participants
and maximise the effective use of inhaled medicines. One of the suggested
measures is a practical reassessment of user’s technique by their healthcare
providers, such as a trained nurse during clinic visits, even if a patient claims
to know how to use these devices correctly. A second suggestion could be
the introduction of short- or long-term structured education programmes for
all patients without exception. It is important to check whether the disease is
well controlled by the proper use of COPD medication before introducing new
and costly therapeutic measures.
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6.6 Cleaning inhalation devices
After using the inhalation devices, the manufacture’s cleaning instructions
should be followed, as the performance of the inhalation devices and
medication dose delivery may be affected by improper cleaning and
maintenance. Additionally, in the case of the nebulisers there is a high risk of
infection due to bacterial colonisation of these devices, which may possibly
transmit to patients during their use (Colombo et al, 2012).
Maybe it [Turbohaler twist grip] has stopped rotating because it seems to be a
build-up of some powder or whatever, so what I did is just wash it but it did not
work afterwards.
Male, 67 yrs old, using Ventolin pMDI, Symbicort Turbohaler, Spiriva Handihaler
and Phyllocontin tablets
The proper maintenance of inhalation devices includes daily care of cleaning
and drying. Manufacturers advise patients to clean their inhalation devices
such as nebulisers, spacers and Handihaler device with warm water or warm
soapy water, rinsing in tap water and then allowing them to air dry. Others
(e.g. pMDIs, Turbohaler and Accuhaler) are recommended to be wiped with a
dry tissue or paper towel (Table 6-6 and Table 6-7).
When participants were asked if they cleaned their inhalation devices used at
home, more than half of the participants (N=26) indicated that they always
did so properly, whereas 20 participants indicated that they never cleaned
their inhalers. Those who did not clean their devices were either not
motivated to clean them or found it difficult to do so, especially single-dose
devices such as Handihaler. Others were unaware of the fact that they
should be cleaned regularly or they did not know how to do it. Lack of
education regarding cleaning and maintaining of the inhalation devices in a
good condition was a reason reported by participants who did not comply
with the cleaning and maintenance instructions provided by the surgery or
patient information leaflets for each device.
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Now I do not do any cleaning, no, because that one [Spiriva Handihaler] is a bit
fussy because you got to go through a long process to clean.
Male, 95 yrs old, using Ventolin pMDI, Seretide Accuhaler and Spiriva
Handihaler
I have never been told how I should clean or store my inhalers and I have never
asked for such advice.
Female, 65 yrs old, using Ventolin pMDI and Symbicort Turbohaler
Well, I do not do that [clean]. I am a bit silly about that. Why, should we clean
the inhalers? Are there methods to clean these?
Male, 72 yrs old, using Ventolin pMDI, Pulmicort Turbohaler and Spiriva
Handihaler
Another reported reason for not cleaning the inhalation devices, as
acknowledged by four participants, was that the devices were limited to
single patient use (personal use only). They claimed that, in the absence of
the concept of sharing the devices, there was no need to clean the device.
As nobody else uses them, why should I clean them? So that is one of the
reasons why I do not clean them and they do not get dirty or wet or anything like
that.
Male, 87 yrs old, using Bricanyl Turbohaler, Symbicort Turbohaler and
Bumetanide tablets
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Table 6-6: Frequency of cleaning inhalation devices
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Table 6-7: Method of cleaning inhalation devices
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In this study, the majority of participants were found to either not clean their
devices at all or to be non-compliant with the manufacturer’s
recommendations and guidelines on how to properly clean their devices. This
may affect the performance of these devices and therefore the drug delivery,
which may lead to treatment failures. Therefore, COPD patients should be
aware of current practice guidelines and recommendations provided for the
inhalation device in regards to the cleaning and maintenance. Additionally,
they have to be encouraged by healthcare professionals to comply with these
guidelines and recommendations during each visit.
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7 Chapter Seven: The use of medicines in the management
of COPD
This chapter addresses the first and the second objectives of this study which
concern the use of multiple inhalation therapies by COPD patients in the
management of their condition. It also describes patients’ use of their COPD
medication in the context of their daily lives. In addition, it gives an insight
into patients’ decision-making regarding using inhalation therapy and the
factors that influenced their decisions to use these medicines, in order to
provide all the necessary assistance tailored to each patient who is at high
risk of non-adherence or treatment failures, which may in turn maximise the
use of medicines and reduce the number of treatment failures and healthcare
costs.
7.1 The use of multiple inhalation therapies by patients in the
management of their condition
Data analysis indicated that participants’ positive attitude towards the disease
by accepting it as incurable and living with it helped them to be more realistic
about the treatment and its outcomes. Participants who accepted their
disease and understood the role of medications were using their inhalation
therapy as suggested and coped well. On the other hand, denial of illness
can be a contributory factor to medication non-adherence and subsequent
treatment failures.
I have no concerns that stop me from taking my inhalers because asthma is not
curable. I would like to take nothing but it is not curable.
Female, 78 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
I presume medication is doing me good. It is not curing it because it cannot cure
it but it is keeping it at bay.
Female, 80 yrs old, using AeroChamber Spacer Plus with adult comfortSeal
mask, Ventolin Evohaler pMDI, Seretide Evohaler CFC-free, Seretide Accuhaler
and Prednisolone tablets
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In terms of medication use, the data showed that the majority of participants
accepted their medication regimens after questioning and evaluating the
need for therapy and did not articulate any worries or concerns about taking-
medication, especially when their condition was well controlled by the
regimen. They were happy to continue on their current drug regimens,
despite in some instances making some alterations to the drug regimens
(see section 7.3)
Actually my COPD is stable on the current regimens. It is usually not at all a
problem.
Male, 67 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler, Spiriva
Handihaler and Phyllocontin tablets
In general I am happy with what I am using and they [COPD medications] are
doing what they are supposed to do.
Female, 74 yrs old, using Ventolin Evohaler pMDI, Seretide Evohaler and
Spiriva Handihaler
In contrast, a few participants were not using their COPD medications as
suggested because they either had worries or concerns about taking these
medications or considered their medications as a ‘poison’ or ‘harmful
substances’, and therefore tried to avoid them as much as possible. This was
articulated by three participants who tried to either tolerate the symptoms, or
looked for alternatives or returned to the doctor asking for advice or changes
to the current regimens.
My own doctor felt I should have taken more medicines but I did not really like
taking it and you know it is a drug, is it not?
Female, 78 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
I did not want to have steroids. Steroids are artificial products inside your body.
Female, 65 yrs old, using Symbicort Turbohaler and Ventolin Evohaler pMDI
I went to see the person who does the COPD but I was not impressed by him
because he told me I need to take two of these inhalers twice a day [she
pointed to Spiriva and Seretide] but when I went to see my doctor in my old
surgery and told her about what happened, she said, “No you only need to take
this one once” [she pointed on Spiriva] and I said, “Well that is what he said”.
She said, “He should not have told you that”.
Female, 77 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler, Spiriva
Handihaler and Salamol Steri-Neb
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Participants made judgments and alterations to their current COPD
medicines based on different factors (Figure 7-2). Participants were therefore
questioned to see whether they were adherent to their prescribed regimens,
what alterations were made, what medication(s) was/were not taken as
suggested and what the reasons were behind their actions. As a result,
adherence to COPD medications was measured using the self-report Morisky
Medication Adherence Scale (MMAS). In addition to enhancing the validity of
the data, and examining and gaining insights into medication-taking
behaviours among these participants, participants were asked to answer
some open questions regarding their medication use (e.g. for your regular
medicines, people often do not take their medicines exactly as prescribed for
different reasons. Thinking of the medicines you use for your COPD, when
was the last time you did not take the dose of your regular medicines? How
many times in the last week have you missed a dose of your regular COPD
medicines and why did you miss them?) to understand the unanticipated
results from quantitative data (Morisky scale) and to identify issues behind
non-adherence to COPD medicines.
The eight-item MMAS usually scores range from 0 to 8, which have been
categorised as high, medium and low adherence (MMAS score of 8, 6 to <8,
and <6, respectively) (Figure 7-1). However, in this study participants were
identified as ‘adherent’, if they scored eight in MMAS, whereas, if a
participant scored less than eight in the Morisky scale, their adherence was
classified as suboptimal. According to the MMAS scores, 24 participants
were adherent to their COPD medicines (scored 8), whereas 22 (48%)
participants had suboptimal adherence (scored<8). Therefore, close attention
should be paid to those with suboptimal adherence, to see what
medication(s) was/were not taken as required and why, to optimise the use of
medicines in this group.
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Figure 7-1: The total adherence score of the MMAS scale
When participants started inhalation therapy, they tended to make some
amendments or alterations to their prescribed regimens (e.g. discontinuation
or adjustments to therapy or intermittent use of therapy). These behaviours
were directed by the balance of an individual’s reasons for and against taking
medication. Intermittent or discontinued use of COPD medicines was
associated more with the long-term use of long-acting bronchodilators and
inhaled corticosteroids, or adjusted to meet certain needs, especially with the
use of short-acting bronchodilators. Short-acting bronchodilators were over-
used as a preventative approach, to prevent symptoms from getting worse
and prolong symptom-free periods, which exceeds the use based on the
symptoms to include taking a prophylactic dose as a precautionary measure
(see section 7.3). This behaviour was related to the perceived immediate
benefit of short-acting medication on symptom relief.
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Well, I take this one as a preventative [salbutamol] when I will probably be
climbing stairs or something like that because it gives me instant relief.
Male, 83 yrs old, using Ventolin Evohaler pMDI, Clenil Modulite pMDI and
Spiriva Handihaler
Adherence to long-acting bronchodilators and ICS was found to be
suboptimal with those who reported suboptimal medication adherence. This
resulted from the prolonged efficacy provided by long-acting bronchodilators
and ICS on the symptom’s relief.
Probably I do not need that [tiotropium] but I take it sometimes. Those two
[beclometasone and tiotropium] are something that does not affect you as soon
as you take them. Does it? You need to give it time but if I took Ventolin
[salbutamol] it would help immediately, so I take it but neither of those
[beclometasone and tiotropium] is going to help me immediately if I was in a bad
way.
Female, 72 yrs old, using Ventolin Evohaler pMDI with spacer, Clenil Modulite
pMDI and Spiriva Handihaler
This one [salbutamol] might make an improvement because it has immediate
effect whereas this [tiotropium] does not have an immediate effect, so I am not
sure whether it does me good or not and whether I should use it.
Male, 95 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and Spiriva
Handihaler
Among the LABA and ICS users, more concerns expressed for ICS. The
reason for these concerns is that some participants responded better and
quicker to the LABA than the ICS and, for this reason, preferentially used the
LABA. In addition, experiencing side effects or fears of side effects with the
use of ICS was greatest among participants (see section 7.3).
The doctor decided to put me on Seretide [salmeterol /fluticasone] and he said
try this but it was painful for the first week because it gives you cramps and
everything else like that, so I stopped it for a while until these signs
disappeared.
Male, 63 yrs old, using Ventolin Evohaler pMDI, Clenil Modulite pMDI,
Mometasone furoate nasal spray, Seretide Accuhaler and Carbocisteine
Capsule
The next sections give further information on the factors that influenced
medication use among patients with COPD. Understanding these factors and
addressing patients’ adherence issues may help in optimising medicine use
and improve treatment outcomes.
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7.2 Factors affecting patients’ decision to use the inhalation therapy
Various factors were found to affect patients’ decision making to use the
inhalation therapy (Figure 7-2).
Figure 7-2: Factors which affected patients’ decision to use their inhalation therapy
7.2.1 The presence of symptoms
Some participants reported using inhalation therapy in response to their
symptoms, with intermittent dosing usually in response to worsening
symptoms. Lack of COPD symptoms (feeling well) for some participants
resulted in discontinuation of inhalation therapy or some alteration in dosing
frequency, as at such times medication was seen as unnecessary.
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I have not used any inhaler today or yesterday because I felt good and I do not
need to take any. Whether I have missed… I missed a bit, maybe half a dozen
[six doses] because as I said I just used them as an emergency.
Male, 83 yrs old, using Bricanyl Turbohaler and Symbicort Turbohaler
I stopped using it [salbutamol] without telling my doctor because I felt it was
unnecessary
Male, 74 yrs old, using Ventolin Evohaler pMDI with Volumatic spacer, Seretide
Accuhaler
In the past I have reduced some doses of my COPD medicines especially the
Clenil [beclometasone] because I felt good. You know sometimes you do self-
medicate yourself, increase or decrease doses based on your condition.
Female, 72 yrs old, using Ventolin Evohaler pMDI with spacer, Clenil Modulite
pMDI and Spiriva Handihaler
Participants stated that their decisions to use inhalers, timing, and frequency
of dosing depended on their views and perceived needs for COPD therapy.
Participants reported using their inhalation therapy at less or more than the
prescribed dose frequency based on their judgments. Underuse of
medication was identified more in asymptomatic patients or in those who
have noticed signs of improvement in their symptoms. Some asymptomatic
participants reduced doses, stopped medication for a while, or decreased
dosing frequency. Participants made such judgments based on what they
thought would benefit their respiratory condition.
I usually take one inhalation in the morning and one inhalation in the evening of
this one [formoterol/ budesonide]. If my case gets bad, I take two puffs twice a
day instead.
Female, 65 yrs old, using Symbicort Turbohaler and Ventolin Evohaler pMDI
They suggest using this [beclometasone] morning and evening but I feel if I am
feeling ok, you know, I do not bother to use it. I only use it for necessary things.
I usually take two puffs when I feel bad, giving a little time between each one.
Female, 76 yrs old, using Ventolin Evohaler pMDI and Clenil Modulite pMDI
In contrast, overuse of medication was reported more for symptomatic
patients who experienced deteriorations in their symptoms. In response to
this some participants reported taking more than one formulation or
increasing the dosing frequency to compensate.
Sometimes I get very breathless or if I go upstairs I feel wheezy, so I take one
inhalation more of the Symbicort [formoterol/ budesonide] and I feel better.
Female, 67 yrs old, using Ventolin Evohaler pMDI and Symbicort Turbohaler
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Other participants reported using their inhalation therapy preventatively to
prevent symptoms worsening, especially when doing activities such as
walking up hills, climbing stairs or when sleeping at night. Participants
worked out a new dosing schedule to prolong the symptoms-free period.
I use it [formoterol/ budesonide] first thing in the morning when I get up
whenever the time is and then last thing in the evening before I go to bed I take
a couple of puffs because it stops the congesting during the night.
Male, 77yrs old, using Ventolin Evohaler pMDI and Symbicort Turbohaler
Generally, if I go walking with a friend I take two puffs of the Ventolin
[salbutamol] before I go out and I even carry it with me. I would not go anywhere
without it. But if I am going to exercise, I do it [take a dose] before, you know. I
sometimes need to use it again.
Female, 78 yrs old, using Ventolin Evohaler pMDI and Symbicort Turbohaler
Sometimes when I go upstairs, you know if I am busy and I am up and down the
stairs, then I find sometimes I use those [COPD medicines].
Female, 76 yrs old, using Ventolin Evohaler pMDI and Clenil Modulite pMDI
7.2.2 Actual/perceived effectiveness of medication
The actual or perceived effectiveness of inhaled therapy was found to
influence a participant’s decision to use the therapy. Participants were likely
to exhibit medication non-adherence especially if the medication was
perceived as not fully effective, or as unnecessary (see section 7.3). Such
participants deliberately skipped some daily doses, or discontinued therapy,
especially if not considered effective.
The only one I skipped deliberately is the Spiriva [tiotropium], because I do not
think it does any good quite honestly. It is not making any difference, no.
Male, 83 yrs old, using Ventolin Evohaler pMDI, Clenil Modulite pMDI and
Spiriva Handihaler
Section 7.3 gives more information on patients’ perceptions regarding
effectiveness of therapy and their influence on medication-taking behaviours.
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7.2.3 Actual/perceived safety of medication
The actual or perceived side effects of therapy were also found to influence
participants’ decision to use the inhaled medication. Individuals were more
likely to be non-adherent if the medication was perceived as unsafe or
caused unwanted side effects. Previously experienced side effects influenced
participants’ decision to use the inhalation therapy, especially inhaled
steroids. In order to decrease exposure to the inhaled corticosteroid, some
participants deliberately decreased dosing and adopted a dosing schedule to
decrease their exposure to the drug. Section 7.3 gives more information on
the actual and perceived safety of the COPD medication and the influence of
these perceptions on medication-taking behaviours.
I know most people would take Seretide twice a day but I do not. As you know it
[salmeterol/ fluticasone] contains steroids and I was already in the past taking
lots of steroids, so with that I do believe this amount would kill me at the end.
Female, 78 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
7.2.4 Embarrassment at using inhalers
Feeling embarrassed using inhalers in a public place also impacted on
decision-making regarding using therapy. Three participants worked out a
dosing schedule to use all their inhalation therapy whilst they were at home
only. Even if the need arose or the daily dose was due when they were away
from home, these participants tended to ignore this dose due to being
embarrassed or ashamed to use their inhaled medications in public. They
preferred either to miss a dose or sit and wait for the symptoms to resolve or
wait until they were able to use their inhalers in private.
I also sometimes do not use Ventolin in public as I feel embarrassed to use it in
public, because COPD is a disease that you feel very guilty about. Even when I
am out in a theatre or a party, I carry around my inhaler with me all the time, but
I either do not use or use it in a private area because I am very embarrassed
about this disease. I know it is stupid.
Female, 71, yrs old, using Ventolin Evohaler pMDI and Seretide Accuhaler
Sometimes when I am out or visiting friends, my Ventolin will be in my hand bag
but I do not like to use it in public because I do not like to draw attention to
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myself or maybe I just go to the toilet and take it as I do not like to make people
think that there is a problem with me.
Female, 65 yrs old, using Symbicort Turbohaler and Ventolin Evohaler pMDI
I should be honest with you. I have never used my inhalers in public even if I felt
I need to, except in front of my husband.
Female, 76 yrs old, using Ventolin Evohaler pMDI and Clenil Modulite pMDI
7.2.5 Medication regimen-related factors
The number of COPD medications being used by an individual was found to
influence their decision to use the inhalation therapy. A number of
participants reported that, when the number of medicines used per day
increases, the adherence to the recommended drug regimens decreases.
I tried to use it [formoterol/ budesonide] for a certain period of time as I was told.
But you see I have got so many things wrong with me in the heart and eyes, so
it is not a thing you adore, is not it [laughs], and because I have got so many
medications, so I stopped it.
Female, 89 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler and
Spiriva Handihaler
The greater the complexity of the medication (e.g. the number of medications
and the number of doses/day), the less likely the patient was to fit
medications into their daily schedule, and, therefore, the less likely to adhere
to the medication regimen. One participant, who had a complicated drug
regimen with frequent doses, was unable to fit medication taking into his daily
schedule, and found medication taking hard to deal with.
My dosage regimen is such a nuisance because sometimes you have got to
take too many medicines during the day and you should take some before
meals, some after meals and some with meals, which is so hard and drives me
mad.
Male, 87 yrs old, using Bricanyl Turbohaler, Symbicort Turbohaler and
Bumetanide tablets
7.2.6 Emotional distress
Three participants reported that significant emotional changes triggered
COPD symptoms. For example, emotional incidents, especially deaths of
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“dear ones”, worsened the condition itself, and compromised COPD
medication intake and led to unhealthy lifestyle choices; as the absence of a
strong motivational factor influenced patients to be non-adherent to their
COPD medication.
I do have a major problem at the moment; obviously I was a smoker and have
been for 15 years. That’s what causes this. Two years ago, I stopped smoking
for nine months but them a huge thing happened in my life which was a death
and it was very emotional. Then I stopped taking my medication for a while and
I started smoking and again six weeks ago something else happened in my life
which was sad and I have started again. Anyway, if a major thing happened in
your like a death you tend to automatically go back to smoking. I know it is not
good and not helping and I think that what is probably making my breathing
worse.
Female, 71 yrs old, using Ventolin Evohaler pMDI and Seretide Accuhaler
I found after my husband died I started to get nervous asthma and sometimes I
missed a dose or two of my medications [COPD medication]. Anytime that I was
actually, you know, very nervous or anxious about anything, I found it hard to
breathe. I find since I have got older, I am being anxious about anything. You
can get to this stage where things go wrong and you start to kind of feel a bit of
anxiety and I have this problem with my grandchildren as well, which causes
lots of problems.
Female, 68 yrs old, using Qvar Easi-breathe and Bricanyl Turbohaler
In summary, this study has shown that medication-taking behaviours are
dynamic, being directed by different factors which are related to the patient’s
treatment and disease. These factors had an influence on patients’ decisions
to use the inhalation therapy leading to treatment failures and poor clinical
outcomes. Addressing patient challenges to medication use (adherence),
may help in introducing some interventions by healthcare professionals in the
future to alleviate some of the issues that prevent patients from using their
inhalation therapy as suggested. The next section, 7.3, discusses patients’
perception about the efficacy and safety of therapy in greater detail, and how
this can affect the patients’ use of their COPD medications.
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7.3 Participants’ views and experiences regarding actual and
perceived efficacy and safety of the inhalation therapy
This section describes participants’ views and experiences with regards to
the actual and perceived effectiveness and safety of the inhalation therapy,
and the benefits and drawbacks raised by participants regarding therapy
used at home. Providing this information to healthcare services may enable
healthcare professionals to assist COPD patients who are using this therapy
in their homes in optimizing medicine use and improving treatment outcomes.
7.3.1 Perceptions regarding treatment efficacy
This section provides an insight into COPD patients’ perceptions about the
inhalation therapy they use at home, what medication was perceived to be
not fully effective, and how this affected participants’ decisions to continue or
discontinue therapy.
7.3.1.1 Efficacy of therapy perceived as suboptimal
To identify the number of participants who perceived their inhalation therapy
was effective from those who did not, the following procedure was
undertaken: a direct question was asked to all participants (N=46), i.e. what
do you think of your regular COPD medicines in regards to their efficacy and
which one do you find helpful? The data revealed that three-quarters of
participants (N=34) perceived their inhalation therapy to be effective,
especially when it was used in combination. Their answers were followed in
more depth by asking them to explain in more detail what they meant by
being effective or not fully effective.
One-quarter of participants (N=12) reported that they believed their inhalation
therapy was not fully effective, leading to treatment failures represented by
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recurring symptoms, persistence of symptoms, exacerbations or hospital
readmissions.
I cannot say they are good [COPD medicines]. I do not know, but I wonder if
there is one that may have a bit of a stronger effect. It will be preferable
because until now I cannot clear up my chest.
Male, 68 yrs old, using Symbicort Accualer and Spiriva Handihaler
My case [breathing] is definitely getting worse because the medication does not
seem to do that much good I have to say. We have got a park opposite; it is not
hilly but there are some light heights which I find difficult to climb. I also meet
lots of friends there and I cannot talk due to becoming too breathless.
Female, 71 yrs old, using Ventolin Evohaler pMDI and Seretide Accuhaler
I often get a panic attack of asthma. I had a panic attack about a month ago
when I could not breathe, so we called the ambulance. They said all I needed
was oxygen, I was low on oxygen.
Female, 77 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler, Spiriva
Handihaler and Salamol Steri-Neb
The reasons for treatment failures are likely to be due to factors such as
disease progression, behaviours that contribute to suboptimal efficacy of the
therapy such as smoking, circumstances that contribute to suboptimal
efficacy of the therapy, for instance getting a seasonal infection such as
influenza, developing resistance to the medication, suboptimal adherence to
therapy, which was detected in nearly half of the sample and/or suboptimal
inhalation technique, which was detected in more than half of the sample.
The result is discontinuation of therapy, the intermittent use of treatment, or
decrease in the dosing frequencies, which may lead to a further treatment
failure and suboptimal outcomes.
The only one I skipped deliberately is the Spiriva [tiotropium], because I do not
think it does any good quite honestly. Since I used it, it is not making any
difference, no.
Male, 83 yrs old, using Ventolin Evohaler pMDI, Clenil Modulite pMDI and
Spiriva Handihaler
Disease progression and persistence of symptoms
The progression of COPD and/or the persistence of symptoms influenced
participants’ decisions and perceptions regarding treatment and its
effectiveness. For example, when adequate control of symptoms was not
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achieved, due to increase in the severity of the disease, some cases of
treatment failures were registered; consequently alterations to patients’ drug
regimens were made by healthcare professional adding a new medication,
stepping up therapy or switching to another therapeutic group such as from
bronchodilators to adding steroids or steroids to adding other steroids.
I was on Clenil [beclometasone] for 20 years but it was not good. Recently the
doctor discontinued this one [beclometasone] because I had a very bad
shortness of breath when I was teaching at school and he put me on this
[formoterol/ budesonide].
Female, 65 yrs old, using Symbicort Turbohaler and Ventolin Evohaler pMDI
Well, this Pulmicort [budesonide], which I used to take and this particular night
we were going on a holiday on Friday. On Saturday night, I took that one
[budesonide] which kept making me sleepy, very sleepy, and I fell asleep and
then went for a bath; the following morning I found all my ribs were weakened
and I could hardly walk. My breathing was very bad, so it was discontinued by
the doctor because I was having some side effects as well and the doctor put
me on this one [beclometasone].
Female, 68 yrs old, using Qvar Easi-breathe and Bricanyl Turbohaler
Developing resistance may contributes to suboptimal efficacy of the therapy
Developing resistance to some medication such as salbutamol due to long-
term use has made some participants think that their salbutamol is no longer
effective. This belief influenced the use of the medication by COPD
participants as it was used at a minimum level or was discontinued for a
certain period of time, which led to treatment failures. Participants reported
that the effectiveness of their salbutamol declined over a prolonged period of
time as the symptoms-relieving effect was noticeably less than when
salbutamol was first started.
I used to take the Ventolin first thing in the morning before anything else
because initially I used to get a bit of relief with that. Now I do not know; I do not
get any relief. Does it seem to change things? I do not know. After a while I did
not seem to get any relief so I stopped using it for a while.
Male, 76 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler and
Spiriva Handihaler
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Suboptimal adherence and/or inhalation technique which may contributes to
suboptimal efficacy of the therapy
Suboptimal adherence to inhalation therapy was apparent for nearly half of
the sample (48%) and suboptimal inhalation technique for more than half of
participants (61%). These factors may cause treatment failures among
COPD patients. Nearly one-quarter of patients (N=6) who received tiotropium
treatment perceived that their tiotropium therapy was not fully effective. The
lack of efficacy reported by these participants could be due to the following:
firstly, this medicine was not taken by participants as directed because it was
perceived to be not fully effective, as long-acting bronchodilators such as
tiotropium have no immediate effect on symptoms. Secondly, when
assessing inhalation technique, it was found that the percentage of
participants who made at least one deviation from the recommended
technique when using the Handihaler device, which delivers the tiotropium,
was 85.7% of all participants (see Chapter 6). Treatment failures and
worsening of symptoms were reported, and, therefore, participants
deliberately missed some daily doses or discontinued tiotropium.
I do not notice any difference between my inhalers but I was told you must take
these continuously. Now and again, in the past a year ago or something like that
they found I was not going back to the chemist for the next one [tiotropium] just
to see what is going to happen  if I did not take it. They did a review in the
practice and noticed that I have not been taking it because it was useless.
Male, 76 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler and
Spiriva Handihaler
ICS therapies were perceived by some participants to be not fully effective,
and lacking in efficacy or causing side effects. Unwanted adverse effects, or
concerns about future adverse effects, were a major issue raised by
participants who were unwilling to use a particular medicine, especially
medicines that contain steroids, such as beclometasone and budesonide.
I had a small concern when I was first prescribed Symbicort. I do remember that
I asked the doctor about whether there is a steroid in it because I did not want to
have steroids due to their side effects.
Female, 65 yrs old, using Symbicort Turbohaler and Ventolin Evohaler pMDI
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Behaviours that may contribute to suboptimal efficacy of the therapy
One reason for treatment failures, and therefore the perception that the
inhalation therapy was not fully effective, was in relation to smoking. For
example, some participants who have a smoking history perceived their
inhalation therapies were suboptimal. They blamed themselves or spouses
for the worsening of their symptoms, or development of their condition into a
more severe stage.
Emphysema is a build-up of smoking because I used to smoke but I am not
convinced that smoking… yes it is a contributing factor… but I am not convinced
that smoking is totally responsible for lung problems generally and even since I
stopped smoking I have not noticed any improvement in my lung function and
my medicines do not do that much.
Male, 76 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and Spiriva
Handihaler
The doctor told me I have got a chronic bronchitis and this is through passive
smoking. I gave up smoking but my husband smokes around me all the time
that’s why I feel sometimes that my inhalers are not helping.
Female, 78 yrs old, using Ventolin Evohaler pMDI and Symbicort Turbohaler
Circumstances that may contribute to suboptimal efficacy of the therapy
Getting a seasonal infection, such as a viral or bacterial infection, was
another reason that participants believed contributed to failure of treatments
and therefore participants’ views on the suboptimal efficacy of the treatment.
Two participants judged their inhalation therapy was not fully effective due to
getting chest infections more frequently during the past year.
Until now I cannot clear up my chest. I also have some difficulties with getting a
virus infection every month. Last month I got a viral infection and could not
breathe and I thought I am going to die and my medicines did not help at all.
Male, 68 yrs old, using Symbicort Turbohaler and Spiriva Handihaler
To conclude, participants who perceived their inhalation therapy was
suboptimal had either stopped and then restarted their medication, or
discontinued it without keeping the doctor informed, due to either the lack of
the actual effect or participants’ views on the suboptimal effect of the
treatment received.
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I stopped using it [salbutamol] without telling my doctor because I felt it was
unnecessary
Male, 74 yrs old, using Ventolin Evohaler with Volumatic spacer, Seretide
Accuhaler
Providing information for healthcare providers in regards to what medication
was perceived to be suboptimal by participants, how these views influenced
the use of medicines, and what patients actually did will enable a better
understanding of patients decision-making, permitting interventions to correct
erroneous views or actions toward treatments, and provide the appropriate
education and guidance for patients so that decisions are based on the
balanced views of the facts. This may help in optimising medicine use and
improving treatment outcomes.
7.3.1.2 Efficacy of therapy perceived to be optimal
The majority of participants (N=34) perceived that their inhalation therapy
was effective, especially when used in a combination of drug classes.
Participants referred to clinical measures such as FEV1 or indicators (e.g.
relief of breathlessness) to assess the impact and efficacy of their medicines.
As reported by participants, the benefit was seen in the relief of COPD
symptoms, stopping bronchoconstriction during the night and making it easier
to breathe while sleeping, and an increase in their activity levels, in making
daily activities possible.
My COPD medicines are good. Lately I went to the hospital and the nurse
tested my FEV1 and she was happy with the results.
Female, 71 yrs old, using Ventolin Evohaler pMDI and Seretide Accuhaler
Somehow they [inhaled medicines] relax the muscles and the airways.
Male, 71 yrs old, using Bricanyl Turbohaler, Symbicort Turbohaler and Spiriva
Handihaler
Well, these inhalers make the normal activities possible.
Male, 67 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler, Spiriva
Handihaler and Phyllocontin tablets
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I find [salbutamol] helpful and it saves my life. I use it sometimes during the
night when I feel tight-chested to help me sleep.
Female, 78 yrs old, using Ventolin Evohaler pMDI and Symbicort Turbohaler
The improvement in patients’ symptoms was related to the perceived
immediate benefit of short-acting bronchodilators for symptom relief, when
used in combination with long-acting bronchodilators, or benefit of the ICS
that provide prolonged efficacy with respect to symptom relief. For example,
participants who used a combination therapy of short-acting bronchodilators
(e.g. salbutamol) and maintenance therapy of LABA and ICS reported that
the relief was seen immediately, especially with the use of short-acting β2-
agonist drugs.
I am happy with the current regimen because the Ventolin [salbutamol] is good
and very helpful if you hoover over something or when you do something you
should not do like polishing or dusting. Then you instantly take the Ventolin and
you feel better after 10 or 15 minutes, and when I take these
[fluticasone/salmeterol and tiotropium] later on, they usually take a longer period
to act but they add a stronger effect.
Female, 84 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
Well, they both have different functions [Symbicort and Bricanyl]. Symbicort
(budesonide/ formoterol) is to combat COPD.. Right! Whereas, Bricanyl
(terbutaline) is a reliever, it helps symptoms to disappear not to cure. Do you
follow what I am trying to say? I think Symbicort is a very good thing to use
because it stops the symptoms from taking over, if you like, whereas, Bricanyl
eases my breathing as a reliever.
Male, 87 yrs old, using Bricanyl Turbohaler, Symbicort Turbohaler and
Bumetanide tablets
Participants reported that relief was felt immediately with short-acting β2-
agonist drugs, although it was temporary or for a short period of time and the
medication needed to be repeated 2 to 4 times during the day to maintain the
effect. Some participants stated a gradual relief (happening slowly) with all
other COPD medicines, especially products that contained long-acting
bronchodilators (e.g. tiotropium and salmeterol) and long-acting
corticosteroids (e.g. fluticasone and beclometasone). This gradual effect
made some participants uncertain about how effective these medicines were
and whether they were doing them any good or not. As a result, doubts were
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expressed about the effectiveness of long-acting bronchodilators and inhaled
steroids, which may affect patients’ use of their medications.
Those two are something that does not affect you as soon as you take it
[beclometasone and tiotropium]. Does it? You need to give it a time but if I took
Ventolin [salbutamol] it would help immediately, so neither of those
[beclometasone and tiotropium] is going to help me immediately if I was in a bad
way.
Female, 72 yrs old, using Ventolin Evohaler pMDI with spacer, Clenil Modulite
pMDI and Spiriva Handihaler
Most helpful, is this Ventolin [salbutamol]. Because after taking it, I feel it calms
me because it gives an instant relief. The rest are good but I am just using them
as the doctor told me.
Male, 74 yrs old, Ventolin Evohaler pMDI with spacer, Symbicort Turbohaler,
Spiriva Handihaler and Carbocisteine Capsule
Some participants, who were unclear of the exact effect of their inhaled
medicines, made judgments based on others’ (e.g. friends or neighbours)
prior experiences with medications. Consequently medicines use was
influenced by others’ judgments about efficacy and usefulness of therapy.
These judgments may change over time based on further experiences.
I do not think that makes much difference [tiotropium] but people say that’s very
good. I feel I just need to take it but people say it is really good. I think it is good
for COPD practically.
Female, 72 yrs old, using Ventolin Evohaler pMDI with spacer, Clenil Modulite
pMDI and Spiriva Handihaler
Well, I do not use the Ventolin [Salbutamol] these days as they said it is
supposed to help you breath but I never found that it did but they said it does,
so I used it.
Male, 73 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and Spiriva
Handihaler
In summary, the efficacy of inhalation therapy especially in combination was
highly appreciated by participants. Providing such information about what
participants thought of their COPD medicines, how they actually used them,
how this was different from the participants who perceived their therapy as
not fully effective, and how this influenced the use of medicines may enable
healthcare providers to assist COPD patients who are using inhalation
therapy in their homes to optimise medicine use and improve treatment
outcomes.
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7.3.2 Perceptions regarding treatment safety
All participants (N=46) were asked about their views on the perceived safety
of the inhalation therapy they used at home. Almost two-thirds (N=28)
reported that they had never experienced any adverse effect since
commencing their inhalation therapy, perceiving their inhalation therapy to be
safe.
Usually I have no concern about my medicines and no side effects. They are
simply safe.
Male, 84 yrs old, using Ventolin Evohaler pMDI and Spiriva Handihaler
I am quite happy that they do not cause any harm and I do not think they have a
side effect; I have been taking them as a part of my life plan.
Male, 91 yrs old, using Ventolin Evohaler pMDI, Seretide Evohaler and Spiriva
Handihaler
On the other hand, more than one-third of the participants (N=18) expressed
some concerns regarding experiencing adverse effects in the future, or
reported experiencing adverse effects when the inhalation therapy was used,
especially with long-term use of steroids. Two participants considered COPD
medications in general as ‘poisons’ or ‘harmful substances’, because they
believed they were not ‘natural’. They tried to avoid medicines as much as
possible and found other ways to compensate, such as undertaking daily
exercise.
My own doctor tried to persuade me to take more COPD medicines. He felt I
should have taken more medicines, but I did not really like taking it and you
know it is a drug, is it not? So, I put my energy, etc. into running and I became a
powerful runner and that helped me and my asthma.
Female, 78 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
I will be honest with you, I am also not a great believer in pills and things
because they affect me.
Female, 68 yrs old, using Qvar Easi-breathe and Bricanyl Turbohaler
Unwanted adverse effects or concerns about future adverse effects were a
major issue raised by participants who were unwilling to use a particular
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medicine, especially medicines containing steroids such as beclometasone
and budesonide. These medicines were found to be more prone to misuse
because they were used intermittently or not as prescribed. Some inhaled
medicines (e.g. budesonide and beclometasone) were replaced due to the
untolerated side effects caused by inhaled steroids.
I know I should take the Seretide twice a day but I only take it once every
morning. I know most people would take it twice a day but I do not. As you
know, Seretide contains steroids and I was already in the past taking lots of
steroids, so with that I do believe this amount would kill me in the end.
Female, 78 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
Previously, I also decided not to use Becotide because it has lots of steroids
and I was already on prednisolone. Too much steroids may cause lots of side
effects especially on bones, so I did not like it.
Female, 78 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
Actually, I am not happy with steroids. I take it because generally I do
everything they tell me but lately I have been suffering from restless legs and
Pinn Medical Centre gave me a booklet about restless legs. Then I read some
information about the causes and I found that taking steroids is one of the main
reasons.
Female, 84 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
Participants reported that the adverse effects occurred more often after each
use. In most cases, adverse effects were either dose-dependent caused by
using a combination of drugs that contained steroids, a double dose or higher
strength of steroids, or after a prolonged administration of steroids therapy.
Table 7-1 shows more information about the most common side effects
experienced by COPD patients due to their medicines.
Chapter 7 – The use of medicines
184
Table 7-1: The most commonly reported adverse effects with the use of inhalation
therapy
Side effect Number of participants
who reported this side
effect
Potentially
caused by
Shaky hands, tremors, muscle pain and
cramps
5 Bronchodilators
Osteoporosis 5 ICS
Persistent cough 4 ICS
Dry mouth and throat irritation 4 Bronchodilators
Voice hoarseness 3 ICS
Oral thrush 3 ICS
Palpitations (increase in heart rate) 1 Bronchodilators
Skin atrophy 1 ICS
 Some participants stated more than one side effect
Medications that contain steroids were the major cause of adverse effects
among this group of patients, including dry mouth and oral thrush
(overgrowth of fungus in the mouth), caused by not gargling or rinsing the
mouth with water, after using inhaled corticosteroids.
The only concern I had was the thrush which I found nasty but the hospital told
me to rinse my mouth after each use, so I use now a mouth wash.
Male, 83 yrs old, using Bricanyl Turbohaler and Symbicort Turbohaler
What I do as far as I am concerned is after each dose I swallow it up [steroids
left inside the mouth] with water because once when I was in the hospital I
caught thrush in my mouth. That was when I was really ill.  No one told me to
rinse my mouth after each dose but now I do.
Male, 72 yrs old, using Ventolin Evohaler pMDI, Pulmicort Turbohaler and
Spiriva Handihaler
Yes, the chemist told me once to rinse my mouth with water after taking these
inhalers, which I sometimes forget to do and you end up with a very dry mouth.
Male, 73 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and Spiriva
Handihaler
Some participants reported being informed by their doctor to rinse their
mouth after each use of inhaled steroids, to minimise the risk of developing
adverse effects. However, some participants had developed oral thrush and
voice hoarseness, despite rinsing their mouth, whereas some participants did
not rinse their mouth after the inhalation of steroids because they were not
given enough explanations about the reason behind it.
Chapter 7 – The use of medicines
185
I also wonder about the reason for brushing or cleaning my teeth after the
Seretide. It does not make much difference and it does not really seem to help,
you know, rinsing and sometimes I forget. If it was helping I would stick to it but I
thought, “What I am doing this for?”
Female, 84 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
I do gargle it out but still it does irritate me, so I decided to stop it.
Female, 65 yrs old, using Ventolin Evohaler pMDI and Seretide Accuhaler
Persistent cough, voice hoarseness, tremors, muscle pain and cramps were
problems raised by participants due to the continuous and prolonged use of
steroids or bronchodilators. However, some participants were uncertain
about what was causing these adverse effects. In response to this, they
decided to go back to the surgery to discuss the issue with their general
practitioner. In some instances a decision was made to change their therapy.
Well, that is a steroid is it not [Seretide] and I am already taking steroid tablets
for something else and because of the things I have in my legs and bones. I am
not happy with taking all these steroids but I have an appointment with [Dr.
Name] on Monday and I hope he is going to cut it back again because he said,
“We need to get you off them”.
Female, 80 yrs old, using AeroChamber Spacer Plus with adult comfortSeal
mask, Ventolin Evohaler pMDI, Seretide Evohaler CFC-free, Seretide Accuhaler
and Prednisolone tablets
Actually, I have an appointment with my doctor on the 16th of this month but I
might go earlier because I have got shaky hands and the shake is getting a lot
worse and I am wondering what is causing this.
Male, 72 yrs old, using Ventolin Evohaler pMDI, Pulmicort Turbohaler and
Spiriva Handihaler
Well, I have a concern about either one of those [Sympicort and Spiriva]
because I have had for years a bad shake, right; I cannot carry more than one
cup. I can carry a cup but I cannot carry two and I was told that it is probably the
medicine that is causing this. I told the people about my shake but I do not
emphasis it too much to the doctor but what I would like is somebody to say,
“Oh we can treat that or we can give you something to stop that tremor”.
Anyway, I have an appointment this afternoon to talk about this issue to see
what is causing this.
Male, 76 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler and
Spiriva Handihaler
The majority of participants who reported experiencing adverse effect (N=12),
accepted and tolerated the adverse effects caused by their medicines, and
reported not stopping their regular COPD medicines as a result. For others
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(N=6), the experience of adverse effects from COPD medicines impacted
their decision to use the therapy, either stopping their therapy, reducing the
daily dose, decreasing dosage frequency, or consulting their doctor for
alternatives.
I do not use the Symbicort that often because the twice a day dose seems to
burn my throat.
Male, 71 yrs old, using Bricanyl Turbohaler, Symbicort Turbohaler and Spiriva
Handihaler
I usually take two inhalations of Seretide in the morning and sometimes in the
evening because if I take the evening dose I cough a lot, so I try not to take it in
the evening before I go to bed. I was taking it but it makes me cough.
Female, 65 yrs old, using Ventolin Evohaler pMDI and Seretide Accuhaler
The Symbicort: I reduce it from two puffs twice a day to two puffs once a day,
because it is irritating and congesting my throat.
Male, 71 yrs old, using Bricanyl Turbohaler, Symbicort Turbohaler and Spiriva
Handihaler
My voice is a bit hoarse and it got worse after I took the steroids. I have this
problem for quite a while and because this one has doubled the steroids
[Seretide 250 mcg] from what I was on [Seretide 125 mcg], that is why I do not
take it as prescribed. I was not over-happy about that because ok she [her
doctor] is doing this for my benefit but I am not taking double strength and
double the amount, so what I have done is take this, one puff in the morning in
case I need a heavier dose [Seretide 250 mcg] and I just take one puff at night
from the one I used to take [Seretide 125 mcg].
Female, 84 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
Two participants reported discontinuing their therapy due to adverse effects
such as oral thrush and heart palpitations caused by steroids and
bronchodilators respectively. In these two cases, the drug products causing
the adverse effects were discontinued after consulting their doctor.
I went back to my GP and he put me on Symbicort and discontinued the old one
[Clenil (beclometasone)]. With this one [beclometasone] when I first used it I got
thrush in my mouth and a horrible taste; of course after that I had to use a
mouthwash after each use.
Male, 83 yrs old, using Bricanyl Turbohaler and Symbicort Turbohaler
I had Seretide 200 mcg. I was very unwell earlier this year and my heart rate
had increased from it. Then, I saw [Dr. Name], oh she is a lovely, she said,
“Could I change your medicine?”, and then I said, “Well yes”, then she put me
on Symbicort and took me off the Seretide
Female, 67 yrs old, using Ventolin Evohaler pMDI and Symbicort Turbohaler
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In this study, the use of inhalation therapy in general was considered to be
safe and well tolerated. However, 18 participants had experienced an actual
adverse effect, mainly with the long-term use of steroids including
budesonide and beclometasone in particular. As a consequence, six cases of
non-adherence to the inhaled steroid were identified with intermittent use of
therapy, or discontinuations. The rest of the participants (N=12) had accepted
and tolerated the adverse effects caused by their medicines. This section
informs the healthcare system about the main concerns and adverse effects
that COPD patients experience that may lead them to underuse their
medicines, leading to treatment failures. It is important that healthcare
providers monitor the effects and adverse effects of the inhaled therapy and
try to reduce these adverse effects if possible, and educate their patients
about the importance of continuing to use their inhaled medicines for their
condition and provide the proper advice and assistance tailored to each
patient, to maximise medicine use and treatment outcomes.
7.4 Experience of COPD medication: alterations over time
The findings obtained from the interviews were compared to the data
obtained from patients’ notes in the surgery regarding participants’
experience of COPD medication changes over time. Some changes were
made to the patients’ dosing regimen and were adjusted over time, as
reported by 19 participants and obtained from the medical notes. In regards
to the medication itself, the changes were made by medical prescribers by
adding a new medication, switching to another group or step-up of COPD
therapy from bronchodilators to adding steroids. As acknowledged by
participants, these adjustments were made when side effects emerged or
were raised by participants, when adequate control of COPD symptoms was
not achieved, when the severity of the disease increased, or exacerbations
occurred more frequently due to inadequate management.
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I was on Clenil [beclometasone] for 20 years but recently the doctor
discontinued this one because I had a very bad shortness of breath when I was
teaching at school and he put me on this [Symbicort (formoterol/ budesonide)].
Female, 65 yrs old, using Symbicort Turbohaler and Ventolin Evohaler pMDI
At the time, which was about a year ago, my chest was very bad, so a lady
pharmacist who was in charge of the bronchi-problems gave me a Ventolin
[albutamol] which I did not agree with, because it irritated my lungs more rather
than making it better. So I went back again, then they gave me a blue one
[Bricanyl (terbutaline)] which is to be taken when necessary.
Male, 71 yrs, using Bricanyl Turbohaler, Symbicort Turbohaler and Spiriva
Handihaler
Medical professionals were making changes to COPD medication over time.
Examining patients’ medication history, by exploring what COPD patients are
currently using, what they had been using in the past, what the changes were
and the reasons for these changes, is a crucial element to be examined. The
reason for this examination is to see what worked and what did not work in
regards to these alterations and to obtain the information regarding what
COPD patients use in the management of their condition, how COPD
patients felt after these changes, and whether they were useful or not. The
poor assessment of consequences when inappropriate changes are made to
patients’ drug regimen by their doctors may lead to improper use of COPD
medicines and therefore treatment failures.
7.5 Strategies in fostering appropriate medication use among COPD
patients
COPD patients were prescribed more than one inhalation device to be used
at home and had complex medication regimens, with some alterations made
to their drug regimen based on disease progression and seasonal changes.
The aim of this section is to examine how COPD patients fitted their
treatments into their daily routines and describe strategies employed by
patients to facilitate the use of their COPD medicines, when several
inhalation devices were being used.
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Many participants referred to their medication-taking behaviour as a habit
due to the long-term use. They had no difficulties in using their COPD
medication daily as required. Some made inhalers part of the daily routine
(e.g. linking COPD medicines to mealtimes), and had strict and well-
organized routines in taking medicines. This allows even complex regimens
to be easy to cope with.
It is more than difficult to keep track of everything but we have our routine to
remind us.
Male, 85 yrs old, using Ventolin Evohaler pMDI and Seretide Accuhaler
Well, I used the usual, one capsule of Spiriva before breakfast first and three
inhalations of Symbicort after breakfast and dinner.
Male, 67 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler, Spiriva
Handihaler and Phyllocontin tablets
It is a breakfast routine, everything happens in the breakfast time; I take Spiriva
and Symbicort first then all my heart pills followed by the blood pressure tablet
and finally my eye drop.
Female, 89 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler and
Spiriva Handihaler
For some participants, the daily drug regimen was complicated due to the
total number of prescribed medications and the number of doses that should
be taken daily in addition to the changes in prescribed drug regimens which
occurred over time. These participants developed their own strategies to
facilitate the use of COPD medicines to stay well and independent for as long
as possible. Firstly, some participants worked out a dosing schedule to make
it easier for them to remember to take their COPD medicines. For example,
seven participants reported that morning was the easiest time during the day
for them to remember to take all their COPD medicines. This was due to
minimal distractions that occur in the morning, whereas remembering to take
the afternoon or evening doses was problematic for other participants. Those
participants tended to take all their COPD medicines every morning and
made it like a habit to take them as soon as they stepped out of the shower,
or as soon as they got out of bed.
I take both of these [Seretide and Spiriva] at 7 o’clock in the morning when I
wake up but one before the other. I take them first thing in the morning because
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it is more convenient and I can remember the morning doses better with no
distractions.
Female, 78 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
I take most of my COPD medications in the morning before taking a shower
because I find it easier to remember the morning doses. Sometimes I actually
go to the shower and I think, “Oh I have not taken my Spiriva or Seretide”, so I
go and take them.
Female, 77 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler, Spiriva
Handihaler and Salamol Steri-Neb
Others stored their COPD medicines with items that were associated with
habitual behaviour (e.g. mobile phones) or in a conspicuous location (e.g. on
a kitchen counter) which is visited often (N=9). Others placed their inhalation
devices near something they need to deal with on a daily basis such as a
wrist watch or toothbrush. Some participants (N=3) set up a visual or auditory
reminder (e.g. sticky notes, cell phone alarms).
I have never forgotten to take the morning dose because it is upstairs on the
dressing table in my bedroom, where my mobile, watch and medicines are,
looking at me.
Male, 76 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler and
Spiriva Handihaler
I am not very good at remembering but I do keep some sticky notes on the
fridge door to remind me to take my medicines.
Female, 78 yrs old, using Ventolin Evohaler pMDI and Symbicort Turbohaler
The participants used memory triggers provided by informal care givers (e.g.
a spouse) to remind them to take their COPD medication at the
recommended time, and to help them to accommodate their COPD
medication within their daily routine and lifestyle.
My wife does everything starting from making sure that I take my medicines
everyday on time because I usually forget.
Male, 89 yrs old, using Salamol Easi-breathe and Seretide Accuhaler
Two participants had developed their own way to avoid missing their
medication by using compliance aids or sorting their medications using a
mouthpiece cover or cap system. For example, one participant, who was
prescribed three puffs of Symbicort to be taken three times daily, reported
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placing the Symbicort with three caps on the counter in front of him; each cap
represents one puff. As he takes one puff, he places one cap to the left of the
counter, making two puffs left. This way he organised the number of puffs
that should be taken at the same time by remembering that the number of
puffs left for the morning dose, for example, is at the front, whereas the ones
he has already taken are to the left.
I have got to have a system to remember taking my medicines; I have got a box
with all my morning, afternoon, and evening medicines, so I never miss.
Male, 72 yrs old, using Ventolin Evohaler pMDI, Pulmicort Turbohaler and
Spiriva Handihaler
I am a very compliant patient I do what I was told. The only problem I had with
the Symbicort, and it is nothing to do with the designer, is in the morning if I am
making breakfast I usually forget how many inhalations I take but I have devised
a system which helps. What I do is I have three things lined up like that [he
pointed to three caps lined up together] and when I take the first inhalation I
move the cap let’s say, so now I have taken one then I take the next one and
move the next cap, so I know now I have taken two and then I take the last
inhalation; but in the past it has been a problem and that is why I now I take
them pretty quickly one after the other.
Male, 67 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler, Spiriva
Handihaler and Phyllocontin tablets
Some COPD patients in this study found a way to work out their dosing
schedule for fostering medication taking which may in turn optimise medicine
use. These strategies were perceived as successful and efficient in
promoting medication use, by those with high self-reported adherence.
Illustrating patient's medication-taking behaviours and the way they fitted
their medication into the daily life may help healthcare providers in the future
to suggest some strategies to foster medication taking, especially for those
with low self-reported adherence.
7.6 Participants’ beliefs about COPD medicines
Similarly to adherence, participants’ beliefs were assessed using a
triangulation method. Firstly, a direct method was used with a self-report
scale (Specific Beliefs about Medicines Questionnaire BMQ) to measure
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participants’ beliefs about their COPD medicines (Horne et al., 1999).
Secondly, semi-structured interviews which consisted of open and close-
ended questions were undertaken (discussed earlier in section 7.3).
Table 7-2 gives more information on participants’ responses to the BMQ-
specific scales.
Table 7-2: Mean scores and ranges of participants' beliefs using BMQ-specific scales
*BMQ subscale Mean score
(SD)
Minimum Maximum
Total necessity 18 (3.23) 10 25
Total concerns 12 (2.85) 5 23
Total differential (necessity-
concerns)
6 (4.504) -8 17
*(Potential range of scores is from 5-25 from BMQ necessity and BMQ concerns: potential range for
differential is from -20 to +20)
During the interview, when participants were asked about their perceptions
regarding the treatment efficacy, three-quarters of participants (N=34)
perceived their inhalation therapy to be effective, whereas, when they were
asked about their perceptions regarding the treatment safety, almost one-
third of the participants (N=18) expressed some concerns regarding
experiencing adverse effects in the future, or reported experiencing adverse
effects when the inhalation therapy was used. Therefore, the number of
participants who perceived their inhalation therapy as effective was more
than those who had some concerns regarding the treatment safety. When
these findings were compared with the BMQ, the same results were found,
as a positive differential score of six, which was scored by participants in this
study (Table 7-2) indicated that participants perceived the benefits of their
COPD medication to outweigh their concerns about the risk of their COPD
medications. As a result, more than half of the sample were adherent to their
inhalation therapy and scored 8 in the MMAS. See Figure 7-3 and Figure 7-4
for more information regarding BMQ-specific necessity subscale (Figure 7-3)
and BMQ-specific concerns subscale (Figure 7-4).
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BMQ-specific necessity subscale
The majority of participants responded that they either agreed (57%) or
strongly agreed (17%) about the necessity of taking their COPD medicines.
However, 22% of participants were not sure whether these medicines are
necessary or not. A small proportion of participants 4% disagreed about the
necessity of taking COPD medicines. Figure 7-3 illustrates the participant’s
responses to the 5-items of BMQ-specific necessity subscale.
Figure 7-3: Percentage of participant’s responses to individual items of the 5-items
BMQ-specific necessity subscale
BMQ-specific concerns subscale
Figure 7-4 shows that a larger proportion of participants either disagreed
(71.72%) or strongly disagreed (6.1%) that they were concerned about their
COPD medicines comparing to those who either agreed (10.42%) or strongly
agreed (3.1%) that they had concerns about their medicines.
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Figure 7-4: Percentage of participant’s responses to individual items of the 5-items
BMQ-specific concerns subscale
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8 Chapter Eight: The care and services provided for
patients with COPD
This chapter is divided into two sections. The first section documents the
nature of care or support provided for COPD patients with their medication in
their homes and the role of informal carers in supporting these patients with
their medicines, and how often this help was sought. Providing such
information to the healthcare professionals in regards to how informal carers
and COPD participants divided tasks and shared responsibilities may help in
optimising medicine use and health outcomes. The second section
documents patients’ priorities and concerns regarding the current and
potential future service provision, to enable healthcare providers to introduce
interventions if required, to meet patients’ needs and expectations to
maximise medicine use and health outcomes.
8.1 The informal care provided for COPD participants with their
medicines
COPD is a life-threatening illness. It needs constant attention to control its
symptoms. Patients with COPD in this study were asked to follow a
recommended treatment plan and medication courses; the mean number of
all prescribed medicines including COPD was seven (SD= 3), which ranged
from two to 12. Patients were also asked to use inhalation devices correctly
for an effective drug delivery. Some patients may need some help to use
these medications properly; suggesting the potential role of the informal
carers.
Chapter 8 – The care and services provided for patients with COPD
196
Forty-six participants were asked during the interviews to declare whether
they received help or assistance with their COPD medication and to
document the nature of the support provided, how often and in which
circumstances or on which occasions help is needed. It was reported that
two-thirds of participants (N=32) reported not receiving any help with their
COPD medicines; they were able to manage their COPD medications on
their own. However, nearly one-third of participants (N=14) claimed to receive
help from their informal carers in their homes. However, the frequency of
assistance provided by informal carers was only when required or if needed
but not on a daily basis.
The next stage was to examine who these informal carers are. As a result,
participants who reported receiving help at home with their COPD medicines
were asked to name the person who provided such help or assistance. The
majority of participants (N=10) who acknowledged getting help from informal
carers reported receiving help from family members, especially spouses. A
further two participants reported receiving help from friends or neighbours.
The remaining two participants reported receiving help from multiple sources
including family and friends.
As a result, spouses were the primary carers for COPD participants in this
study, as 72% of informal care was provided by them. The findings of the
current study regarding receiving major help from spouses are consistent
with those of Trivedi et al (2012) who reported that, when examining the
association of informal carers and adherence among COPD patients, the
major help was received from spouses by providing some medical support
(e.g. managing pill-boxes or getting prescriptions refilled). In addition, it was
found that the greater involvement of spousal caregivers often translates into
closer monitoring of and a greater influence on patient behaviours (Trivedi, et
al., 2012). In a secondary analyses, the Lung Health Study reported that
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COPD patients who were married were more likely to be adherent to their
medications than non-married participants, reflecting the important role of
spouses in the disease management (Rand, et al., 1995). In another study
conducted among patients with COPD, it was found that most of the
caregivers were close family, especially spouses (74%). However, 26% of
the patients received help from neighbours or friends regularly (Gautun, et
al., 2012).
In this study, participants were also asked to document the nature of
assistance or help provided by their informal carers in terms of the following:
ordering or collecting the prescription from the surgery or the pharmacy,
opening containers, reading labels, understanding, reading or obtaining
information, administration (e.g. breaking tablets, measuring, putting in eye
drops, etc.), advice on when to take or how much (especially for prn
medicines), and advice on need for medicines and/or on side effects.
Participants reported receiving help with some activities regarding ordering or
collecting prescriptions from the surgery or pharmacy and, to a much lesser
extent, helping in obtaining and reading information. The two participants
who received help from their informal carer in obtaining or reading
information either had poor vision or hearing difficulties, but this was not a
major concern because they were receiving help from their informal carers
when required. Table 8-1 gives more information regarding the help provided
for COPD participants in this study.
Table 8-1: Types, frequencies, and percentages of assistance provided for COPD
participants (N=14)
Type of assistance Number of
participants
(N=14)
Help received with ordering or collecting prescription from the
surgery or pharmacy.
13
Help received with obtaining and reading information 2
Help received with administering COPD medicines 0
Giving advice or a recommendation on a prescribed medicines 0
*Some participants reported receiving more than one type of assistance with their medicines; therefore, the
total is more than 100%
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Although these results on the nature of help differ from some published
studies (Essue et al., 2010; Trivedi et al., 2012), they are consistent with that
of Gautun, et al. (2012), who reported that the most common help provided
for COPD patients was practical support in transportation and accompanying
the patient to the doctor, hospital, and other healthcare services. Whilst, in
the studies by Essue and Trivedi, the nature of support was technical support
such as operation of medical equipment (e.g. supplementary oxygen
concentrators and medication management (Essue et al., 2010), including
filling prescriptions (Essue et al., 2010; Trivedi et al., 2012), and ensuring
adherence to the prescribed medication regimen (Essue et al., 2010; Trivedi
et al., 2012). The differences between this study’s findings and all other
previous studies in regards to the frequency of assistance provided by
informal carers and the nature of help could be due to the fact that the
characteristics of each sample were different; as the sample of this was study
characterised by patients with mainly moderate disease status (N=26), with a
mean age group of 77 years and a mean number of COPD medicines of
three inhalers.
In summary, almost one-third of participants sought help from their informal
carer with their medicines and this was mainly in ordering or collecting their
prescriptions. This help was mainly sought when required but not on a daily
basis. However, it is always important to keep a record of whether COPD
patients require help or assistance with their medicines and whether this help
is sufficient to meet their needs because informal care is one of the
cornerstones of maintaining health and function in many older adults with
COPD.
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8.2 The priorities and concerns for patients in the context of current
and potential future service provision
8.2.1 Accessing healthcare services
Forty-six participants were asked if they had accessed the healthcare
services in the last year to speak to a healthcare professional in regards to
their COPD and its medicines, the reasons for accessing the healthcare
system and how often they did so. All participants (N=46) had accessed the
healthcare services in the last year at least once in regards to their condition
and/or medication, including primary and secondary care. The data suggest
that COPD patients (N=46) were initially managed in primary care (e.g. Pinn
Medical Centre, which was the most recent contacted site for most
participants), followed by emergency services from secondary care (e.g.
Northwick Park Hospital), as reported by participants (N=5). The reasons
given by COPD participants for accessing healthcare services are
demonstrated in Table 8-2.
Table 8-2: Services accessed by COPD participants during the last year.
1. Physician consultation
+++ cough, shortness of breath (7)
Exacerbation of COPD (3)
Inhalation technique (14)
Follow up/ review appointment (23)
2. Nursing consultation
Diagnostic testing  (9)
3. Hospital visit
Annual review (2)
In-patient stay/ hospital admission (3)
4. Supply of medication
Repeat medication (46)
Antibiotics and steroids (5)
Nebuliser medication (1)
Other respiratory medications (13)
8.2.2 Satisfaction with healthcare system and its service
In this study, COPD participants were generally satisfied with the healthcare
services. However, some participants had concerns about accessing the
healthcare system and were relatively dissatisfied with their own healthcare
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arrangements. Fear of change to the current medication regimens was the
first reason reported by two participants who were unwilling to access the
healthcare services. Others decided to avoid getting in touch with the medical
centre (Pinn Medical Centre) intentionally due to previous bad experience
with their doctors.
Actually, I have a tendency not to phone the surgery too much, you know,
asking for advice or help because they might do other changes to my
medicines, which I won’t be happy with.
Female, 84 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
Actually, I used to have a very regular doctor who was very good and I wanted
to keep him as my doctor because he was able to keep my regular medicines
without changing them every time and my chest was not bad as it is now.
Unfortunately, this doctor is now working part-time because he is about to retire.
So, I do not go to Pinn Medical Centre to see doctors like I used to.
Male, 74 yrs old, using Ventolin Evohaler pMDI with spacer and Seretide
Accuhaler
Honestly I am trying very much to keep away from doctors because I am afraid
of doctors. I also have had some bad experiences with doctors and things.
Female, 68 yrs old, using Qvar Easi-breathe and Bricanyl Turbohaler
Participants’ satisfaction with healthcare services was judged by the amount
of time they spend with their doctors in a consultation, keeping their regular
doctor, the quantity and the quality of information provided to each one, and
the appointment system. Patients expected their doctors to spend enough
time with them explaining everything about their disease and medication.
Failure to meet these expectations caused dissatisfaction and delayed
access to healthcare services, subsequently leading to lack of medical
supervision and information, which may lead to treatment failures.
Sometimes, it is very hard to get an appointment. I mean their [Pinn Medical
Centre] appointment system was very poor at one time mainly after they took
over that other surgery – that sort of flooded them out, overwhelmed them – but
I think now it is improved. However, it is sometimes quite difficult to get any
appointment and talk about your medicines.
Male, 83 yrs old, using Ventolin Evohaler pMDI, Clenil Modulite pMDI and
Spiriva Handihaler
Actually, I used to have a very regular doctor who was very good and I wanted
to keep him as my doctor because he was able to keep my regular medicines
without changing them every time and my chest was not bad as it is now.
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Unfortunately, this doctor is now working part-time because he is about to retire.
So, I do not go to Pinn Medical Centre to see doctors like I used to.
Male, 74 yrs old, using Ventolin Evohaler pMDI with spacer and Seretide
Accuhaler
You will get nothing from that surgery... It is useless. If you do not phone them
up asking for help they will not do anything without asking. You cannot even get
an appointment now!! You have to wait for two weeks for an appointment. Some
doctors even rush you through just to finish early. They give you less than five
minutes. They cannot be bothered at all.
Male, 85 yrs old, using Ventolin Evohaler pMDI and Seretide Accuhaler
It is very very difficult to spend time with your doctor and honestly I am trying
very much to keep away from doctors because I am afraid of doctors. I also
have had some bad experiences with doctors and things; half of the time they
have not got the time to listen to you, unfortunately, yeaaah.
Female, 68 yrs old, using Qvar Easi-breathe and Bricanyl Turbohaler
8.2.3 Obtaining information, prescriptions and/or medicines about
medicines and its sources
Forty-six participants were asked during the interview if they have received
any information from the healthcare providers in regards to their COPD
medicines, and who provides such information. More than half of the
participants (N=24) claimed that they had not received any information
regarding their COPD medicines in the last year. Twenty-two participants
reported receiving either verbal or written instructions from a member of the
healthcare team on medication dosage, frequency of dosing or how to
operate and maintain their devices. In most cases (N=17), these instructions
were mainly received when the medication or inhaler was first prescribed and
the patient has not followed the instructions. Participants claimed receiving
information mainly from their doctors (N=11) and/or a practice nurse (N=6) or
a pharmacist (N=5).
Other participants (N=18) reported obtaining this information mostly from the
medicine information leaflet or the instruction booklet. However, one
participant reported that, although she reads the information leaflet that
comes with each device, she had the tendency to forget what she read.
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Another participant complained about the small font size provided in the
leaflet.
Not that I recall any advice... Not recently no, I do not think so... I may have... I
am not sure but I would like to receive the information if possible. I have read
most of the leaflets very carefully but I have forgotten what is in each one
[laughs].
Female, 76 yrs old, using Ventolin Evohaler pMDI and Clenil Modulite pMDI
I now get all this information from a piece of paper in the packet. I just read the
packet leaflet and it is so descriptive but too small and not easy to follow or
understand.
Female, 78 yrs old, using Ventolin Evohaler, Seretide Accuhaler and Spiriva
Handihaler
As a result, it should not be assumed that COPD patients will learn how to
use their inhalers only by reading the package leaflets. If participants have
the tendency to forget the information they have read over time, it is
suggested to keep monitoring patients and to provide continuous education
and training about each device.
8.2.4 Faith in healthcare professionals
Faith in healthcare professionals was found to influence participants’ decision
to follow a recommended treatment plan. Some participants had a strong
faith and great trust in their doctors, which made them take their medicines
consistently without worrying about the long-term effect of their medicines.
In the future if I had to go on steroids I would rather not to use it but if the need
was there and I was told by my doctor to use it I will, because I trust my doctor
completely and simply.
Female, 65 yrs old, using Symbicort Turbohaler and Ventolin Evohaler pMDI
I do not have any concern because I trust what the doctor prescribed.
Female, 76 yrs old, using Ventolin Evohaler pMDI and Clenil Modulite pMDI
I mean if the doctor told me that’s the one I should use for the rest of my life,
that’s what I will be on.
Female, 68 yrs old, using Qvar Easi-breathe and Bricanyl Turbohaler
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In contrast, losing patients’ trust may result in delay in seeking help or advice
if needed and further delays in recovery will occur, as was expressed by one
participant.
The last time I went to Pinn Medical Centre was when I first moved here. They
said I should go and see the doctor. Anyway, I went to see the person who does
the COPD but I was not impressed by him because he told me I need to take
two of these inhalers twice a day [she pointed to Spiriva and Seretide] but when
I went to see my doctor in my old surgery and told her about what happened,
she said, “No you only need to take this one once” [she pointed to Spiriva] and I
said, “Well that is what he said”. She said, “He should not have told you that”, so
now I do not go to see him [laughs]. I only have faith in somebody or I do not.
Female, 77 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler, Spiriva
Handihaler and Salamol Steri-Neb
8.2.5 Patients’ participation in decision-making in regards to their
COPD medicines
Sharing decision-making with patients regarding their prescribed medicines
and involving the patient in the management process were found to give
desirable results in medicine taking. The opposite was found to contribute to
suboptimal adherence and lead to treatment failure. Four participants
reported that, when a decision was made by their doctor to change their
current medicines without giving any explanation or without sharing the
decision-making with the patient, they were unwilling to follow their doctor’s
recommendations; therefore, they either continued taking their old medicines
when the doctor asked them to switch to something else or decreased the
dose when the doctor asked them to double it, without informing their doctor,
which of course may lead to treatment filatures.
I used to see an ordinary GP, but now it has been changed to an asthma
specialist. She rang to say that my prescription was made out but she was
altering it from this 125mcg to double up and from one puff twice a day to two
puffs, also doubling up. I was not over-happy about that because ok she is
doing this for my benefit but she only did it on the telephone. Obviously I had a
scan few months ago and it was not good, I had severe emphysema and I got a
very bad attack.
Female, 84 yrs old, using Ventolin Evohaler pMDI, Seretide Accuhaler and
Spiriva Handihaler
I used to take it [she pointed to Symbicort], as prescribed but I am not using it
now because I do not need it. I told the pharmacist of what I need but they over-
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prescribe things [laughs]. Well I suppose they are trying to help me but we are
not stupid [laughs].
Female, 89 yrs old, using Ventolin Evohaler pMDI, Symbicort Turbohaler and
Spiriva Handihaler
In summary, the majority of COPD participants were generally satisfied with
the healthcare services. However, the data suggest that participants’
satisfaction with the healthcare services was influenced by different factors
such as accessing the service quickly and easily, quantity and quality of
information provided, faith in healthcare professionals, and getting the patient
involved in the management process by sharing the decision-making.
Meeting patients’ needs and expectations may enhance the recovery time,
whereas failing to meet these needs and expectations caused delays in
accessing healthcare services and delays in recovery time.
This study informs healthcare professionals about COPD patients’ views and
concerns regarding the current and future service provision, to allow them to
intervene and try to reduce these concerns and provide the best quality of
care which is continuously viewed by patients. This may increase patients’
satisfaction and confidence in the healthcare system and therefore maximise
the use of medicines by patients, leading to better outcomes.
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9 Chapter Nine: General discussion
9.1 Methodological issues
In this chapter, the main findings of this study are summarized, discussed
and general conclusions drawn. Furthermore, the strengths and limitations of
this thesis are considered and suggestions for further research into the use of
COPD medications and/or devices are presented. This chapter concludes
with recommendations for COPD patients and policy makers.
9.1.1 Sampling and recruitment
The recruitment process for COPD patients from the Pinn Medical Centre
was quick and went smoothly. However, the surgery tended to be very busy
and was often unable to provide a private room for the researcher to access
the surgery records when needed. In response to the surgery’s busy
schedule, the researcher requested to complete the recruitment process and
identify eligible participants as quick as possible, to maximize the availability
of the consultation room available for the GPs to consult their patients. An
issue emerged when identifying eligible patients, which was that some
patients had recently been diagnosed with COPD according to the records,
whilst others were previously diagnosed with asthma and then developed
COPD. This created a challenge in identifying the eligible patients. Therefore,
it was decided to look through the clinical variables such as record of
spirometry test, FEV1, FVC, and smoking history, to confirm the diagnosis,
which was a time-consuming process. This caused confusion for some
participants, who introduced themselves to the researcher during the
interview as asthmatic patients, for example, whereas they were registered in
the databases in the surgery as COPD patients. In addition, when the
invitation letter was sent to patients asking them to take part, some patients
Chapter 9 – General discussion
206
refused to participate by reporting that they were not aware of being
diagnosed with COPD.
Another challenge was that, in order to comply with the ethical requirements
set by the local ethics committee, the identification process was undertaken
alongside a respiratory specialist based in Pinn Medical Centre. Medical
professionals have very little time to conduct such processes due to their
busy schedules. However, convenient dates and times were set to help the
researcher to identify the eligible participants under specialist supervision.
The researcher attended the centre only on Fridays, to be under the
supervision of a respiratory specialist when carrying out this process.
9.1.2 Response rate and participants’ characteristics
This study comprises a relatively small sample size (N= 46), which is
appropriate for a study intending to produce predominantly qualitative data.
Qualitative research, which is observation and interview-based, often uses a
small sample size (e.g. less than 50), to facilitate the researcher’s close
collaboration with the participants and ensure that the data collected
accurately depict their experiences with their medicines (Richey and Klein
2007; Smith, 2010). A small number also increases the accuracy of the data
obtained and in-depth inquiry in naturalistic settings (patients’ homes)
(Richey and Klein, 2007; Smith, 2010).
The sample of 46 participants comprised individuals from different age
groups and ethnicity. In addition, a similar proportion of males and females
were recruited with different disease status and smoking history, which would
confer some generalizability to the general COPD population.
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9.2 Key findings of the study
9.2.1 The use of multiple inhalation devices used in combination by
COPD patients in the management of their condition.
There is a lot of information available in the British National Formulary (BNF),
the Summary of Product Characteristics (SPC), or other sources regarding
the recommended doses and dosing frequency for medicines used to treat
COPD. However, little is reported in the literature about the actual drug
usage, whether patients are taking their inhaled drug regimens at home as
directed or not. If not, why they do not adhere; what beliefs they have about
their medicines that may affect medication taking. In addition, what problems
are faced by patients that may make them stop taking their medicines as
recommended, and how this can be resolved.
This study is unique in examining the relationship between using multiple
inhalation therapies of all medication classes, and different devices. Studies
that have examined adherence to inhaled medications in COPD have been
restricted to only one (van Grunsven et al., 2000) or three medications
(Cecere et al., 2012; Huetsch et al., 2012). Additionally, many previous
studies of medication adherence in COPD patients were performed prior to
the common use of long-acting medications, and included only short-acting
medications (Dolce et al., 1991, Rand et al., 1995; Turner et al., 1995;
Corden et al., 1997).
In this study, medication taking among COPD participants was found to be
suboptimal. Suboptimal adherence to inhalation therapy was identified in
almost 50% of the sample, which was consistent with the rate of non-
adherence in seven past studies (Melani et al., 2001; Boyter and Carter,
2005; George et al., 2005; Mehuys et al., 2010; Cecere et al., 2012; Huetsch
et al., 2012; Trivedi et al., 2012). In contrast, four previous studies showed
that the rate of adherence was identified in more than 50% of the sample
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(Barta et al., 2002; Chen et al., 2007; Agh et al., 2011; Khadour et al., 2012).
This variation may be due to differences in patient populations, definition of
non-adherence, methods employed, disease status, or respiratory conditions
included in each study, as some studies included a variety of lung diseases
such as asthma and COPD. For example, almost all studies in adherence
research among patients with COPD have measured patients’ adherence
using only one self-report questionnaire on medication utilisation (Melani et
al., 2001; Barta et al., 2002; George et al., 2005; Mehuys et al., 2010; Agh et
al., 2011; Cecere et al., 2012; Huetsch et al., 2012; Khadour et al., 2012;
Trivedi et al., 2012), whilst this study combined different approaches, tools
and methods to gather the data from different sources to maximise the
validity of the findings. These tools were the previously validated self-report
adherence measure (Morisky) and open/close-ended questions in regards to
medication consumption (Morisky, 2008).
In terms of medication non-adherence, adherence to long-acting
bronchodilators and ICS was found to be suboptimal among those who
reported low medication adherence (N=22). This was justified by the
prolonged efficacy provided by long-acting bronchodilators and ICS on the
symptoms’ relief.
Among the LABA and ICS users, it was found that participants adhered more
to the LABA than ICS. However, the adherence was suboptimal for both
classes among those with a low-adherence rate. The reason behind being
more adherent to the LABA than the ICS is that some participants responded
better and quicker to the LABA than the ICS and for this reason preferentially
used the LABA, which provides superior relief. In addition, experiencing an
actual side effect or fears of side effects with the use of ICS was greater
among participants who used different classes. Factors that influenced
adherence to inhalation therapies were different and dependent on the
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medication being examined. These findings were in line with Cecere et al.’s
(2012) study which reported that, although adherence to LABA was better
than ICS, adherence to LABA was suboptimal. However, no explanation was
given for the reasons behind these behaviours.
Although there are a variety of classes of agents to be used in COPD,
depending on the severity of the disease, one of the most prescribed and
used classes of drug were the short-acting bronchodilators, whereas
tiotropium was the second most commonly prescribed and frequently used
not as prescribed. These findings are consistent with Chen et al.’s study
(2007) which investigated patients’ attitudes and actions toward their COPD
treatment. Within the three months of the study, the most commonly used
drugs were short-acting bronchodilators including theophylline (53.7% of
patients) and iprotropium (39.8% of patients), whereas the least used drug as
prescribed was tiotropium (27.1% of patients). In this study, the main reason
identified for the underuse of tiotropium was because nearly one-quarter of
participants (N=6) who were prescribed tiotropium treatment perceived their
tiotropium therapy was not fully effective. There is no doubt that these
changes in the medication dose or dosage regimen were contrary to the
recommendations published in the guidelines and the existing literature. The
NICE and the GOLD guidelines indicate that tiotropium should be inhaled
once daily, not intermittently, because its duration of action is 24 hours
(NICE, 2010; GOLD, 2013).
The suboptimal use of COPD medications by almost half of the participants
in this study raises a series of concerns for healthcare professionals. Non-
adherence to inhalation therapy at this extent may lead to suboptimal
management and treatment failures. These findings highlight the need for
healthcare professionals to continuously review patients’ adherence to their
prescribed regimen and provide comprehensive assessment, assistance and
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education for patients to maximise medicines’ use. In addition, healthcare
providers should assess the need for therapy, identify cases when the
inhalation therapy is not used as suggested, study the reasons and find
appropriate solutions to address concerns and misapprehensions and avoid
unnecessary costs.
Examining how patients make decisions regarding the use of inhalers, and
how those decisions and difficulties contribute to suboptimal outcomes and
treatment failures will help in evaluating and assessing each patient
individually to try to maximise the use of therapy and minimise the number of
treatment failures. It is therefore advised that all healthcare professionals do
the following: firstly, adherence screening, assessment and evaluation should
be routinely performed using direct and indirect methods. Secondly, in the
event of non-adherence or if non-adherence is suspected, healthcare
professionals should identify the nature and the reasons for non-adherence
and develop strategies for overcoming this problem, as the disease
management is a dynamic process influenced by the presence or absence of
these trigger factors. Thirdly, over time adherence may decline, therefore
healthcare professionals should be encouraged to provide feedback and
counsel their COPD patients about the role of treatment and the importance
of adherence, which may in turn enhance patients’ adherence. See section
9.5 for recommendation and suggestions to healthcare providers in the
context of the current policy.
9.2.2 COPD patients’ use of their medication and decision-making
regarding using the inhalation therapy, beliefs and perceived
effectiveness and safety of therapy.
In this study, numerous factors were found to affect patients’ decisions
regarding the use of inhalation therapy. The two major influences impacting
on the decision-making were patients’ perceptions about the efficacy and
safety of therapy and their actual experiences using it. These factors are
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consistent with the findings obtained from the previous studies (Dolce et al.,
1991; George et al., 2005; George et al., 2006; Huetsch et al., 2012; Khdour
et a., 2012) in regards to this aspect.
Patient beliefs and experiences with treatment used at home were found to
be the most powerful predictors of medication non-adherence (Section 7.3).
Patients were more likely to use their inhalation therapy if it was perceived to
be effective. Otherwise, patients were found to make changes to their
treatment plan in terms of dosing frequency, number of doses and adding or
stopping a drug, until they achieve what they consider a satisfactory efficacy
level with their medicines.
In regards to the safety of the inhaled therapy, actual or fears of developing
adverse effects was found to limit its use. Participants in this study made
some alteration to their daily drug regimens, such as reducing the dosing
frequency or the number of puffs, as a result of experiencing adverse effects,
due to the prolonged use of some medication, particularly steroids. Patients
were previously reported to underuse their COPD medication with the
emergence of adverse effects, or the existence of fears of adverse effects
(Dolce et al., 1991; Barta et al., 2002; Calverley et al., 2007; Khdour et a.,
2012), with inhaled steroids (Dolce et al., 1991; Huetsch et al., 2012).
Patients’ beliefs and experiences regarding the efficacy of inhaled
therapy and/or devices
In this study, the use of multiple inhalation therapy in combination was highly
supported by participants. Three-quarters of COPD participants (N=34)
perceived their inhalation therapy to be effective especially when it was used
in combination. The benefit was seen in the relief of COPD symptoms, the
increase in their activity levels, being able to sleep all night and decreased
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hospital admissions due to exacerbations. The marked improvement in
patients’ symptoms was related to the perceived immediate benefit of
symptoms’ relief for short-acting bronchodilators when used in combination
with long-acting bronchodilators or ICS that provide prolonged relief of
symptoms.
Participants who perceived their inhalation therapy to be effective reported
that the combination of a nebuliser and DPI provided a sustained and
adequate control of symptoms at home due to the fact that these devices
deliver medication with prolonged efficacy, such as long-acting
bronchodilators and/or steroids, whereas the benefit of the pMDI, which
delivers mainly medication that provides instant relief such as salbutamol,
particularly appeared when they were away from home. Tashkin et al., (2007)
conducted a 12-week study among 126 COPD patients using two
medications (salbutamol + ipratropium) delivered by a nebuliser and a pMDI.
Patients were randomised into three groups: nebuliser users, pMDI users, or
concomitant treatment users. It was found that patients who used nebuliser
therapy morning and night in combination with a mid-day pMDI (viewed as
portable therapy), had great improvements in quality of life. This concomitant
regimen combines symptom relief offered by a nebuliser with the
convenience of a pMDI when patients were away from home (Tashkin et al.,
2007).
During the interview, participants were asked to state one inhaler that they
feel is most effective when compared to others. From their perspective,
participants (N=3) who had experienced using all types of inhalation devices
including pMDIs, DPIs and nebulisers were in favour of the nebulisers based
on the current or past experience with the nebulisation therapy. They
perceived their nebulisation therapy to be the most effective in terms of
immediacy of relieving the symptoms especially when a combination of short-
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acting bronchodilators was given and when higher doses were required.
Additionally, these participants reported being more confident to use the
nebuliser device efficiently and independently at home, when compared to
alternative hand-held inhaler devices due to the former being easier to use.
These results are in line with two previous studies of nebulisation therapy
users who perceived their nebulisation therapy as effective in controlling and
managing their respiratory condition; therefore, they were less dependent on
healthcare systems (Melani et al., 2001; Barta et al., 2002). Barta et al.
(2002) showed 82 COPD patients using home nebulisation treatment (either
salbutamol and/or ipratropium), and concluded that patients overwhelmingly
reported that the benefit of using a nebuliser at home far outweighed the
disadvantages (98.2% vs. 1.8%). The majority of participants agreed that
using domiciliary nebulisers made a big difference to their life in reducing
their COPD symptoms and in making their daily activities possible, as they
felt they could walk further following nebuliser treatment. Three-quarters of
the participants found the nebulisers were superior to their inhalers in
symptom relief; breathing was commonly reported as much easier after using
a nebuliser (Barta, et al., 2002).
However, a systematic review showed no difference in the efficacy between
nebulisers and hand-held inhalers (Brocklebank et al., 2001). Using a pMDI
with a spacer has also been reported as being as effective as a nebuliser
with respect to airways drug deposition, with fewer oral side effects (Cates et
al., 2006a, 2006b). However, it should be noted that these studies mainly
involved a sample of primary care patients with severe disease status and
excluded patients with inadequate or incorrect inhalation technique.
Nevertheless, these findings have supported the use of pMDIs and DPIs in
preference to nebulisers (NICE, 2010).
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Among the hand-held device users (DPIs and pMDIs) (N=43) three-quarters
(N=32) perceived their combination therapy of formoterol/budesonide
(Symbicort) delivered by the Turbohaler or salmeterol/fluticasone (Seretide)
delivered by the Accuhaler as more effective than hand-held devices which
deliver a single therapy of either a bronchodilator or inhaled steroid. This was
explained in terms of the relief in the COPD symptoms after commencing this
treatment, and the increase in their activity levels. These findings are
consistent with the findings from earlier research and guidelines. It is highly
advised to commence a therapy of LABA in combination with inhaled
corticosteroids (ICS), as this combination was approved to improve
symptoms and lung function in COPD (NICE, 2010). Furthermore, it is
strongly recommended in the management of COPD to add ICS to
bronchodilators, as the combination was shown in previous studies to
significantly reduce treatment failure rates and length of hospital stays, if they
are used correctly (Quon et al., 2008; Lindenauer et al., 2010).
In one study of patients with COPD comparing the efficacy of the
combination of long-acting bronchodilator and long-acting ICS (salmeterol/
ﬂuticasone) delivered by Accuhaler device against long-acting anti-
cholinergic agent LAMA (tiotropium) delivered by Handihaler device, it was
indicated that there were no significant differences in the efficacy of the
salmeterol/ﬂuticasone and tiotropium in decreasing the rate of exacerbation
in COPD patients. However, the mortality rate was significantly lower in the
salmeterol/ﬂuticasone users compared with tiotropium users (Wedzicha et
al., 2008). In contrast, in a randomised controlled trial conducted by Aaron et
al. among 449 patients with moderate or severe COPD, the exacerbation
rates were similar in both users of salmeterol/ﬂuticasone and tiotropium
(Aaron et al., 2007). However, the quality of life improved with the use of
tiotropium.
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When using tiotropium in conjunction with the combination therapy of LABA
and ICS, participants perceived their inhalation therapy as more effective
than when using the combination of LABA and ICS alone. This agrees with
two studies that evaluated the efficacy and tolerability of triple therapy of
formoterol/budesonide added to tiotropium in COPD patients. This triple
therapy gave greater bronchodilation and decrease in exacerbation rates
than occurred with individual components (Singh et al., 2008; Welte et al.,
2009). Based on this evidence, it is recommended to add the long-acting
anti-cholinergic drug to the combination therapy of LABA and ICS for
participants with breathlessness or worsening dyspnoea (NICE, 2010).
However, further studies are needed to clarify the impact of inhaling a long-
acting anti-cholinergic drug with the combination of LABA and ICS on quality
of life and exacerbations. Until then, this regimen is only given to patients at
the severe stage of COPD (FEV1 <50% of predicted) or to those who were
lately hospitalised or admitted to hospital for an exacerbation (NICE, 2010).
It can be concluded that, based on the participants’ perceptions, this study
supports the use of multiple inhalation therapies in combination by patients in
their homes. The reason behind this was due to the fact that most
participants reported that they benefited from their combination therapies
used at home; when these multiple therapies were given in combination, they
provided a complementary effect in disease management. However, some
participants responded differently to medications. After analysing the data, it
was shown that patients’ perceptions of the effectiveness of the inhalation
therapy were different and were influenced by their own or others’ previous
experiences or expectations with the inhalation therapy. These perceptions
and expectations may undergo changes with further experience. This
indicates a need for tailoring an individual care plan for each patient,
especially given that one-quarter of participants perceived their inhalation
therapy was not fully effective, due to treatment failures resulting in recurring
symptoms, persistence of symptoms, exacerbations or hospital
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readmissions, despite using their therapy. See section 9.5 for
recommendation and suggestions to healthcare providers in the context of
the current policy.
Patients’ beliefs and experiences regarding the safety of inhaled
therapy and/or devices
Approximately two-thirds of the participants (N=28) reported that they had
never experienced any adverse effects since commencing inhaled therapy,
and therefore they perceived their inhalation therapy to be safe. However,
one-third of the participants (N=18) reported experiencing adverse effects
after using the inhalation therapy, especially inhaled steroids. Systematic and
local side effects (e.g. oral thrush, voice hoarseness, persistent cough and
osteoporosis) were mostly reported by a number of participants in this study
with the long-term use of steroids. These side effects appeared to be dose-
dependent and did not disappear with persistent use. This was consistent
with a previous study, which found that half of COPD patients who reported
one or more side effects with the long-term use of steroids did not develop
tolerance to side effects, even after three years of use (O’Driscoll et al.,
1997).
Some of the local side effects such as oral thrush and voice hoarseness were
dose-dependent, well tolerated, and totally reversible, especially when rinsing
the mouth after each use with water or mouthwash. These findings were in
line with two previous studies investigating the safety of the inhaled steroids
from a patient’s point of view (Roland et al., 2004; Park, et al., 2012). In
Roland et al.’s study (2004), which was conducted among COPD patients
using ICS, long-term use of ICS was found to raise the risk of persistent
cough by 4% every year, oral thrush by 9% and voice hoarseness by 2%.
These risks would be eliminated by washing the mouth or gargling after each
use (Roland et al., 2004). Another side effect reported by participants in this
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study was skin atrophy (N=1). The risk of developing skin atrophy was
calculated as 1% and of cataracts by less than 1% every year with the
continuous use of ICS (Park et al., 2012). Tremor, shaky hands and heart
palpitations were other side effects reported by participants resulting from the
use of inhaled bronchodilators. However, they were well tolerated by
participants, and tolerance to these side effects was developed after
prolonged use.
To conclude, the findings of this study suggest systematic or local adverse
effects especially with the long-term use of ICS. Therefore, safety concerns
exist with the use of inhaled steroids in patients with COPD, particularly when
using a combination of drugs that contains steroids, double dosing, or higher
strength. To improve patients’ use of inhalation therapy, see the
recommendations in section 9.5.
9.2.3 The frequency and range of problems experienced by COPD
patients in technical aspects that may lead to suboptimal care or
treatment failure
This is believed to be the only study that has examined and described the
problems encountered by COPD participants with all aspects of the use of
multiple inhalation devices, including technical issues with each device and
practical issues of the operation, cleaning and maintenance of inhaler
equipment of all classes, i.e. pMDIs, DPIs and nebulisers. In addition, it has
explored the reasons for mishandling and misuse of the inhalation devices,
which may lead to poor drug delivery and potentially failure of disease
control. By highlighting these issues, information has been generated which
will help inform healthcare professionals, in supporting these patients and
their carers in the use of inhaled therapy at home, and optimising medicines’
use.
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A total of 46 inhalation demonstrations were made by the 46 participants to
the researcher: DPIs (N=35), pMDIs (N=8), and nebulisers (N=3). No errors
were observed for those demonstrating their use of a nebuliser. Comparison
of other devices with nebulisers was thus not possible since only three
participants used nebulisation therapy and no error was made. However,
they were the only participants who had used all types of inhalation therapy
in this study, whereas all the rest (N=43) used a combination of pMDIs and/or
DPIs. Therefore, their judgments about the inhalation devices and their
preferences are considered potentially important.
The nebuliser users (N=3) performed the inhalation technique completely and
correctly without any deviation from the recommended technique. They
preferred and perceived their COPD therapy delivered by a nebuliser to be
more effective than aerosol therapy delivered by hand-held devices (pMDIs
and DPIs), despite nebulisers being less convenient and less portable. The
use of a nebuliser was considered simple and easy by the participants
because it requires minimal coordination of breathing and was considered
less effort to use than hand-held devices. The aerosol of a nebuliser device is
continuously produced when the user is sitting and inhaling the dose using
normal tidal breathing. Correct use may result from this simple operation
and/or due to the NHS providing clear descriptive guidelines regarding the
proper use of nebulisers (published in 2003 and updated in 2006) for all
users (Morgan, 2003). These guidelines include a guide on how a nebuliser
works, its components and the correct use and care.
Considering participants’ use of pMDIs and DPIs, it was found that the
deviation from the recommended technique was common among users of
both types of devices, although COPD participants made more errors when
using the pMDIs than DPIs. A general practice study conducted among 558
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adults with COPD and asthma showed that the type of inhalation device was
the strongest independent determinant of an incorrect inhalation technique
(Hesselink et al., 2001). Findings of patients’ handling of their inhalation
devices were in agreement with previous studies which have reported that
pMDI devices had higher rates of incorrect handling than DPIs (Lenney et al.,
2000; Molimard et al., 2003; Khassawneh et al., 2008; De Moraes Souza et
al., 2009; Rootmensen et al., 2010). In an observational study conducted in
the UK among 100 participants with COPD and asthma aged between 22
and 88 years, it was found that, although more than half of the participants
(55%) were using the pMDI, the performance scores and participants’
preference were highest for the DPIs, including Accuhaler and Turbohaler
(Lenney et al., 2000).
In another observational study of 3811 adults with COPD and asthma using
pMDIs and DPIs in primary care, deviation from the recommended technique
was common for many of the participants, especially those using pMDIs
(76% of participants), though for the DPI users also had poor technique but
the proportion of deviation was less (49-55%), including those using
Accuhaler, Turbohaler and Aerolizer (Molimard et al., 2003). One study found
elderly patients with COPD used a dry powder inhaler more correctly than a
pMDI, even in combination with a large volume spacer (Ho et al., 2004). A
further cross-sectional observational study was conducted by Khassawneh et
al. in Jordan among 300 patients with COPD, to see how they handled their
inhalation devices. It was found that DPIs had a significantly lower rate of
incorrect inhalation technique when compared to the pMDIs (Khassawneh et
al., 2008).
However, some previous studies (Melani, et al (2011); Sestini, et al (2006)),
have suggested that the ease of use of inhalation devices (e.g. pMDIs and
DPIs) was linked to patients’ training. The problem of individuals having
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inadequate inhalation technique was similar between the pMDIs and DPIs
(Accuhaler, Turbohaler and Aerolizer), when participants received
appropriate training before using each device (Melani et al., 2011), whilst
deviation from recommended inhalation technique was common among
users of pMDIs and DPIs, and was associated with lack of instruction in their
use by healthcare professionals (Sestini et al., 2006). To ensure the correct
use of inhalation therapy whatever the device, appropriate training and
education by the healthcare professionals must be given, more frequently to
improve the patients’ ability to use the inhalation devices correctly. After
receiving appropriate teaching in regards to how to perform a complete and
correct inhalation technique, there may be no difference in COPD patients’
ability to use DPIs or pMDIs (Brocklebank et al., 2001; Melani et al., 2011,
Sestini et al., 2006).
Among the DPIs users in this study, the proportion of participants who made
at least one deviation was greater for the Handihaler device (86%) than for
the Turbohaler (59%) or Accuhaler (45%). In relation to the problems
encountered with the use of the Accuhaler device, this study agrees with the
findings of Schlaeppi et al. (1996), Sumby et al. (1997) and Molimard et al.
(2003) which showed that the Accuhaler device had a consistent
performance, being reliable and trusted, and has broad patient acceptance.
In a study by Moore and Stone (2004) for patients with COPD who were
aged over 60 years, two-thirds were able to use the Accuhaler without a
single deviation or mistake, compared with less than 3% of those who used a
Handihaler. An observational study in Jordan of 300 patients with COPD
found that among the DPIs the Accuhaler device had the lowest rate of
incorrect handling (Khassawneh et al., 2008). It can be concluded that
amongst the DPIs the Accuhaler is something of a gold standard, although
this study has revealed it was inaccurately used by almost half of those
whose technique was observed.
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When participants were asked to state their preferences for one inhaler, they
were not in favour of the Handihaler device. Participants’ use of the
Handihaler was inferior to other DPIs. This could be due to the complicated
procedures associated with the use of the single-dose DPI, starting from
loading the dose, which is not easy to accomplish for elderly participants,
especially those who have manual or dexterity problems. Therefore, many
were not able to perform all the essential steps, from getting the capsule out
of the blister pack, loading it, and piercing it. In addition, when a COPD
patient is experiencing a sudden attack of shortness of breath and needs
immediate drug delivery of short-acting bronchodilator, these devices will not
be practical because they do not deliver short-acting bronchodilators and the
inhalation process takes time to perform. Previously, it has been shown that
participants favoured the use of the Accuhaler over the Handihaler (Moore
and Stone, 2004). According to that study, the two top-rated features for an
inhaled device were being quick to use when needed, and overall ease of
use (Moore and Stone, 2004).
The deviations from correct use or device mishandlings in this study were
due to many reasons. Firstly, checking the inhalation technique was not an
integral part of the routine management of COPD patients. If participants
complained that they were not receiving the therapeutic effect from their
inhalation therapy, physicians tended to step up therapy, increase the
frequency of dosing or switch to another device instead of investigating the
reasons (section 7.4). This indicates that inhalation technique should be
regularly assessed, not only provided with the initiation of a new inhaler
device. Secondly, the information about how to use the inhalation devices
was found to be mostly obtained from the patient information leaflets that
come with each device. These are usually written using a medical language
that is not easily understood by some patients. Additionally, despite the fact
that the pharmaceutical companies tend to give a lot of description in the
information leaflet about the use of each inhaler, this information is usually
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written in a very small font size accompanied by illustrations, which were
hard to read for some of the participants in this study (Section 8.2.3).
Therefore, healthcare providers, including medical staff, nursing staff and
pharmacists should not assume that patients are able to obtain all the
required information in regards to use from reading the package leaflets
alone. Healthcare providers need to assist patients on the proper use of each
device. In addition, it was acknowledged by some participants that doctors do
not usually spend enough time counselling their patients during peak hours at
the outpatient clinic. Therefore, doctors should be encouraged to spend
adequate time (more than 10 minutes) and provide sufficient resources such
as handouts or videos for inhaler technique training.
Another reason for the differences seen in handling the inhalation devices
among COPD participants can be due to the differences in the properties in
the design of each device and instructions given for each patient, which may
be related to patients’ manual dexterity problems. If any one of these cases
arises, quick action should be taken to evaluate each case individually and
find the proper solution. In addition, healthcare prescribers are advised to
avoid prescribing a device with a complex design and to consider the ease of
use when prescribing inhalation therapy.
To conclude, inhalation therapy is central in the management of chronic
obstructive pulmonary disease, and pMDIs and DPIs remain primary devices
to manage this condition. Checking inhalation technique and the proper use
of the inhalation therapy for each prescribed device need to be an integral
part of the routine management of any COPD patient, ensuring the proper
use of devices by patients and optimising therapy. In addition, nebulisers
should be considered in patients with a severe condition and those with
manual dexterity limitations who cannot optimally use hand-held inhalers,
because nebulisers require less coordination and no special breathing
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manoeuvres are required. The dual use of nebulisers and pMDI or DPI is
recommended because it may obtain the best efficacy and convenience.
However, continuous review, assessment, training and education are also
suggested to minimise any confusion or misuse and maximise the medicine
use. See section 9.5 for recommendation and suggestions to healthcare
providers in the context of the current policy.
9.2.4 The role of carers and the assistance with medicines that
patients receive
This study was conducted to explore the extent of involvement of informal
carers in the disease management process for COPD patients, and to
address the gap in the literature by describing the nature of support or care
provided for COPD patients in their homes. Understanding the range and
extent of care provided by informal caregivers regarding inhalation therapy at
home is crucial to support and empower carers to fulfil their roles, and to
ensure the effective use of COPD medication by patients.
In this study the informal carers were involved in the following activities:
ordering and collecting a prescription from the surgery or pharmacy (N=13)
and obtaining or reading information (N=2). Women (generally spouses) were
the main sources of care for COPD patients with their medicines. These
findings are supported by the studies of Essue et al. (2010) and Gautun et al.
(2012). In these two studies most support received was practical (e.g.
accompanying the patient to healthcare services and getting prescriptions
filled). Additional support comprised operation of medical equipment (e.g.
supplementary oxygen concentrators and carrying out testing procedures)
(Essue et al., 2010; Gautun et al., 2012) and ensuring adherence to the
prescribed medication regimen (Essue et al., 2010; Trivedi et al., 2012).
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Three studies have previously concluded that COPD patients received
inadequate support from the formal care sector; therefore, they have unmet
needs that are managed by informal caregivers (Simpson et al., 2008;
Spence et al., 2008; Caress et al., 2009), highlighting the important role of
informal carers in helping homebound patients with their medicines. The
involvement of informal care may substantially improve patient outcomes
(Lilleaas, 2003; Gautun et al., 2012).
Understanding the range and extent of care provided by informal caregivers
in relation to the use of inhalation therapy at home is crucial to support and
empower these individuals to fulfil their roles in supporting of the patients,
and to ensure the effective use of COPD medication by patients.
9.2.5 The priorities and concerns for patients in the context of current
and potential future service provision
Excluding patients' involvement in the management process of COPD and
fears of change regarding the current medication regimens were the main
reasons reported by participants who were unwilling to access the healthcare
system and follow the medical advice due to being dissatisfied with their own
healthcare provider’s arrangements. This was in line with the previously
published studies. Thomas’s study (2009), conducted among 499 patients
with asthma, found that 50% of the participants refused to use their DPIs
because they had been replaced with a substitute device for no apparent
reasons. In a further study which used in-depth interviews of five patients
with asthma, four participants were concerned about switching their existing
DPIs to another inhalation device, with the presence of confusion about the
need for change (Booker, 2005).
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Healthcare professionals therefore have to be aware that, when a patient has
any concern or confusion regarding switching their inhalation devices, they
may not only not request clarification or assistance from professionals, but
also continue using the old drug regimen without informing their doctors.
Therefore, it is necessary to describe to the patient the need for the change
and to educate the patient on the new treatment including the indications, the
frequency of dosing and the inhalation technique. Furthermore, it is important
to always try to get the patients involved in the management process, to
maximise the medicine use.
9.3 Limitations of the study
From a total of 116 COPD patients who were eligible to take part and were
invited to participate in this study, only 33 participants responded following an
initial mailing. In order to increase the participation rate, a reminder letter was
sent to those who had not yet responded. Ultimately, in total 46 participants
who met the criteria and agreed to take part were enrolled in this study and
interviewed (response rate 40%). This was lower than expected, since the
feasibility of conducting this study and the accessibility of COPD patients was
examined with Pinn Medical Centre staff in the preliminary fieldwork. Based
on the feedback of respondents this could be due to the fact that this study
was conducted mainly during the spring and summer seasons, when most
non-participants were either working or out of the country. Despite the small
sample size, the sample of 46 participants consisted of people from different
age groups, ethnicity, disease status and smoking history. In addition, a
similar proportion of males and females were recruited with different disease
status and smoking history, which would make the sample representative
and generalisable to the general population. In addition, it can be applied to a
wider population with COPD.
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In terms of assessing patients’ adherence and beliefs about medicines, this
assessment was done at a particular point of time (when the study was
conducted). Patients’ adherence and beliefs about medicines may undergo
changes over time based on further experiences of their own or others’ prior
experiences with the treatment (George et al, 2006). Therefore, it would be
interesting to know whether these beliefs may change over time and whether
this affects patients’ medication-taking behaviours. As a result, repeated
assessment may enable the assessment of the consistency of adherence to
and beliefs about COPD medicines over time.
9.4 Contribution to existing knowledge and implication for future
research
To our knowledge, this is the only study that has examined the use of
multiple inhalation devices (all medication classes and inhalation devices)
used in combination by COPD patients in the management of their disease in
the context of their daily lives. In addition, this study provides information
about how COPD patients made decisions about use of devices, what
problems they had in the past with different inhalers, what worked and what
did not work. Semi-structured interviews and participant observation were
employed together to provide a detailed assessment. This is the first single
study to explore the frequency and range of technical and practical problems
experienced by COPD patients with all inhalation devices in aspects of their
use including operation, cleaning and maintenance of inhaler equipment.
Moreover, it is one of very few studies that have explored informal carers’
contribution in the assistance of COPD patients with their medicines at home.
This study adds to the field of medication use at home in the following ways:
 It has reported the perceived barriers to using the inhalation therapy
by COPD patients with the description of the factors that affect the
decision-making with regards to the use of inhalation therapy.
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 It has reported the actual and perceived effectiveness and safety of
the inhalation therapy in regards to symptoms’ control and disease
management.
 It has identified the frequency and range of problems experienced by
COPD patients in technical aspects of the operation, cleaning and
maintenance of inhaler equipment that may lead to suboptimal care or
treatment failure.
 It has documented the role of carers and the assistance with
medicines that COPD patients receive from family and friends, and
had identified the priorities and concerns for patients in the context of
current and potential future service provision.
 This study made some recommendations to healthcare professionals
to optimise medicine use and maximise the efficacy of the therapy,
leading to better health outcomes for COPD patients.
Based on the results found in this thesis, further research is suggested with
respect to the following:
 Different tools were used previously by researchers to assist the
inhalation technique among the pMDIs and DPIs users. As far as we
are aware, no tool has been published to assess the nebulisation
technique among nebuliser users. This study assessed the
nebulisation technique among three nebuliser users. However, more
studies are required in this aspect to assess the effective use of the
nebulisation therapy among COPD patients in a wider context and
examine what problems the nebuliser users had in the past with
different nebulisers, what worked and what did not work.
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 Future work can be done to investigate the contribution of informal
carers in assisting patients with their COPD medicines at home, as
very little was found in the literature on what is the nature of support
provided for COPD patients in terms of their COPD medication in their
homes, from whom and how often this help is sought. Therefore, it can
be said that the nature of informal support provided for COPD patients
with their medication in their homes remains understudied. The few
existing studies that have examined the informal care provided for
COPD patients have focused on carer experiences and needs,
neglecting the needs of homebound patients with COPD and the
important role of the informal carers in disease management among
COPD patients. Therefore, there is a need to know if the dependent
patient is getting any help or assistance with their COPD medicines,
whether formal or informal, and how does the carer help – in which
activity or tasks and how often. Understanding the range and extent of
care given by the caregivers in relation to the use of inhalation therapy
at home is crucial to support and empower carers to fulfil their roles
and to ensure the effective use of COPD medication and optimise
health outcomes for COPD patients.
9.5 Considerations of the study results in regards to the current
policies
 In the last two decades, the profile of COPD as a disease has
been raised by a number of British organisations (e.g. NHS, BTS,
BLF) trying to decrease the number of treatment failures,
exacerbations and hospital admissions (BLF, 2008). In order to
accomplish this goal, appropriate medicine usage and the safety of
the inhalation therapy in patients’ homes need to be assured. This
study gives information about the use of multiple inhalation devices
by COPD patients in the management of their disease in the
context of their daily lives, which gives the healthcare
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professionals the opportunity for intervention to optimise medicine
use and maximise management of the condition.
 Medication formed a major component of the National Service
Framework (NSF) plan, which reported that older people and their
carers should be assisted in using their therapy to maximise
medicine use. In order to maintain or enhance their quality and
duration of life and to avoid deteriorations of symptoms resulted
from suboptimal medication use (DH, 2001b). To achieve this goal
another document was published to specifically address the
medicines component of the standards (DH, 2001a). In this
document, the practical aspects of medication use was
emphasised in any medication review. However, findings of this
study revealed that patients with COPD frequently experienced
practical and technical issues with the use of their inhalers.
 It is recommended by the Medical Research Council (MRC) to
guide and formulate adherence-enhancing interventions by
research findings (MRC, 2008). As a result, findings of this study
are used to provide the foundations of program development and
help in designing tailored medication adherence interventions
among patients with COPD. Suboptimal adherence to inhalation
therapy was identified in almost 50% of the sample, which was
consistent with the rate of non-adherence in seven past studies
(Melani et al., 2001; Boyter and Carter, 2005; George et al., 2005;
Mehuys et al., 2010; Cecere et al., 2012; Huetsch et al., 2012;
Trivedi et al., 2012). The suboptimal use of COPD medications by
almost half of the participants in this study raises a series of
concerns as non-adherence to inhalation therapy at this extent
may lead to suboptimal management and treatment failures.
These findings highlight the need for healthcare professionals to
continuously review patients’ adherence to their prescribed
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regimen and provide comprehensive assessment, assistance and
education for patients to maximise medicines’ use. In addition,
healthcare providers should assess the need for therapy, identify
cases when the inhalation therapy is not used as suggested, study
the reasons and find appropriate solutions to address concerns
and misapprehensions and avoid unnecessary costs. This study
examined how each patient made decisions regarding the use of
inhalers, and how those decisions and difficulties contributed to
suboptimal outcomes and/or treatment failures. Providing this
information to healthcare professional may help in evaluating and
assessing each patient individually to try to maximise the use of
therapy and minimise the number of treatment failures.
 Patients with chronic disease conditions including COPD who use
inhalation therapy including bronchodilators, corticosteroids,
theophylline, or other related COPD therapy, comprise one of the
national targets for the current Medicines Use Review (MUR)
services and one of the conditions that was included in the New
Medicine Service (NMS) to assess and improve adherence to
COPD medicines (HSC, 2013) by educating the patients and
reminding them about the chronic nature of their disease and the
importance to keep a track of their medicines and use them as
suggested (HSC, 2013).
 Using inhaled corticosteroids (ICS) is recommended by NICE and
GOLD guidelines, to be used in combination with LABA (e.g.
Symbicort or Seretide), as this combination improves symptoms
and lung function (NICE, 2010). The majority of participants in this
study perceived their combination therapy to be effective in
regards to better lung function and condition control. Therefore,
this regimen should be continued until patients perceive their drug
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therapy to be suboptimal, at which time these cases should be
assessed and further investigated.
 The data from the interviews revealed that two-thirds of
participants perceived their inhalation therapy to be optimal when
delivered by different types of devices including pMDIs, DPIs and
nebulisers. This was due to the relief in their COPD symptoms, the
increase in their activity levels and being able to sleep through the
night. Such findings have led the recommendations to support the
use of other hand-held devices, with a preference for nebulisers,
and nebulisation therapy discontinued in the absence of a clear
benefit to the patients (NICE, 2010). This study shows a clear
appreciation by patients of the continued availability of nebulisers
for drug delivery in the home.
9.6 Implication of the study findings and recommendations for
practice and policy
One of the main values for conducting this research among patients with
COPD is to communicate relevant results of patients’ perspectives to
healthcare professionals, in order to optimise medicines use and maximise
treatment outcomes. It was advocated by Health initiatives to commence
services incorporate the experiences and views of service users (DH, 2010).
The aim of this was to introduce services that are responsive to patients’
needs, beliefs and concerns. To support this aim, this section applied the
findings of this study to inform healthcare professionals of patients’ beliefs,
concerns and needs. Additionally, recommendations for healthcare
professionals were made in light of the study results to support the use of
medicines by COPD patients using multiple inhalation therapy in combination
in their own homes, leading to optimizing health outcomes. These
recommendations are:
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 Healthcare professional should consider using multiple inhalation
therapy in combination and a wider use of nebuliser therapy: patients’
reports indicated nebuised therapy was perceived to be effective by
all users. However, currently nebulisers are considered only in
patients with a severe condition and those with manual dexterity
limitations who cannot optimally use hand-held inhalers (NICE, 2010),
because nebulisers require less coordination and no special breathing
manoeuvres are required.
 Based on the participants’ perceptions, this study supports the use of
multiple inhalation therapies in combination by patients in their
homes. The reason behind this was due to the fact that most
participants reported that they benefited from their combination
therapies used at home; when these multiple therapies were given in
combination, they provided a complementary effect in disease
management. However, some participants responded differently to
medications.
 Nebulisers should be considered in patients with a severe condition
and those with manual dexterity limitations who cannot optimally use
hand-held inhalers, because nebulisers require less coordination and
no special breathing manoeuvres are required.
 The dual use of nebulisers and pMDI or DPI is recommended
because it may obtain the best efficacy and convenience. However,
continuous review, assessment, training and education are also
suggested to minimise any confusion or misuse and maximise the
medicine use.
 Healthcare professional should consider the efficacy of therapy used
in combination by COPD patients: the data from the interviews
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revealed that two-thirds of participants perceived their inhalation
therapy to be optimal when delivered by different types of devices
including pMDIs, DPIs and nebulisers. This was due to the relief in
their COPD symptoms, the increase in their activity levels and being
able to sleep through the night. Such findings have led the
recommendations to support the use of other hand-held devices, with
a preference for nebulisers, and nebulisation therapy discontinued in
the absence of a clear benefit to the patients (NICE, 2010). This study
shows a clear appreciation by patients of the continued availability of
nebulisers for drug delivery in the home.
 After analysing the data, it was shown that patients’ perceptions of the
effectiveness of the inhalation therapy were different and were
influenced by their own or others’ previous experiences or
expectations with the inhalation therapy. These perceptions and
expectations may undergo changes with further experience. This
indicates a need for tailoring an individual care plan for each patient,
especially given that one-quarter of participants perceived their
inhalation therapy was not fully effective, due to treatment failures
resulting in recurring symptoms, persistence of symptoms,
exacerbations or hospital readmissions, despite using their therapy.
 Treatment failures were of concern to patients who had experienced
multiple episodes of exacerbation. The study identified factors which
were potential contributors to treatment failures one of which is non-
adherence to therapy or misuse of therapy. Therefore, to improve
patients’ use of inhalation therapy, it is suggested that healthcare
professionals should be aware of how individual COPD patients use
their inhalation therapy to manage their condition in the context of
their daily lives, and what the reasons that guide the use were, to
provide all the necessary assistance tailored to each patient,
particularly whose is at high risk of suboptimal adherence.
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 Adherence screening, assessment and evaluation should be routinely
performed by healthcare professionals using direct and indirect
methods.
 In the event of non-adherence or if non-adherence is suspected,
healthcare professionals should identify the nature and the reasons
for non-adherence and develop strategies for overcoming this
problem, as the disease management is a dynamic process
influenced by the presence or absence of these trigger factors.
 Over time adherence may decline, therefore healthcare professionals
should be encouraged to provide feedback and counsel their COPD
patients about the role of treatment and the importance of adherence,
which may in turn enhance patients’ adherence.
 Patients’ medical progress and adherence to their treatment should
be reviewed and assessed periodically along with a review of the
problems experienced by patients in the use of medicines and care.
 To increase adherence to medicines and correct use of devices,
patients should get involved in shared decision-making in regards to
the treatment and devices alternatives and state their preferences
when any alteration is suggested. However, they should be first well
educated about the available treatment.
 Increasing the dose or adding a new medication to the treatment plan
may achieve better control of symptoms but may in turn lead to more
side effects or medication non-adherence. Therefore, negotiating
patients’ choices, decisions and requests is recommended before
making any alterations. Patients may also benefit from continuous
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education in regards to each inhalation device and medication and its
mode of action, to enable them to distinguish between the immediate
and the long-term treatment benefits along with the possible side
effects and risks.
 Patients’ previous experiences and expertise with medicines used at
home should be considered in medical practice, to detect and
overcome perceived barriers to adherence.
 When asking patients to follow a treatment plan involving multiple
inhalation devices, this plan should be practicable and fit into each
patient’s daily routine. In addition, instructions should be adapted to
each patient’s knowledge level and should be clear, simple,
personalised and operational in terms of how many to take, what kind
and when to use. After receiving advice, patients should be asked to
paraphrase their understanding of the given advice and the rationale
behind it.
 The findings of this study suggest systematic or local adverse effects
especially with the long-term use of ICS. Therefore, safety concerns
exist with the use of inhaled steroids in patients with COPD,
particularly when using a combination of drugs that contains steroids,
double dosing, or higher strength. As a result, it is recommended that
patients’ fears and concerns should be addressed carefully during
each consultation which should be patient-centred, with all their
questions answered clearly.
 In regards to the safety of the inhalation therapy, participants have to
be counselled during each visit about the possible side effects, and in
particular they should be informed about the need to rinse their mouth
after each use of ICS, to avoid developing oral thrush due to
deposition of the drug in the oro-pharynx. In addition, participants who
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experienced side effects with the long-term use of steroids delivered
by a pMDI should be encouraged to use a spacer device with their
pMDI. Spacer devices are recommended for use with pMDIs to
increase drug delivery to the airways, and decrease the side effects
resulting from deposition in the mouth or throat (Roland et al., 2004).
 Before stepping up doses or dosing frequencies of the therapy,
healthcare providers are advised to make assessment of inhalation
technique an integral part of the routine management of COPD
patients. Checking inhalation technique and the proper use of the
inhalation therapy for each prescribed device need to be an integral
part of the routine management of any COPD patient, ensuring the
proper use of devices by patients and optimising therapy.
 Inhalation technique assessment should occur at regular intervals, not
only with the initiation of a new inhaler device. Therefore, during visits
to the surgery, COPD patients should be encouraged to bring their
prescribed devices and should be asked to demonstrate their use and
maintenance. In addition, adequate time and resources need to be set
aside for inhaler technique training, if needed.
 Patients’ visual acuity and manual dexterity should be assessed often,
especially for those who have tremors, arthritis and coordination
problems, as this could affect the successful use of inhalation
devices.
 Some participants tended to forget the information they have read or
heard with time, due to their age or cognitive problems. Therefore, it is
suggested to keep monitoring the patients and to provide continuous
education and training, as appropriate.
Chapter 9 – General discussion
237
 When an inhaled therapy is used by patients for a long period of time,
it should not be assumed that patients became familiar and proficient
in the use of this device. Appropriate assessments should be
undertaken.
 After the assessment, if the inhalation devices were handled
inappropriately by patients, quick action should be taken (e.g. training
or consideration of a spacer device or breath-actuated devices, when
use of pMDIs is problematic or an alternative device).
 The training session should provide a clear explanation of why a
particular inhaler was prescribed, how it works and the steps needed
to use it efficiently. In addition, patients also need to know how and
when to clean these devices and how to tell when the device is empty
and needs to be replaced.
 Almost one-third of participants in this study sought help from their
informal carer with their medicines and this was mainly in ordering or
collecting their prescriptions. This help was mainly sought when
required but not on a daily basis. However, it is always important to
keep a record of whether COPD patients require help or assistance
with their medicines and whether this help is sufficient to meet their
needs because informal care is one of the cornerstones of
maintaining health and function in many older adults with COPD.
 Understanding the range and extent of care provided by informal
caregivers in relation to the use of inhalation therapy at home is
crucial to support and empower carers to fulfil their roles, and to
ensure the effective use of COPD medication by patients.
 Excluding patients' involvement in the management process of
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COPD, dissatisfaction with the services provided and fears of change
to the current medication regimens were the main reasons reported
by participants who were unwilling to access the healthcare system
and follow the medical advice due to being dissatisfied with their own
healthcare provider’s arrangements. Healthcare professionals
therefore have to be aware that, when a patient has any concern,
confusion or dissatisfaction, they may not only not request clarification
or assistance from professionals, but also continue using the old drug
regimen without informing their doctors. Therefore, it is necessary to
describe to the patient the need for the change and to educate the
patient on the new treatment including the indications, the frequency
of dosing and the inhalation technique.
 It is also recommended to always try to get the patients involved in
the management process, to maximise the medicine use.
 Participants’ satisfaction with healthcare services was judged by the
amount of time they spend with their doctors in a consultation,
keeping their regular doctor, the quantity and the quality of information
provided to each one, and the appointment system. Therefore, it is
recommended that healthcare professionals spend enough time with
their patients in a consultation explaining everything about their
disease and medication. Failure to meet these expectations caused
dissatisfaction and delayed access to healthcare services,
subsequently leading to lack of medical supervision and information,
which may lead to treatment failures. A named regular GP is also
recommended to coordinate patients’ care and in an effort to meet
patients’ satisfactions.
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10 Chapter Ten: The conclusion
Treatment failures were a major concern for COPD patients in this study as
almost half of participants reported suboptimal adherence. Therefore,
screening of medication taking among patients with COPD should be
routinely done on all aspects of management using simple and practical
tools. This is required for all COPD patients including those whose non-
adherence has not been a concern in the past. However, more time should
be spent with patients whose non-adherence is of concern, paying lots of
attention to the identification of the nature of non-adherence and the reasons
behind this behaviour, which are also critical in clinical practice along with its
detection and quantification.
Most patients experienced problems with inhalation devices used at home,
especially with the pMDIs and DPIs. Therefore, practical measures (e.g.
repeated instruction and supervision on the proper use of an inhaler) should
be undertaken to minimise the number of deviations from the inhalation
technique made by patients when using inhalation devices, to allow better
control of symptoms and optimise the disease management. Further and
larger research which is related to the proper use of the inhalation therapy
and proper handling of the inhalation devices in real practice with clinical
efficacy and disease control is needed.
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